|
Issued:
Wednesday, 27 July 2022, London U.K.
|
|
GSK delivers strong Q2 2022 sales of £6.9 billion +19% at AER,
+13% at CER and Total EPS1
from continuing operations2
17.5p -42% AER,
-58% CER; Adjusted EPS
of 34.7p +23% AER, +6% CER
|
|
|
||
|
Highlights
|
||
|
|
||
|
Strong commercial execution across Specialty Medicines, Vaccines
and General Medicines drives double-digit sales growth
|
||
|
●
|
Total
sales: £6.9 billion +19% AER, +13% CER, excluding COVID-19
solutions +16% AER, +10% CER
|
|
|
|
-
|
Specialty
Medicines £2.7 billion +44% AER, +35% CER; HIV +14% AER, +7%
CER; Oncology +29% AER, +23% CER; Immuno-inflammation and other
specialty +32% AER +24% CER; COVID-19 solutions (Xevudy) sales £0.5
billion
|
|
|
-
|
Vaccines
£1.7 billion +9% AER, +3% CER; Shingrix £731 million >100%
AER, >100% CER
|
|
|
-
|
General
Medicines £2.5 billion +5% AER, +2% CER
|
|
|
|
|
|
Continued cost discipline supports delivery of improved adjusted
operating margin
|
||
|
●
|
Total
continuing operating margin 16%. Total EPS 20.8p -40% AER, -53%
CER; Total continuing EPS 17.5p -42% AER, -58% CER; primarily
reflecting increased contingent consideration charges driven by
exchange rates and adverse comparison
due to a credit for the revaluation of deferred tax in Q2
2021
|
|
|
●
|
Adjusted operating margin 29%. Adjusted operating profit growth
+22% AER, +7% CER. The impact on growth from lower margin COVID-19
solutions was approximately -16% AER, -14% CER
|
|
|
●
|
Adjusted EPS 34.7p +23% AER, +6% CER. The impact on growth from
lower margin COVID-19 solutions was approximately -20% AER,
-18% CER
|
|
|
●
|
Q2 2022 continuing cash generated from operations £1.6
billion. Free cash flow £0.3 billion
|
|
|
|
|
|
|
Strengthening late-stage R&D pipeline with positive data
read-outs and strategic business development
|
||
|
●
|
US FDA
approval for Priorix (MMR
vaccine); Vocabria plus
rilpivirine approval in Japan for HIV; Cervarix approval in China for
cancer-causing human papillomavirus
|
|
|
●
|
Positive
phase III high-level results for respiratory syncytial virus
vaccine candidate in older adults. Full results to be presented at
an upcoming scientific meeting with regulatory submissions
anticipated in H2 2022
|
|
|
●
|
Proposed
acquisition of Affinivax provides access to next-generation phase
II 24-valent pneumococcal vaccine candidate and innovative
MAPSTM technology
|
|
|
●
|
Promising
phase IIb interim data presented for bepirovirsen, a potential new
treatment for chronic hepatitis B. Phase III monotherapy trial is
anticipated to start in H1 2023
|
|
|
●
|
Completed acquisition of Sierra Oncology on 1 July 2022. Data from
momelotinib’s MOMENTUM phase III trial presented at 2022 ASCO
Annual Meeting; results showed a statistically significant and
clinically meaningful benefit on symptoms, splenic response, and
anaemia. NDA submitted to the US FDA
|
|
|
●
|
Phase
III data readouts expected in H2 2022: pentavalent (MenABCWY)
meningitis vaccine candidate, otilimab in rheumatoid arthritis,
Jemperli in 1L endometrial
cancer, and Blenrep in 3L
multiple myeloma
|
|
|
|
|
|
|
Improving revenues and margin support confidence in full-year
outlooks
|
||
|
●
|
Expect
2022 sales growth of between 6% to 8% (previously 5% to 7%) and
Adjusted operating profit growth of between 13% to 15% (previously
12% to 14%); both at CER. Adjusted EPS expected to grow by around
1% lower than operating profit. 2022 guidance excludes any
contribution from COVID-19 solutions
|
|
|
●
|
Dividend
of 16.25p/share (13p before Share Consolidation) declared for Q2
2022. No change to expected dividend of 61.25p/share (49p before
Share Consolidation) for FY 2022
|
|
|
|
|
|
|
Successful demerger and listing of Haleon on 18 July, creating a
new global leader in consumer health
|
||
|
●
|
Balance
sheet strengthened for GSK, through dividend of more than £7
billion from Haleon
|
|
|
|
||
|
Emma Walmsley, Chief Executive Officer, GSK:
“This
is GSK’s first set of results as a newly focused biopharma
company, and we have delivered an excellent second quarter
performance, with strong growth in Specialty Medicines, including
HIV, and a record quarter for our shingles vaccine
Shingrix. With this momentum in sales and operating profit
growth, we have raised our full-year guidance and are confident in
delivering the long-term growth outlooks we set out for
shareholders last year. We continue to strengthen our pipeline,
notably with very positive high-level results from our late-stage
RSV vaccine candidate, together with targeted business development
acquisitions of Sierra Oncology and Affinivax. These improvements
in R&D and operating performance, together with a strengthened
post-demerger balance sheet, create new capacity and flexibility
for GSK to invest in growth and innovation for patients and
shareholders.”
|
|
The Total results
are presented in summary on page 2 and under ‘Financial
performance’ on pages 9 and 21 and Adjusted results
reconciliations are presented on pages 17, 18, 29 and 30. Adjusted
results are a non-IFRS measure excluding discontinued operations
that may be considered in addition to, but not as a substitute for,
or superior to, information presented in accordance with IFRS.
Adjusted results are defined on page 37 and £% or AER% growth,
CER% growth, free cash flow and other non-IFRS measures are defined
on page 68, COVID-19 solutions are also defined on page 68. GSK
provides guidance on an Adjusted results basis only, for the
reasons set out on page 37. All expectations, guidance and targets
regarding future performance and dividend payments should be read
together with ‘Guidance, assumptions and cautionary
statements’ on pages 69 and 70.
|
|
(1)
|
Earnings per share
have been retrospectively adjusted to reflect the GSK Share
Consolidation on 18 July 2022, see details on page 53.
|
|
(2)
|
Consumer
Healthcare is now accounted for as a discontinued operation, see
details on page 20.
|
|
Q2 2022 results
|
|||||||||||
|
|
Q2 2022
|
|
Growth
|
|
H1 2022
|
|
Growth
|
||||
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Turnover
|
6,929
|
|
19
|
|
13
|
|
14,119
|
|
28
|
|
25
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
continuing operating profit*
|
1,081
|
|
(15)
|
|
(35)
|
|
3,374
|
|
36
|
|
26
|
|
Total
EPS
|
20.8p
|
|
(40)
|
|
(53)
|
|
65.7p
|
|
6
|
|
(1)
|
|
Total
continuing EPS
|
17.5p
|
|
(42)
|
|
(58)
|
|
54.8p
|
|
9
|
|
-
|
|
Total
discontinued EPS*
|
3.3p
|
|
(27)
|
|
(24)
|
|
10.9p
|
|
(4)
|
|
(8)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted
operating profit
|
2,008
|
|
22
|
|
7
|
|
3,951
|
|
33
|
|
26
|
|
Adjusted
EPS
|
34.7p
|
|
23
|
|
6
|
|
67.0p
|
|
36
|
|
27
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash
flow from operations attributable
to
continuing operations
|
1,584
|
|
17
|
|
|
|
3,936
|
|
>100
|
|
|
|
Free
cash flow
|
264
|
|
>100
|
|
|
|
1,741
|
|
>100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(*)
|
The
amounts presented in the table above for continuing operations and
Adjusted results excludes the Consumer Healthcare business
discontinued operation. The amounts presented for discontinued EPS
are for the Consumer Healthcare business. The presentation of
continuing and discontinued operations under IFRS 5 are set out on
page 50.
|
|
2022 guidance
|
|
With the momentum from the business performance to date,
GSK now expects 2022 sales to increase
between 6 to 8 per cent and Adjusted operating profit to increase
between 13 to 15 per cent, excluding any contributions from
COVID-19 solutions. Adjusted Earnings per share is expected to grow
around 1 per cent lower than Operating Profit. We have delivered
first half performance ahead of our full year guidance, slightly
better than expected, informed by strong business delivery and the
dynamics of prior year comparators.
Predominantly reflecting a more challenging H2 2021 sales
comparator as well as an expected increase in R&D spend, we
expect lower reported growth in the second half. Key external
factors that will influence the second half of 2022 include the
continued risk from COVID-19 dynamics and possible developments in
the current uncertain global economic environment.
Notwithstanding
uncertain economic conditions across many markets in which we
operate, we observe evidence of healthcare systems recovering and
continue to expect full year sales of Specialty Medicines to grow
approximately 10% CER and sales of General Medicines to show a
slight decrease, primarily reflecting the increased genericisation
of established Respiratory medicines. Vaccines sales are now
expected to grow at a low to mid-teens percentage at CER for the
year. Specifically for Shingrix, we continue to expect strong
double-digit growth and record annual sales in 2022, based on
strong demand in existing markets and continued geographical
expansion, however we do expect sales in the second half to be
slightly lower than in H1 2022 due to some channel stocking in the
first half in the US.
From Q2
2022, the Group presents the Haleon plc (Haleon) business as a
discontinued operation according to IFRS 5. Adjusted results
excludes profits from discontinued operations. Comparatives have
been restated to reflect adjusted results from continuing
operations, and guidance is provided on this basis.
Dividend
policies and expected pay-out ratios are unchanged for GSK, but the
dividends per share have been adjusted for the GSK Share
Consolidation completed on 18 July 2022. The future dividend
policies and guidance in relation to the expected dividend pay-out
in 2022 for GSK are provided on page 35.
2022 COVID-19 solutions expectations
The
majority of expected COVID-19 solutions sales for 2022 have been
achieved in the first half of this year. Based on known binding
agreements with governments, we expect that sales of COVID-19
solutions will be substantially lower in the second half. Compared
with 2021, sales will be at a reduced profit contribution due to
the increased proportion of lower margin Xevudy sales. Given the higher than
expected sales achieved in the year to date we now expect this to
reduce Adjusted Operating profit growth (including COVID-19
solutions in both years) by between 4% to 6%. We continue to
discuss future opportunities to support governments, healthcare
systems, and patients whereby our COVID-19 solutions can address
the emergence of any new COVID-19 variant of concern.
All
expectations, guidance and targets regarding future performance and
dividend payments should be read together with ‘Guidance,
assumptions and cautionary statements’ on page 69. If
exchange rates were to hold at the closing rates on 30 June 2022
($1.21/£1, €1.16/£1 and Yen 165/£1) for the
rest of 2022, the estimated positive impact on 2022 Sterling
turnover growth for GSK would be 5% and if exchange gains or losses
were recognised at the same level as in 2021, the estimated
positive impact on 2022 Sterling Adjusted Operating Profit growth
for GSK would be 9%.
|
|
Demerger of Consumer Healthcare
|
|
On 18
July 2022, GSK plc separated its Consumer Healthcare business from
the GSK Group to form Haleon, an independent listed company. The
separation was effected by way of a demerger of 80.1% of
GSK’s 68% holding in the Consumer Healthcare business to GSK
shareholders. Following the demerger, 54.5% of Haleon is held in
aggregate by GSK Shareholders, 6.0% is held by GSK (including
shares received by GSK’s consolidated ESOT trusts) and 7.5%
is held by certain Scottish limited partnerships (SLPs) set up to
provide a funding mechanism pursuant to which GSK will provide
additional funding for GSK’s UK Pension Schemes. The
aggregate ownership by GSK (including ownership by the ESOT trusts
and SLPs) after the demerger of 13.5% will be initially measured at
fair value with changes through profit or loss. Pfizer continues to
hold 32% of Haleon after the demerger.
The
gain on demerger distribution will be recognised in Q3 2022. The
asset distributed was the 54.5% ownership of the Consumer
Healthcare business. The assets distributed were reduced by
Consumer Healthcare transactions up to 18 July 2022 that included
pre-separation dividends declared and settled after the end of Q2
2022 and before 18 July 2022. Those dividends included: £10.4
billion (£7.1 billion attributable to GSK) of dividends funded
by Consumer Healthcare debt that was partially on-lent during Q1
2022 and dividends of £0.6 billion (£0.4 billion
attributable to GSK) from available cash balances. GSK’s
share of the pre-separation dividends funded by debt will result in
a reduction of net debt for GSK on demerger (GSK’s share of
the pre-separation dividends and loans are eliminated in the
consolidated financial statements until demerger).
|
|
Share consolidation
|
|
Following
completion of the Consumer Healthcare business demerger on 18 July
2022, GSK plc Ordinary shares were consolidated in order to
maintain share price comparability before and after demerger on 18
July 2022. Shareholders of GSK plc received 4 new Ordinary shares
for every 5 existing Ordinary shares. Earnings per share, diluted
earnings per share, adjusted earnings per share and dividends per
share have been retrospectively adjusted to reflect the Share
Consolidation in all the periods presented.
|
|
Results presentation
|
|
A
conference call and webcast for investors and analysts of the
half-year and Q2 2022 results will be hosted by Emma Walmsley, CEO,
at 12pm BST on 27 July 2022. Presentation materials will be
published on www.gsk.com prior to the webcast and a transcript of
the webcast will be published subsequently.
Information
available on GSK’s website does not form part of, and is not
incorporated by reference into, this Results
Announcement.
|
|
The
amounts below are from continuing operations unless otherwise
specified.
|
|
Operating performance – Q2 2022
|
|
Turnover
|
Q2 2022
|
||||
|
|
|
|
|
|
|
|
|
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
Specialty
Medicines
|
2,704
|
|
44
|
|
35
|
|
Vaccines
|
1,715
|
|
9
|
|
3
|
|
General
Medicines
|
2,510
|
|
5
|
|
2
|
|
|
|
|
|
|
|
|
Commercial
Operations
|
6,929
|
|
19
|
|
13
|
|
|
|
|
|
|
|
|
Total turnover in the quarter was £6,929 million, up 19% at
AER, 13% at CER, reflecting strong performance in all three product
groups. Commercial Operations turnover excluding pandemic sales
grew 16% at AER, 10% at CER.
Specialty Medicines
Specialty
Medicines sales in the quarter were £2,704 million, up 44% at
AER, 35% at CER, driven by consistent growth in all therapy areas.
Specialty Medicines excluding sales of Xevudy were £2,238 million up 20%
at AER, 13% at CER. In the quarter, HIV sales were £1,404
million with growth up 14% at AER, 7% at CER. Oncology sales in the
quarter were £154 million, up 29% at AER, 23% at CER.
Immuno-inflammation, Respiratory and Other sales were £680
million up 32% at AER, 24% at CER.
Vaccines
Vaccine sales were £1,715 million, up 9% at AER, 3% at CER in
total and up 31% at AER, 24% at CER excluding unrepeated 2021
pandemic adjuvant sales. The performance reflected a favourable
comparator to Q2 2021, which was impacted by COVID-19 related
disruptions in several markets, and the strong commercial execution
of Shingrix. The growth, however, was partially offset by
lower paediatric and adolescent vaccine sales that reflected the
normalisation of the US Center for Disease Control (CDC) purchasing
patterns.
General Medicines
General
Medicines sales in the quarter were £2,510 million, up 5% at
AER, 2% at CER, with the impact of generic competition in US,
Europe, and Japan offset by Trelegy growth in respiratory and the
post-pandemic rebound of the antibiotic market since Q3 2021 in
Other General Medicines. General medicines includes £33
million (Q2 2021: £34 million) of turnover between GSK and
Haleon recorded in continuing operations with an offsetting amount
recorded in discontinuing operations.
Operating profit
Total
operating profit was £1,081 million compared with £1,275
million in Q2 2021. The reduction primarily reflected the higher
re-measurement charges for contingent consideration liabilities,
partly offset by increased profits on turnover growth of 13% at CER
and increased milestone income.
Adjusted
operating profit was £2,008 million, 22% higher than Q2 2021
at AER and 7% at CER on a turnover increase of 13% at CER. The
Adjusted operating margin of 29.0% was 0.9% percentage points
higher at AER and 1.5% percentage points lower at CER than in Q2
2021. This primarily reflected higher COVID-19 solutions sales at
low margin, which reduced Adjusted Operating profit growth by
approximately 16% at AER, 14% at CER and reduced the Adjusted
operating margin by approximately 4.5 percentage points at AER and
4.4 percentage points at CER. This was offset by leverage from
strong sales growth across all product groups, beneficial mix, and
higher royalty income.
Earnings per share (adjusted to reflect the Share Consolidation on
18 July 2022)
Total
EPS was 17.5p compared with 30.3p in Q2 2021. The reduction
primarily reflects increased charges for remeasurement of
contingent consideration liabilities as well as an unfavourable
comparison due to a credit of £325 million to Taxation in Q2
2021. Adjusted EPS was 34.7p compared with 28.2p in Q2 2021, up 23%
at AER, 6% at CER, on a 7% CER increase in Adjusted operating
profit. This primarily reflected higher COVID-19 solutions sales at
low margin with the reduction to growth from COVID-19 solutions
being approximately 20% at AER, 18% at CER. Leverage from growth in
sales of Specialty Medicines, beneficial mix, higher royalty income
and a lower effective tax rate was partly offset by higher supply
chain, freight and distribution costs and higher non-controlling
interests.
Cash flow
Cash
generated from operations attributable to continuing operations for
the quarter was £1,584 million (Q2 2021: £1,357 million).
The increase primarily reflected the increase in operating profit
including beneficial exchange and favourable timing of collections
partly offset by increased contingent consideration payments,
adverse timing of profit share payments for Xevudy sales, a higher seasonal
increase in inventory and adverse timing of returns and
rebates.
|
|
Operating performance – H1 2022
|
|
Turnover
|
H1 2022
|
||||
|
|
|
|
|
|
|
|
|
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
Specialty
Medicines
|
5,839
|
|
69
|
|
63
|
|
Vaccines
|
3,384
|
|
21
|
|
17
|
|
General
Medicines
|
4,896
|
|
3
|
|
2
|
|
|
|
|
|
|
|
|
Commercial
Operations
|
14,119
|
|
28
|
|
25
|
|
|
|
|
|
|
|
|
Total
turnover in the half year was £14,119 million, up 28% at AER,
25% at CER, reflecting strong performance in all three product
groups. Commercial Operations turnover, excluding pandemic sales,
grew 15% at AER, 12% at CER.
Specialty Medicines
Specialty Medicines sales were £5,839 million, up 69% at AER,
63% at CER, driven by consistent growth in all therapy areas.
Specialty Medicines, excluding sales of Xevudy, were £4,066 million up 18% at AER, 14% at
CER. HIV sales were £2,585 million with growth of 14% at
AER,10% at CER. Oncology sales were £281 million, up 23% at
AER, 19% at CER. Immuno-inflammation, Respiratory and Other sales
were £1,200 million up 26% at AER, 21% at
CER.
Vaccines
Vaccines
turnover was £3,384 million, up 21% at AER, 17% at CER.
Excluding unrepeated 2021 pandemic adjuvant sales, vaccine sales
increased 33% at AER, 30% at CER, reflecting a favourable
comparator to H1 2021, which was adversely impacted by COVID-19 related disruptions in several markets,
and the strong commercial execution of Shingrix, particularly in the US and
Europe.
General Medicines
General
Medicines sales in the half year were £4,896 million, up 3% at
AER, 2% at CER, with the impact of generic competition in US,
Europe and Japan offset by Trelegy growth in respiratory and the
post-pandemic rebound of the antibiotic market since H2 2021 in
Other General Medicines. General medicines includes £76
million (H1 2021: £79 million) of turnover between GSK and
Haleon recorded in continuing operations with an offsetting amount
recorded in discontinued operations.
Operating profit
Total
operating profit was £3,374 million compared with £2,485
million in H1 2021. This included the £0.9 billion upfront
income received from the settlement with Gilead Sciences, Inc.
(Gilead) and increased profits on turnover growth of 25% at CER,
partly offset by higher re-measurement charges for contingent
consideration liabilities.
Adjusted
operating profit was £3,951 million, 33% higher at AER and 26%
at CER than H1 2021 on a turnover increase of 25% at CER. The
Adjusted operating margin of 28.0% was 1.0 percentage points higher
at AER and stable at CER compared to H1 2021. This primarily
reflected the impact from low margin COVID-19 solutions sales
(Xevudy), which reduced
Adjusted Operating profit growth by approximately 2% at AER, 1% at
CER and reduced the Adjusted operating margin by approximately 3.3
percentage points at AER and at CER. This was offset by operating
leverage from strong sales growth, beneficial mix, and higher
royalty income.
Earnings per share (adjusted to reflect the Share Consolidation on
18 July 2022)
Total
EPS from continuing operations was 54.8p compared with 50.3p in H1
2021. This primarily reflected the £0.9 billion upfront income
received from the settlement with Gilead and increased profits on
turnover growth of 25% at CER, partly offset by higher
re-measurement charges for contingent consideration liabilities as
well as an unfavourable comparison due to a credit of £325
million to Taxation in Q2 2021. Adjusted EPS was 67.0p compared
with 49.3p in H1 2021, up 36% at AER, 27% at CER, on a 26% CER
increase in Adjusted operating profit. This included higher
COVID-19 solutions sales at low margin with the reduction to growth
from COVID-19 solutions being approximately 2% at AER, 2% at CER.
Leverage from growth in sales of Specialty Medicines, beneficial
mix, higher royalty income and a lower effective tax rate was
partly offset by higher supply chain, freight and distribution
costs, lower associate income and higher non-controlling
interests.
Cash flow
Cash generated from operations attributable to continuing
operations for H1 was £3,936 million (H1 2021: £1,759
million). The increase primarily reflected a significant increase
in operating profit including the upfront income from the
settlement with Gilead, favourable exchange and favourable timing
of collections and profit share payments for Xevudy sales, partly offset by increased contingent
consideration payments reflecting the Gilead settlement and a
higher seasonal increase in inventory.
|
|
Q2 2022 pipeline
highlights
(since 27 April 2022)
|
|
|
Medicine/vaccine
|
Trial (indication, presentation)
|
Event
|
|
Regulatory approvals or other regulatory action
|
Nucala
|
Severe eosinophilic asthma,
40mg prefilled syringe for
6-11 year olds
|
Regulatory approval (EU)
|
|
Vocabria/Rekambys (cabotegravir/rilpivirine)
|
HIV
|
Regulatory approval (Japan)
|
|
|
Priorix
|
Measles-mumps-rubella
|
Regulatory approval (US)
|
|
|
Cervarix
|
Human papillomavirus, two-dose vaccine schedule for girls aged 9-14
years
|
Regulatory approval (China)
|
|
|
Regulatory submissions or acceptances
|
momelotinib
|
MOMENTUM (myelofibrosis with anaemia)
|
Regulatory submission (US)
|
|
Shingrix
|
Shingles, at-risk adults aged 18+ years
|
Regulatory acceptance (Japan)
|
|
|
Phase III data readouts or other significant events
|
bepirovirsen
|
B-Clear (hepatitis B virus)
|
Positive phase IIb interim data
|
|
RSV older adult vaccine candidate
|
RSV, older adults aged 60+ years
|
Positive phase III data
|
|
|
COVID-19 vaccine candidate (SK Bioscience)
|
COVID-19
|
Positive phase III data
|
|
Anticipated news flow
|
|
Timing
|
Medicine/vaccine
|
Trial (indication, presentation)
|
Event
|
|
H2 2022
|
otilimab
|
contRAst programme (rheumatoid arthritis)
|
Phase III data readout
|
|
Blenrep
|
DREAMM-3 (3L+ multiple myeloma)
|
Phase III data readout
|
|
|
Blenrep
|
DREAMM-3 (3L+ multiple myeloma)
|
Regulatory submission (US, EU)
|
|
|
Jemperli
|
RUBY (1L endometrial cancer)
|
Phase III data readout (interim analysis)
|
|
|
Jemperli
|
PERLA (non-small cell lung cancer)
|
Phase II data readout
|
|
|
momelotinib
|
MOMENTUM (myelofibrosis with anaemia)
|
Regulatory submission (EU)
|
|
|
gepotidacin
|
EAGLE (uncomplicated urinary tract infection)
|
Phase III data readout (interim analysis)
|
|
|
MenABCWY (gen 1) vaccine candidate
|
Meningitis ABCWY
|
Phase III data readout
|
|
|
RSV older adult vaccine candidate
|
RSV, older adults aged 60+ years
|
Regulatory submission (US)
|
|
|
Menveo
|
Invasive meningococcal disease, liquid formulation
|
Regulatory decision (US)
|
|
|
Rotarix
|
Rotavirus, liquid formulation
|
Regulatory decision (US)
|
|
|
COVID-19 vaccine candidate (SK Bioscience)
|
COVID-19
|
Regulatory submission (EU)
|
|
|
COVID-19 vaccine candidate (SK Bioscience)
|
COVID-19
|
Regulatory decision (EU)
|
|
|
COVID-19 vaccine candidate (Sanofi)
|
COVID-19
|
Regulatory submission (US)
|
|
|
COVID-19 vaccine candidate (Sanofi)
|
COVID-19
|
Regulatory decision (US)
|
|
|
H1 2023
|
bepirovirsen
|
B-Together (hepatitis B virus)
|
Phase IIb data readout
|
|
daprodustat
|
ASCEND (anaemia of chronic kidney disease)
|
Regulatory decision (US, EU)
|
|
|
momelotinib
|
MOMENTUM (myelofibrosis with anaemia)
|
Regulatory decision (US)
|
|
|
Blenrep
|
DREAMM-8 (2L+ multiple myeloma)
|
Phase III data readout
|
|
|
Blenrep
|
DREAMM-7 (2L+ multiple myeloma)
|
Phase III data readout
|
|
|
Jemperli
|
RUBY (1L endometrial cancer)
|
Regulatory submission (US, EU)
|
|
|
letetresgene-autoleucel
|
IGNYTE-ESO (2L+ synovial sarcoma)
|
Phase II data readout
|
|
|
RSV older adult vaccine candidate
|
RSV, older adults aged 60+ years
|
Regulatory decision (US)
|
|
|
MenABCWY (gen 1) vaccine candidate
|
Meningitis ABCWY
|
Regulatory submission (US)
|
|
|
Malaria (fractional dose) vaccine
|
Malaria
|
Phase II data readout
|
|
|
Covifenz (Medicago)
|
COVID-19
|
Regulatory submission (US)
|
|
|
Covifenz (Medicago)
|
COVID-19
|
Regulatory decision (US)
|
|
|
H2 2023
|
otilimab
|
contRAst programme (rheumatoid arthritis)
|
Regulatory submission (US, EU)
|
|
linerixibat
|
GLISTEN (cholestatic pruritus in primary biliary
cholangitis)
|
Phase III data readout
|
|
|
Blenrep
|
DREAMM-3 (3L+ multiple myeloma)
|
Regulatory decision (US, EU)
|
|
|
Blenrep
|
DREAMM-8 (2L+ multiple myeloma)
|
Regulatory submission (US, EU)
|
|
|
Blenrep
|
DREAMM-7 (2L+ multiple myeloma)
|
Regulatory submission (US, EU)
|
|
|
Jemperli
|
RUBY (1L endometrial cancer)
|
Regulatory decision (US)
|
|
|
momelotinib
|
MOMENTUM (myelofibrosis with anaemia)
|
Regulatory decision (EU)
|
|
|
Zejula
|
FIRST (1L maintenance ovarian cancer)
|
Phase III data readout
|
|
|
gepotidacin
|
EAGLE (uncomplicated urinary tract infection)
|
Regulatory submission (US, EU)
|
|
Refer
to pages 59 to 66 for further details on several key medicines and
vaccines in development by therapy area.
|
|
Contents
|
Page
|
|
|
|
|
Q2 2022
R&D pipeline highlights
|
2
|
|
Financial
performance – Q2 2022
|
9
|
|
Financial
performance – H1 2022
|
21
|
|
Cash
generation
|
33
|
|
Returns
to shareholders
|
35
|
|
Total
and Adjusted results
|
37
|
|
Income
statement – three months and six months ended 30 June
2022
|
39
|
|
Statement
of comprehensive income – three months and six months ended
30 June 2022
|
40
|
|
Balance
sheet
|
44
|
|
Statement
of changes in equity
|
45
|
|
Cash
flow statement – six months ended 30 June 2022
|
46
|
|
Segment
information
|
47
|
|
Legal
matters
|
49
|
|
Additional
information
|
50
|
|
Reconciliation
of cash flow to movements in net debt
|
58
|
|
Net
debt analysis
|
58
|
|
Free
cash flow reconciliation
|
58
|
|
R&D
commentary
|
59
|
|
Principal
risks and uncertainties
|
67
|
|
Reporting
definitions
|
68
|
|
Guidance,
assumptions and cautionary statements
|
69
|
|
Directors’
responsibility statement
|
71
|
|
Independent
review report
|
72
|
|
Contacts
|
|
GSK plc (LSE/NYSE:GSK) is a global biopharma company with a purpose
to unite science, technology, and talent to get ahead of disease
together. Find out more at www.gsk.com.
|
|
GSK enquiries:
|
|
|
|
|
Media
|
Tim
Foley
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Kathleen
Quinn
|
+1 202
603 5003
|
(Washington)
|
|
|
|
|
|
|
Investor
Relations
|
Nick
Stone
|
+44 (0)
7717 618834
|
(London)
|
|
|
James
Dodwell
|
+44 (0)
7881 269066
|
(London)
|
|
|
Mick
Readey
|
+44 (0)
7990 339653
|
(London)
|
|
|
Joshua
Williams
|
+44 (0)
7385 415719
|
(London)
|
|
|
Jeff
McLaughlin
|
+1 215
589 3774
|
(Philadelphia)
|
|
|
|
|
|
|
Registered in England & Wales:
No. 3888792
|
|||
|
|
|||
|
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
|
|||
|
Financial performance
– Q2 2022
|
|
Total results
|
|
The
Total results for the Group are set out below.
|
|
|
Q2 2022
£m
|
|
Q2
2021
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
|
|
Continuing Operations
Turnover
|
6,929
|
|
5,838
|
|
19
|
|
13
|
|
|
|
|
|
|
|
|
|
|
Cost of
sales
|
(2,176)
|
|
(1,708)
|
|
27
|
|
28
|
|
|
|
|
|
|
|
|
|
|
Gross
profit
|
4,753
|
|
4,130
|
|
15
|
|
7
|
|
|
|
|
|
|
|
|
|
|
Selling,
general and administration
|
(2,066)
|
|
(1,689)
|
|
22
|
|
19
|
|
Research
and development
|
(1,242)
|
|
(1,167)
|
|
6
|
|
2
|
|
Royalty income
|
159
|
|
77
|
|
>100
|
|
>100
|
|
Other
operating income/(expense)
|
(523)
|
|
(76)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating
profit
|
1,081
|
|
1,275
|
|
(15)
|
|
(35)
|
|
|
|
|
|
|
|
|
|
|
Finance
income
|
21
|
|
4
|
|
|
|
|
|
Finance
expense
|
(204)
|
|
(189)
|
|
|
|
|
|
Loss on
disposal of interest in associates
|
-
|
|
(36)
|
|
|
|
|
|
Share
of after tax (losses)/profits of associates and
joint
ventures
|
(2)
|
|
16
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit before taxation
|
896
|
|
1,070
|
|
(16)
|
|
(40)
|
|
|
|
|
|
|
|
|
|
|
Taxation
|
(150)
|
|
201
|
|
|
|
|
|
Tax rate %
|
16.7%
|
|
(18.8)%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit after taxation from continuing operations
|
746
|
|
1,271
|
|
(41)
|
|
(58)
|
|
|
|
|
|
|
|
|
|
|
Profit
after taxation from discontinued operations
|
229
|
|
267
|
|
(14)
|
|
(16)
|
|
|
|
|
|
|
|
|
|
|
Profit after taxation for the period
|
975
|
|
1,538
|
|
(37)
|
|
(51)
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to non-controlling interest from
continuing
operations
|
40
|
|
57
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to shareholders from continuing
operations
|
706
|
|
1,214
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to non-controlling interest from
discontinued
operations
|
97
|
|
86
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to shareholders from discontinued
operations
|
132
|
|
181
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
975
|
|
1,538
|
|
(37)
|
|
(51)
|
|
|
|
|
|
|
|
|
|
|
Total
profit attributable to non-controlling interest
|
137
|
|
143
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
profit attributable to shareholders
|
838
|
|
1,395
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
975
|
|
1,538
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings
per share from continuing operations
|
17.5p
|
|
30.3p
|
|
(42)
|
|
(58)
|
|
|
|
|
|
|
|
|
|
|
Earnings
per share from discontinued operations
|
3.3p
|
|
4.5p
|
|
(27)
|
|
(24)
|
|
|
|
|
|
|
|
|
|
|
Total earnings per share
|
20.8p
|
|
34.8p
|
|
(40)
|
|
(53)
|
|
|
|
|
|
|
|
|
|
|
Adjusted results
|
|
The
Adjusted results for the Group are set out below. Adjusted results
are from continuing operations and exclude the Consumer Healthcare
business (see details in page 52). Reconciliations between Total
results and Adjusted results for Q2 2022 and Q2 2021 are set out on
pages 17 and 18.
|
|
|
Q2 2022
£m
|
|
%
of
turnover
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
|
|
Turnover
|
6,929
|
|
100
|
|
19
|
|
13
|
|
|
|
|
|
|
|
|
|
|
Cost of
sales
|
(1,970)
|
|
(28.4)
|
|
29
|
|
31
|
|
Selling,
general and administration
|
(1,955)
|
|
(28.2)
|
|
19
|
|
16
|
|
Research
and development
|
(1,155)
|
|
(16.7)
|
|
4
|
|
(1)
|
|
Royalty
income
|
159
|
|
2.3
|
|
>100
|
|
100
|
|
|
|
|
|
|
|
|
|
|
Adjusted
operating profit
|
2,008
|
|
29.0
|
|
22
|
|
7
|
|
|
|
|
|
|
|
|
|
|
Adjusted
profit before tax
|
1,825
|
|
|
|
24
|
|
7
|
|
Adjusted
profit after tax
|
1,548
|
|
|
|
26
|
|
9
|
|
Adjusted
profit attributable to shareholders
|
1,398
|
|
|
|
24
|
|
7
|
|
|
|
|
|
|
|
|
|
|
Adjusted
earnings per share
|
34.7p
|
|
|
|
23
|
|
6
|
|
|
|
|
|
|
|
|
|
|
Operating profit by segment
|
|
|
Q2 2022
£m
|
|
%
of
turnover
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
|
|
Commercial
Operations
|
3,304
|
|
47.7
|
|
15
|
|
6
|
|
Research
and Development
|
(1,152)
|
|
|
|
3
|
|
(2)
|
|
|
|
|
|
|
|
|
|
|
Segment
profit
|
2,152
|
|
31.1
|
|
23
|
|
10
|
|
Corporate
& other unallocated costs
|
(144)
|
|
|
|
31
|
|
66
|
|
|
|
|
|
|
|
|
|
|
Adjusted
operating profit
|
2,008
|
|
29.0
|
|
22
|
|
7
|
|
|
|
|
|
|
|
|
|
|
Turnover
|
|
Commercial
Operations
|
|
|
Q2 2022
|
||||
|
|
|
|
|
|
|
|
|
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
HIV
|
1,404
|
|
14
|
|
7
|
|
Oncology
|
154
|
|
29
|
|
23
|
|
Immuno-inflammation,
respiratory and other
|
680
|
|
32
|
|
24
|
|
|
|
|
|
|
|
|
|
2,238
|
|
20
|
|
13
|
|
Pandemic
|
466
|
|
>100
|
|
>100
|
|
|
|
|
|
|
|
|
Specialty Medicines
|
2,704
|
|
44
|
|
35
|
|
|
|
|
|
|
|
|
Meningitis
|
235
|
|
4
|
|
-
|
|
Influenza
|
32
|
|
(3)
|
|
(9)
|
|
Shingles
|
731
|
|
>100
|
|
>100
|
|
Established
Vaccines
|
717
|
|
(5)
|
|
(9)
|
|
|
|
|
|
|
|
|
|
1,715
|
|
31
|
|
24
|
|
Pandemic
Vaccines
|
-
|
|
(100)
|
|
(100)
|
|
|
|
|
|
|
|
|
Vaccines
|
1,715
|
|
9
|
|
3
|
|
|
|
|
|
|
|
|
Respiratory
|
1,649
|
|
9
|
|
4
|
|
Other
General Medicines
|
861
|
|
(1)
|
|
(2)
|
|
|
|
|
|
|
|
|
General Medicines
|
2,510
|
|
5
|
|
2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Commercial Operations
|
6,929
|
|
19
|
|
13
|
|
|
|
|
|
|
|
|
US
|
3,317
|
|
19
|
|
7
|
|
Europe
|
1,549
|
|
23
|
|
25
|
|
International
|
2,063
|
|
15
|
|
14
|
|
|
|
|
|
|
|
|
Commercial Operations by region
|
6,929
|
|
19
|
|
13
|
|
|
|
|
|
|
|
|
Total
turnover in the quarter was £6,929 million, up 19% at AER, 13%
at CER, reflecting strong performance in all three product groups.
Commercial Operations turnover, excluding pandemic sales, grew 16%
at AER, 10% at CER. Specialty Medicines included £466 million
sales of Xevudy, which
contributed 24 percentage points of growth in the quarter at AER,
22 percentage points at CER. Vaccines growth reflected strong
Shingrix performance
assisted by demand recovery and channel inventory build in the US,
partially offset by pandemic adjuvant
sales in Q2 2021. General Medicines reflected the recovery
of the antibiotics market and in particular the strong performance
of Trelegy in respiratory
in all regions.
Specialty Medicines
Specialty
Medicines sales in the quarter were £2,704 million, up 44% at
AER, 35% at CER, driven by consistent growth in all therapy areas.
Specialty Medicines excluding sales of Xevudy were £2,238 million up 20%
at AER, 13% at CER.
HIV
HIV
sales were £1,404 million with growth up 14% at AER, 7% at CER
in the quarter. The performance benefitted from strong patient
demand for the new HIV medicines (Dovato, Cabenuva, Juluca, Rukobia, and Apretude) and a favourable US pricing
mix, however, this was partially offset by the unfavourable phasing
of Tivicay tenders. US
pricing contributed 7% at AER, 4% at CER, with tenders reducing
growth by 5% at AER, 6% at CER in the quarter.
New HIV
medicines delivered for the first-time quarterly sales of over half
a billion pounds at £571 million, up 73% at AER, 63% at CER,
representing 41% of the total HIV portfolio compared to 27% in the
same quarter last year. Sales of the oral two drug regimens
Dovato and Juluca were £320 million and
£152 million, respectively, with a combined growth of 49% at
AER, 41% at CER. Cabenuva,
the first long-acting injectable for the treatment of human
immunodeficiency virus type-1 (HIV-1) infection, recorded sales of
£72 million. Apretude,
the first long-acting prevention injectable for the prevention of
HIV-1, delivered sales of £8 million.
Oncology
Oncology
sales in the quarter were £154 million, up 29% at AER, 23% at
CER. Zejula sales were
£120 million, up 22% at AER, 16% at CER, and Blenrep, sales of £30 million up
43% at AER, 33% at CER; the performance reflected growth in
recently launched markets.
Immuno-inflammation,
Respiratory and Other
Immuno-inflammation,
Respiratory and Other sales were £680 million up 32% at AER,
24% at CER. Benlysta sales
were £297 million, up
39% at AER, 29% at CER reflecting strong underlying demand in US
and worldwide. Nucala
sales were £367
million, up 26% at AER, 19% at CER including US sales of £236
million up 30% at AER, 18% at CER on continued strong demand and
launch of additional indications.
Pandemic
In the
period, sales of Xevudy
were £466 million, with the overwhelming majority of sales
achieved in Europe £123 million and International £320
million. In the US, the government contract was completed in Q1
2022.
Vaccines
Vaccine
sales were £1,715 million, up 9% at AER, 3% at CER in total
and up 31% at AER, 24% at CER
excluding unrepeated 2021 pandemic adjuvant sales. The performance
reflected a favourable comparator to Q2 2021, which was adversely
impacted by COVID-19 related
disruptions in several markets, and the strong commercial execution
of Shingrix,
particularly in the US and Europe. The
growth, however, was partially offset by lower paediatric
and adolescent vaccine sales that reflected the normalisation of the US CDC purchasing
patterns.
Shingles
Shingrix sales more than doubled to £731 million
primarily due to demand recovery, strong commercial execution aimed
at shifting the shingles vaccination season forward, and
earlier-than- expected channel inventory build in the US, and
higher demand in Germany. All regions grew significantly in Q2
2022, with 40% of the growth contributed from outside of the US.
Shingrix is now available
in 23 countries including four new launches in the last
quarter.
Established
Vaccines
Established Vaccines decreased 5% at AER, 9% at CER to £717
million reflecting unfavourable CDC
purchasing patterns and competitive pressure for
Infanrix/Pediarix
in the US, lower International sales of Cervarix, MMR/V vaccines and Synflorix, and the negative impact of a CDC stockpile
borrow for Rotarix, partially offset by hepatitis vaccines growth in
the US and Europe.
General Medicines
General
Medicines sales in the quarter were £2,510 million, up 5% at
AER, 2% at CER, with the adverse impact of generic competition in
US, Europe, and Japan offset by Trelegy growth in respiratory and the
post-pandemic rebound of the antibiotic market since Q3 2021 in
Other General Medicines.
Respiratory
Respiratory
sales were £1,649 million, up 9% at AER, 4% at CER. The
performance was driven by Trelegy sales of £467 million, up
60% at AER, 50% at CER with strong growth in all regions and some
benefit of prior period Returns and Rebates (RAR) adjustments in
the US. Advair/Seretide
sales of £262 million continue to be adversely impacted by
generic competition, decreasing 24% at AER, 27% at CER. Overall,
there was no significant impact of prior period RAR adjustments in
the quarter.
Other General
Medicines
Other
General Medicines sales were £861 million, down 1% at AER, 2%
at CER. Augmentin sales
were £130 million, up 43% at AER, 45% at CER reflecting the
post-pandemic rebound of the antibiotic since Q3 2021. This offsets
the ongoing adverse impact of generic competition and approximately
two percentage points impact from the divestment of cephalosporin
products in Q4 2021.
General medicines includes £33 million (Q2 2021: £34
million) of turnover between GSK and Haleon recorded in continuing
operations with an offsetting amount recorded in discontinuing
operations.
By
Region
US
In the
US, sales were £3,317 million, up 19% at AER, 7% at CER. There
were £23 million sales of Xevudy in the quarter following
completion of the government contract in Q1 2022.
In
Specialty Medicines, HIV sales of £894 million were up 25% at
AER, 13% at CER. New HIV medicines delivered sales of £377
million up 75% at AER, 59% at CER driven by strong patient demand
for Dovato, Cabenuva,
Juluca, Apretude, and Rukobia as well as favourable pricing
mix. Nucala and
Benlysta both continued to
grow double digits reflecting ongoing strong demand. Oncology sales
increased 22% at AER, 10% at CER, despite diagnosis and treatment
rates continuing to be adversely impacted by the
pandemic.
Vaccine
sales were £897 million, up 13% at AER, 2% at CER. Vaccine
sales excluding the impact of COVID-19 vaccine adjuvant sales in Q2
2021 grew 53% at AER, 38% at CER. Growth was driven by Shingrix reflecting demand recovery,
strong commercial execution, and channel inventory build. Growth
was reduced by lower paediatric and adolescent vaccines sales
reflecting the normalisation of CDC purchasing
patterns.
General
Medicines sales were £933 million, up 11% at AER, stable at
CER, driven by strong Trelegy performance, up 74% at AER, 58%
at CER on growth of the single inhaler triple therapy market and
demand.
Europe
In
Europe, sales were £1,549 million, up 23% at AER, 25% at CER,
including Xevudy sales of
£123 million contributing ten percentage points of growth at
AER and CER.
In
Specialty Medicines, HIV sales were £336 million, up 15% at
AER, 17% at CER. The performance predominantly reflected strong
patient demand for Dovato
with sales of £118 million during the period. Benlysta in immunology, Nucala in respiratory, and several
Oncology medicines also delivered strong double-digit growth in the
quarter.
Vaccine
sales were £414 million, up 39% at AER, 42% at CER.
Shingrix sales of £151
million, >100% at AER and CER, drove the growth particularly in
Germany, which benefitted from strong demand.
General
Medicines sales were £522 million, decreasing 3% at AER, 2% at
CER, with ongoing generic competitive pressures adversely impacting
Seretide in respiratory;
the performance was partly offset by strong demand for Trelegy. Augmentin grew due to the post-pandemic
rebound of the antibiotic market since Q3 2021.
International
International
sales were £2,063 million, up 15% at AER, 14% at CER,
including Xevudy sales of
£320 million contributing 15 percentage points of
growth.
In
Specialty Medicines, HIV sales were £174 million, decreasing
23% at AER, 27% at CER driven by tender phasing. The performance,
however, was partially offset by strong Dovato growth. Combined Tivicay and Triumeq sales were £130 million,
declining 35% at AER, 40% at CER. Nucala in respiratory and Benlysta in immunology both continued
to grow strongly reflecting growth in the biologics market in Japan
and inclusion on China’s National Reimbursement Drug
List.
Vaccine
sales were £404 million, decreasing 15% at AER, 18% at CER.
Vaccine sales excluding the impact of COVID-19 vaccine adjuvant
sales in Q2 2021 decreased 6% at AER, 8% at CER, primarily
reflecting phasing of public tenders.
General
Medicines sales were £1,055 million up 6% at AER, 5% at CER.
Respiratory sales of £455 million were up 8% at AER, 7% at CER
reflecting strong growth of Trelegy, particularly in Japan, China,
and Canada. This performance offset the impact of generic
competition and lower allergy season in Japan. Other General
Medicines sales increased 4% at AER and at CER to £600
million, reflecting the growth of Augmentin following the post-pandemic
rebound of the antibiotic market since Q3 2022.
|
|
Operating performance
|
|
Cost of sales
Total
cost of sales as a percentage of turnover was 31.4%, and increased
2.1 percentage points higher at AER and 4.0 percentage points
higher in CER terms than Q2 2021. Adjusted cost of sales as a
percentage of turnover was 28.4%, up 2.4 percentage points AER and
4.1 at CER compared with Q2 2021. This primarily reflected higher
sales of lower margin COVID-19 solutions (Xevudy) compared to Q2 2021, which
included £258 million of pandemic adjuvant sales, increasing
cost of sales margin by 4.7 percentage points at AER and at CER as
well as the impact of increased commodity prices and freight costs.
This was partially offset by a favourable mix primarily from
increased sales of Shingrix
in the US and Europe and increased sales of HIV medicines in the
US.
Selling, general and administration
Total
SG&A costs as a percentage of turnover were 29.8%, 0.9
percentage points higher at AER and 1.7 percentage points higher at
CER than in Q2 2021 primarily reflected increased investment in the
launch of innovative vaccines and medicines.
Adjusted
SG&A costs as a percentage of turnover were 28.2%, stable at
AER, 0.7 percentage points higher at CER. Adjusted SG&A costs
increased 19% at AER, 16% at CER which primarily reflected an
increased level of launch investment in Specialty Medicines
particularly HIV and Vaccines including Shingrix to drive post-pandemic
recovery demand and support market expansion. The growth in
Adjusted SG&A also reflected increased freight and distribution
costs and exchange losses on the Vir Biotechnology, Inc.
collaboration profit share. This growth was partly offset by the
continuing benefit of restructuring and tight control of ongoing
costs.
Research and development
Group
R&D expenditure from continuing operations was £1,242
million (17.9% of turnover), up 6% at AER and 2% at CER. Adjusted
R&D expenditure increased in the quarter by 4% at AER, broadly
stable at CER, to £1,155 million. This reflected the continued
efficiencies delivered from the One R&D restructuring
programme, the completion of several late-stage clinical
development programmes, and a favourable comparator to Q2 2021,
which saw increased levels of R&D investment due to COVID-19
pandemic solutions.
In the
quarter, GSK increased investment across Vaccine clinical
development, including its mRNA technology platforms, continued
investment in the late-stage portfolio, and accelerated several
early discovery programmes; these investments partly offset the
decreases above. In addition, the level of investment increased in
Specialty Medicines to support the early-stage HIV portfolio and in
respiratory, the phase III programme for depemokimab, a potential
new medicine to treat severe asthma. The expenditure in the quarter
does not reflect the impact of the acquisition of Sierra Oncology,
Inc. which completed on 1 July 2022.
Royalty income
Royalty
income was £159 million (Q2 2021: £77 million), up
>100% at AER, >100% at CER, primarily reflecting royalty
income from Gilead under the settlement and licensing agreement
with Gilead and higher sales of Gardasil.
Other operating income/(expense)
Net
other operating expense was £523 million (Q2 2021: £76
million) primarily reflecting accounting charges of £699
million (Q2 2021: £101 million) arising from the
re-measurement of contingent consideration liabilities and the
liabilities for the Pfizer, Inc. (Pfizer) put option and Pfizer and
Shionogi & Co., Ltd. (Shionogi) preferential dividends in ViiV
Healthcare. This included a re-measurement charge of £585
million (Q2 2021: £125 million) for the contingent
consideration liability due to Shionogi, including the unwinding of
the discount for £95 million and a charge for £490
million primarily from changes to exchange rates as well as
adjustments to sales forecasts. This was partly offset by increased
milestone income.
Operating profit
Total
operating profit was £1,081 million compared with £1,275
million in Q2 2021. The reduction primarily reflected the higher
re-measurement charges for contingent consideration liabilities,
partly offset by increased profits on turnover growth of 13% at CER
and increased milestone income.
Adjusted
operating profit was £2,008 million, 22% higher than Q2 2021
at AER and 7% at CER on a turnover increase of 13% at CER. The
Adjusted operating margin of 29.0% was 0.9% percentage points
higher at AER and 1.5% percentage points lower at CER than in Q2
2021. This primarily reflected the impact from low margin COVID-19
solutions sales (Xevudy), which reduced Adjusted Operating profit
growth by approximately 16% at AER, 14% at CER and reduced the
Adjusted operating margin by approximately 4.5 percentage points at
AER and 4.4 percentage points at CER. This was offset by operating
leverage from sales growth across all product groups, beneficial
mix, and higher royalty income.
Contingent
consideration cash payments made to Shionogi and other companies
reduce the balance sheet liability and hence are not recorded in
the income statement. Total contingent consideration cash payments
in Q2 2022 amounted to £404 million (Q2 2021: £205
million). These included cash payments made to Shionogi of
£395 million (Q2 2021: £203 million).
Adjusted operating profit by business
Commercial
Operations operating profit was £3,304 million, up 15% at AER
and 6% at CER on a turnover increase of 13% at CER. The operating
margin of 47.7% was 1.5 percentage points lower at AER and 3.2
percentage points lower at CER than in Q2 2021. This primarily
reflected sales of lower margin Xevudy in the quarter compared to Q2
2021 which included higher margin pandemic adjuvant sales. This
also reflected increased investment behind launches in Specialty
Medicines including HIV and Vaccines plus higher commodity, freight
and distribution costs. This was partly offset by continued tight
control of ongoing costs, benefits from continued restructuring and
increased royalty income from Biktarvy sales following the
settlement with Gilead in February 2022 and Gardasil
sales.
R&D
segment operating expenses were £1,152 million, up 3% at AER,
down 2% at CER, primarily reflecting continued efficiencies
delivered from the One R&D restructuring programme, the
completion of several late-stage clinical development programmes,
and a favourable comparator to Q2 2021, which saw increased levels
of R&D investment due to COVID-19 pandemic solutions. This was
partly offset by increased investment in Vaccines including
priority investments for mRNA and late stage portfolio and
Specialty in early stage HIV and depemokimab.
Net finance costs
Total
net finance costs were £183 million compared with £185
million in Q2 2021. Adjusted net finance costs were £181
million compared with £185 million in Q2 2021.
Taxation
The
charge of £150 million represented an effective tax rate on
Total results of 16.7% (Q2 2021: 18.8% credit) and reflected the
different tax effects of the various Adjusting items. Included in
Q2 2021 was a credit of £325 million resulting from the
revaluation of deferred tax assets following enactment of the
proposed change of UK corporation tax from 19% to 25%. Tax on
Adjusted profit amounted to £277 million and represented an
effective Adjusted tax rate of 15.2% (Q2 2021: 16.6%).
Issues
related to taxation are described in Note 14,
‘Taxation’ in the Annual Report 2021. The Group
continues to believe it has made adequate provision for the
liabilities likely to arise from periods that are open and not yet
agreed by relevant tax authorities. The ultimate liability for such
matters may vary from the amounts provided and is dependent upon
the outcome of agreements with relevant tax
authorities.
Non-controlling interests
The
allocation of Total earnings to non-controlling interests amounted
to £40 million (Q2 2021: £57 million). The decrease was
primarily due to an reduced allocation of ViiV Healthcare profits
of £41 million (Q2 2021: £60 million) including increased
credits for re-measurement of contingent consideration
liabilities.
The
allocation of Adjusted earnings to non-controlling interests
amounted to £150 million (Q2 2021: £99 million). The
increase in allocation primarily reflected an increased allocation
of ViiV Healthcare profits of £151 million (Q2 2021: £102
million).
Earnings per share from continuing operations
Total
EPS was 17.5p compared with 30.3p in Q2 2021. The reduction
primarily reflected increased charges for remeasurement of
contingent consideration liabilities as well as an unfavourable
comparison due to a credit of £325 million to Taxation in Q2
2021 resulting from the revaluation of deferred tax
assets.
Adjusted
EPS was 34.7p compared with 28.2p in Q2 2021, up 23% at AER, 6% at
CER, on a 7% CER increase in Adjusted operating profit primarily
reflecting higher COVID-19 solutions sales at low margin, with the
reduction to growth from COVID-19 solutions being approximately 20%
at AER, 18% at CER. Operating leverage from growth in sales of
Specialty Medicines including HIV and Vaccines, beneficial mix,
higher royalty income and a lower effective tax rate was partly
offset by higher supply chain, freight and distribution costs and
higher non-controlling interests.
Profit and earnings per share from discontinued
operations
Discontinued
operations include the Consumer Healthcare business and certain
Corporate costs directly attributable to the Consumer Healthcare.
Profit after taxation from discontinued operations amounted to
£229 million (Q2 2021: £267 million) and EPS from
discontinued operations was 3.3p, compared with 4.5p in Q2 2021.
The reduction in profit and EPS primarily reflected increased
separation costs and increased interest costs. For further details
see page 52, discontinued operations.
Total earnings per share
Total
EPS was 20.8p compared with 34.8p in Q2 2021. The reduction
primarily reflects increased charges for remeasurement of
contingent consideration liabilities as well as an unfavourable
comparison due to a credit of £325 million to Taxation in Q2
2021 resulting from the revaluation of deferred tax
assets.
Currency impact on Q2 2022 results
The
results for Q2 2022 are based on average exchange rates,
principally £1/$1.26, £1/€1.18 and £1/Yen 162.
Comparative exchange rates are given on page 50. The period-end
exchange rates were £1/$1.21, £1/€1.16 and
£1/Yen 165.
In Q2
2022, turnover was up 19% at AER and 13% at CER. Total EPS from
continuing operations was 17.5p compared with 30.3p in Q2 2021.
Adjusted EPS was 34.7p compared with 28.2p in Q2 2021, up 23% at
AER and 6% at CER. The favourable currency impact primarily
reflected the weakening of Sterling against the US Dollar, partly
offset by the strengthening in Sterling against the Euro and
Japanese Yen. Exchange gains or losses on the settlement of
intercompany transactions had a one percent favourable impact on
the 17 percentage points currency impact on Adjusted
EPS.
|
|
Adjusting items
The
reconciliations between Total results and Adjusted results for Q2
2022 and Q2 2021 are set out below.
|
|
Three months ended 30 June 2022
|
|
|
Total
results
£m
|
|
Profit
from
discon-
tinued
operations
£m
|
|
Intangible
amort-
isation
£m
|
|
Intangible
impair-
ment
£m
|
|
Major
restruct-
uring
£m
|
|
Trans-
action-
related
£m
|
|
Divest-
ments,
significant
legal
and
other
items
£m
|
|
Adjusted
results
£m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Turnover
|
6,929
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6,929
|
|
Cost of
sales
|
(2,176)
|
|
|
|
166
|
|
|
|
21
|
|
10
|
|
9
|
|
(1,970)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross
profit
|
4,753
|
|
|
|
166
|
|
|
|
21
|
|
10
|
|
9
|
|
4,959
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling,
general and
administration
|
(2,066)
|
|
|
|
|
|
|
|
107
|
|
|
|
4
|
|
(1,955)
|
|
Research
and development
|
(1,242)
|
|
|
|
26
|
|
55
|
|
6
|
|
|
|
|
|
(1,155)
|
|
Royalty
income
|
159
|
|
|
|
|
|
|
|
|
|
|
|
|
|
159
|
|
Other
operating
income/(expense)
|
(523)
|
|
|
|
|
|
|
|
|
|
675
|
|
(152)
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating profit
|
1,081
|
|
|
|
192
|
|
55
|
|
134
|
|
685
|
|
(139)
|
|
2,008
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
finance cost
|
(183)
|
|
|
|
|
|
|
|
1
|
|
|
|
1
|
|
(181)
|
|
Share
of after tax losses
of
associates and joint
ventures
|
(2)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(2)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit before taxation
|
896
|
|
|
|
192
|
|
55
|
|
135
|
|
685
|
|
(138)
|
|
1,825
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Taxation
|
(150)
|
|
|
|
(41)
|
|
(10)
|
|
(24)
|
|
(78)
|
|
26
|
|
(277)
|
|
Tax rate %
|
16.7%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15.2%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit after taxation from
continuing operations
|
746
|
|
|
|
151
|
|
45
|
|
111
|
|
607
|
|
(112)
|
|
1,548
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit after taxation from
discontinued operations
|
229
|
|
((229)
|
|
|
|
|
|
|
|
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total profit after taxation
for the period
|
975
|
|
1((229)
|
|
151
|
|
45
|
|
111
|
|
607
|
|
(112)
|
|
1,548
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to non-
controlling
interest from
continuing
operations
|
40
|
|
|
|
|
|
|
|
|
|
110
|
|
|
|
150
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to
shareholders
from
continuing
operations
|
706
|
|
|
|
151
|
|
45
|
|
111
|
|
497
|
|
(112)
|
|
1,398
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to non-
controlling
interest from
discontinued
operations
|
97
|
|
(97)
|
|
|
|
|
|
|
|
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to
shareholders
from
discontinued
operations
|
132
|
|
(132)
|
|
|
|
|
|
|
|
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
975
|
|
(229)
|
|
151
|
|
45
|
|
111
|
|
607
|
|
(112)
|
|
1,548
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total profit attributable to
non-controlling interests
|
137
|
|
(97)
|
|
|
|
|
|
|
|
110
|
|
|
|
150
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total profit attributable to
shareholders
|
838
|
|
(132)
|
|
151
|
|
45
|
|
111
|
|
497
|
|
(112)
|
|
1,398
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
975
|
|
(229)
|
|
151
|
|
45
|
|
111
|
|
607
|
|
(112)
|
|
1,548
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings
per share from
continuing
operations
|
17.5p
|
|
|
|
3.8p
|
|
1.1p
|
|
2.8p
|
|
12.3p
|
|
(2.8)p
|
|
34.7p
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings
per share from
discontinued
operations
|
3.3p
|
|
(3.3)p
|
|
|
|
|
|
|
|
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total earnings per share
|
20.8p
|
|
(3.3)p
|
|
3.8p
|
|
1.1p
|
|
2.8p
|
|
12.3p
|
|
(2.8)p
|
|
34.7p
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
average number
of
shares (millions)
|
4,025
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,025
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended 30 June 2021
|
|
|
Total
results
£m
|
|
Profit
from
discon-
tinued
operations
£m
|
|
Intangible
amort-
isation
£m
|
|
Intangible
impair-
ment
£m
|
|
Major
restruct-
uring
£m
|
|
Trans-
action-
related
£m
|
|
Divest-
ments,
significant
legal
and
other
items
£m
|
|
Adjusted
results
£m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Turnover
|
5,838
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,838
|
|
Cost of
sales
|
(1,708)
|
|
|
|
161
|
|
|
|
18
|
|
7
|
|
|
|
(1,522)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross
profit
|
4,130
|
|
|
|
161
|
|
|
|
18
|
|
7
|
|
|
|
4,316
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling,
general and
administration
|
(1,689)
|
|
|
|
|
|
|
|
55
|
|
|
|
(12)
|
|
(1,646)
|
|
Research
and development
|
(1,167)
|
|
|
|
25
|
|
7
|
|
29
|
|
|
|
|
|
(1,106)
|
|
Royalty
income
|
77
|
|
|
|
|
|
|
|
|
|
|
|
|
|
77
|
|
Other
operating
income/(expense)
|
(76)
|
|
|
|
|
|
|
|
|
|
123
|
|
(47)
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating profit
|
1,275
|
|
|
|
186
|
|
7
|
|
102
|
|
130
|
|
(59)
|
|
1,641
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
finance cost
|
(185)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(185)
|
|
Loss on
disposal of interest
in
associates
|
(36)
|
|
|
|
|
|
|
|
|
|
|
|
36
|
|
-
|
|
Share
of after tax losses
of
associates and joint
ventures
|
16
|
|
|
|
|
|
|
|
|
|
|
|
|
|
16
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit before taxation
|
1,070
|
|
|
|
186
|
|
7
|
|
102
|
|
130
|
|
(23)
|
|
1,472
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Taxation
|
201
|
|
|
|
(37)
|
|
(2)
|
|
(22)
|
|
(34)
|
|
(350)
|
|
(244)
|
|
Tax rate %
|
(18.8)%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
16.6%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit after taxation from
continuing operations
|
1,271
|
|
|
|
149
|
|
5
|
|
80
|
|
96
|
|
(373)
|
|
1,228
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit after taxation from
discontinued operations
|
267
|
|
(267)
|
|
|
|
|
|
|
|
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total profit after taxation
for the period
|
1,538
|
|
(267)
|
|
149
|
|
5
|
|
80
|
|
96
|
|
(373)
|
|
1,228
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to non-
controlling
interest from
continuing
operations
|
57
|
|
|
|
|
|
|
|
|
|
42
|
|
|
|
99
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to
shareholders
from
continuing
operations
|
1,214
|
|
|
|
149
|
|
5
|
|
80
|
|
54
|
|
(373)
|
|
1,129
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to non-
controlling
interest from
discontinued
operations
|
86
|
|
(86)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to
shareholders
from
discontinued
operations
|
181
|
|
(181)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,538
|
|
(267)
|
|
149
|
|
5
|
|
80
|
|
96
|
|
(373)
|
|
1,228
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total profit attributable to
non-controlling interests
|
143
|
|
(86)
|
|
|
|
|
|
|
|
42
|
|
|
|
99
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total profit attributable to
shareholders
|
1,395
|
|
(181)
|
|
149
|
|
5
|
|
80
|
|
54
|
|
(373)
|
|
1,129
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,538
|
|
(267)
|
|
149
|
|
5
|
|
80
|
|
96
|
|
(373)
|
|
1,228
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings
per share from
continuing
operations
|
30.3p
|
|
|
|
3.7
|
|
0.1
|
|
2.0
|
|
1.4
|
|
(9.3)
|
|
28.2p
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings
per share from
discontinued
operations
|
4.5p
|
|
(4.5)p
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total earnings per share
|
34.8p
|
|
(4.5)p
|
|
3.7
|
|
0.1
|
|
2.0
|
|
1.4
|
|
(9.3)
|
|
28.2p
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
average number
of
shares (millions)
|
4,003
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,003
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Major restructuring and integration
|
|
Total
Major restructuring charges from continuing operations incurred in
Q2 2022 were £134 million (Q2 2021: £102 million),
analysed as follows:
|
|
|
Q2 2022
|
|
Q2
2021
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash
£m
|
|
Non-
cash
£m
|
|
Total
£m
|
|
Cash
£m
|
|
Non-
cash
£m
|
|
Total
£m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Separation
Preparation restructuring
programme
|
28
|
|
105
|
|
133
|
|
102
|
|
(10)
|
|
92
|
|
Legacy
programmes
|
(1)
|
|
2
|
|
1
|
|
8
|
|
2
|
|
10
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
27
|
|
107
|
|
134
|
|
110
|
|
(8)
|
|
102
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash
charges of £28 million under the Separation Preparation
programme primarily arose from the restructuring of some
administrative functions as well as global Supply Chain and R&D
functions. The non-cash charges of £105 million primarily
reflected the write-down of assets in administrative locations and
impairment of IT assets.
Total
cash payments made in Q2 2022 were £78 million (Q2 2021:
£146 million), £70 million (Q2 2021: £113
million) relating to the Separation Preparation restructuring
programme and £8 million (Q2 2021: £33 million) relating
to other legacy programmes including the settlement of certain
charges accrued in previous quarters.
|
|
The
analysis of Major restructuring charges by Income statement line
was as follows:
|
|
|
Q2 2022
£m
|
|
Q2
2021
£m
|
|
|
|
|
|
|
Cost of
sales
|
21
|
|
18
|
|
Selling,
general and administration
|
106
|
|
55
|
|
Research
and development
|
7
|
|
29
|
|
|
|
|
|
|
Total
major restructuring costs from continuing operations
|
134
|
|
102
|
|
|
|
|
|
|
Materially
all of the Separation Preparation restructuring programme has been
included as part of continuing operations. The legacy Consumer
Healthcare Joint Venture integration programme is now included as
part of discontinued operations.
|
|
Transaction-related adjustments
Transaction-related
adjustments resulted in a net charge of £685 million (Q2 2021:
£130 million). This included a net £699 million
accounting charge for the re-measurement of contingent
consideration liabilities and the liabilities for the Pfizer put
option and Pfizer and Shionogi preferential dividends in ViiV
Healthcare.
|
|
Charge/(credit)
|
Q2 2022
£m
|
|
Q2
2021
£m
|
|
|
|
|
|
|
Contingent
consideration on former Shionogi-ViiV Healthcare joint
Venture
(including
Shionogi preferential dividends)
|
585
|
|
125
|
|
ViiV
Healthcare put options and Pfizer preferential
dividends
|
118
|
|
(37)
|
|
Contingent
consideration on former Novartis Vaccines business
|
(4)
|
|
13
|
|
Other
adjustments
|
(14)
|
|
29
|
|
|
|
|
|
|
Total
transaction-related charges
|
685
|
|
130
|
|
|
|
|
|
|
The £585 million charge relating to the contingent
consideration for the former Shionogi-ViiV Healthcare joint venture
represented an increase in the valuation of the contingent
consideration due to Shionogi, as a result of the unwind of the
discount for £95 million and a charge of £490 million
primarily from exchange rates as well as adjustments to sales
forecasts. The £118 million charge relating to the ViiV
Healthcare put option and Pfizer preferential dividends represented
an increase in the valuation of the put option primarily as a
result of updated exchange rates and adjustments to sales
forecasts.
The
ViiV Healthcare contingent consideration liability is fair valued
under IFRS. An explanation of the accounting for the
non-controlling interests in ViiV Healthcare is set out on page
38.
Divestments, significant legal charges, and other
items
Divestments,
significant legal charges and other items primarily include
milestone income gains and certain other Adjusting
items.
Discontinued operations
GSK satisfied the criteria in IFRS 5 for treating Consumer
Healthcare as a ‘discontinued operation’ effective from
30 June 2022, as it was expected that the carrying amount of the
disposal group will be recovered principally through disposal and a
distribution, it was available for distribution in its present
condition (subject only to the steps to be completed that are usual
and customary for the demerger of a business) and it was considered
highly probable (the date of the demerger being 18 July
2022).
From Q2 2020, the Group started to report additional costs to
prepare for establishment of the Consumer Healthcare business as an
independent entity (“Separation costs”) and these have
been presented as part of discontinued operations. Total separation
costs incurred in Q2 2022 were £163 million (Q2 2021: £74
million). This includes £30 million relating to transaction
costs incurred in connection with the demerger and preparatory
admission costs related to the listing of Haleon.
|
|
Financial performance
– H1 2022
|
|
Total results
|
|
The
Total results for the Group are set out below.
|
|
|
H1 2022
£m
|
|
H1
2021
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
|
|
Turnover
|
14,119
|
|
10,993
|
|
28
|
|
25
|
|
|
|
|
|
|
|
|
|
|
Cost of
sales
|
(4,893)
|
|
(3,362)
|
|
46
|
|
45
|
|
|
|
|
|
|
|
|
|
|
Gross
profit
|
9,226
|
|
7,631
|
|
21
|
|
17
|
|
|
|
|
|
|
|
|
|
|
Selling,
general and administration
|
(3,878)
|
|
(3,198)
|
|
21
|
|
19
|
|
Research
and development
|
(2,345)
|
|
(2,227)
|
|
5
|
|
3
|
|
Royalty income
|
297
|
|
166
|
|
79
|
|
77
|
|
Other
operating income/(expense)
|
74
|
|
113
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating
profit
|
3,374
|
|
2,485
|
|
36
|
|
26
|
|
|
|
|
|
|
|
|
|
|
Finance
income
|
28
|
|
10
|
|
|
|
|
|
Finance
expense
|
(409)
|
|
(387)
|
|
|
|
|
|
Loss on
disposal of interest in associates
|
-
|
|
(36)
|
|
|
|
|
|
Share
of after tax profits of associates and joint ventures
|
(3)
|
|
32
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit before taxation
|
2,990
|
|
2,104
|
|
42
|
|
32
|
|
|
|
|
|
|
|
|
|
|
Taxation
|
(473)
|
|
46
|
|
|
|
|
|
Tax rate %
|
15.8%
|
|
(2.2)%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit after taxation from continuing operations
|
2,517
|
|
2,150
|
|
17
|
|
8
|
|
|
|
|
|
|
|
|
|
|
Profit
after taxation from discontinued operations
|
625
|
|
648
|
|
(4)
|
|
(8)
|
|
|
|
|
|
|
|
|
|
|
Total Profit after taxation for the period
|
3,142
|
|
2,798
|
|
12
|
|
5
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to non-controlling interests
from
continuing operations
|
315
|
|
137
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to shareholders from
continuing
operations
|
2,202
|
|
2,013
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to non-controlling interests
from
discontinued operations
|
187
|
|
193
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to shareholders from
discontinued
operations
|
438
|
|
455
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,142
|
|
2,798
|
|
12
|
|
5
|
|
|
|
|
|
|
|
|
|
|
Total
Profit attributable to non-controlling interests
|
502
|
|
330
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
Profit attributable to shareholders
|
2,640
|
|
2,468
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,142
|
|
2,798
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings
per share from continuing operations1
|
54.8p
|
|
50.3p
|
|
9
|
|
-
|
|
|
|
|
|
|
|
|
|
|
Earnings
per share from discontinued operations1
|
10.9p
|
|
11.4p
|
|
(4)
|
|
(8)
|
|
|
|
|
|
|
|
|
|
|
Total earnings per share
|
65.7p
|
|
61.7p
|
|
6
|
|
(1)
|
|
|
|
|
|
|
|
|
|
|
(1)
|
Earnings
per share have been retrospectively adjusted to reflect the Share
Consolidation on 18 July 2022.
|
|
Adjusted results
|
|
The
Adjusted results for the Group are set out below. Adjusted results
are from continuing operations and excludes the Consumer Healthcare
business (see details in page 52). Reconciliations between Total
results and Adjusted results for H1 2022 and H1 2021 are set out on
pages 29 to 30.
|
|
|
H1 2022
£m
|
|
%
of
turnover
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
|
|
Turnover
|
14,119
|
|
100
|
|
28
|
|
25
|
|
|
|
|
|
|
|
|
|
|
Cost of
sales
|
(4,497)
|
|
(31.9)
|
|
52
|
|
52
|
|
Selling,
general and administration
|
(3,725)
|
|
(26.4)
|
|
20
|
|
18
|
|
Research
and development
|
(2,243)
|
|
(15.9)
|
|
5
|
|
3
|
|
Royalty
income
|
297
|
|
2.2
|
|
79
|
|
77
|
|
|
|
|
|
|
|
|
|
|
Adjusted
operating profit
|
3,951
|
|
28.0
|
|
33
|
|
26
|
|
|
|
|
|
|
|
|
|
|
Adjusted
profit before tax
|
3,569
|
|
|
|
36
|
|
28
|
|
Adjusted
profit after tax
|
3,005
|
|
|
|
38
|
|
29
|
|
Adjusted
profit attributable to shareholders
|
2,694
|
|
|
|
37
|
|
28
|
|
|
|
|
|
|
|
|
|
|
Adjusted
earnings per share
|
67.0p
|
|
|
|
36
|
|
27
|
|
|
|
|
|
|
|
|
|
|
Operating profit by segment
|
|
|
H1 2022
£m
|
|
%
of
turnover
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
|
|
Commercial
Operations
|
6,421
|
|
45.5
|
|
21
|
|
16
|
|
Research
and Development
|
(2,247)
|
|
|
|
5
|
|
2
|
|
|
|
|
|
|
|
|
|
|
Segment
profit
|
4,174
|
|
29.6
|
|
32
|
|
26
|
|
Corporate
& other unallocated costs
|
(223)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted
operating profit
|
3,951
|
|
28.0
|
|
33
|
|
26
|
|
|
|
|
|
|
|
|
|
|
Turnover
|
|
Commercial
Operations
|
|
|
H1 2022
|
||||
|
|
|
|
|
|
|
|
|
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
HIV
|
2,585
|
|
14
|
|
10
|
|
Oncology
|
281
|
|
23
|
|
19
|
|
Immuno-inflammation,
respiratory and other
|
1,200
|
|
26
|
|
21
|
|
|
|
|
|
|
|
|
|
4,066
|
|
18
|
|
14
|
|
Pandemic
|
1,773
|
|
>100
|
|
>100
|
|
|
|
|
|
|
|
|
Specialty Medicines
|
5,839
|
|
69
|
|
63
|
|
|
|
|
|
|
|
|
Meningitis
|
447
|
|
8
|
|
6
|
|
Influenza
|
50
|
|
(2)
|
|
(6)
|
|
Shingles
|
1,429
|
|
>100
|
|
>100
|
|
Established
Vaccines
|
1,458
|
|
1
|
|
(1)
|
|
|
|
|
|
|
|
|
|
3,384
|
|
33
|
|
30
|
|
Pandemic
Vaccines
|
-
|
|
(100)
|
|
(100)
|
|
|
|
|
|
|
|
|
Vaccines
|
3,384
|
|
21
|
|
17
|
|
|
|
|
|
|
|
|
Respiratory
|
3,184
|
|
6
|
|
3
|
|
Other
General Medicines
|
1,712
|
|
(1)
|
|
-
|
|
|
|
|
|
|
|
|
General Medicines
|
4,896
|
|
3
|
|
2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Commercial Operations
|
14,119
|
|
28
|
|
25
|
|
|
|
|
|
|
|
|
US
|
6,903
|
|
38
|
|
29
|
|
Europe
|
3,209
|
|
27
|
|
30
|
|
International
|
4,007
|
|
16
|
|
16
|
|
|
|
|
|
|
|
|
Commercial Operations by region
|
14,119
|
|
28
|
|
25
|
|
|
|
|
|
|
|
|
Total
turnover in the half year was £14,119 million, up 28% at AER,
25% at CER, reflecting strong performance in all three product
groups. Commercial Operations turnover, excluding pandemic sales,
grew 15% at AER, 12% at CER. Specialty Medicines included
£1,773 million sales of Xevudy, which contributed 13 percentage
points of growth at AER and CER. Vaccines growth reflected strong
Shingrix performance
assisted by demand recovery and channel inventory build in the US,
partially offset by pandemic adjuvant
sales in H1 2021. General Medicines reflected the
post-pandemic recovery of the antibiotics market and the strong
performance of Trelegy in
respiratory across all regions.
Specialty Medicines
Specialty
Medicines sales were £5,839 million, up 69% at AER, 63% at
CER, driven by consistent growth in all therapy areas. Specialty
Medicines excluding sales of Xevudy, were £4,066 million, up
18% at AER, 14% at CER.
HIV
HIV
sales were £2,585 million with growth of 14% at AER,10% at
CER. The performance benefited from strong patient demand for the
new HIV medicines (Dovato,
Cabenuva, Juluca, Rukobia, and Apretude). Unfavourable international
tender phasing was broadly offset by favourable US channel
inventory movements.
New HIV
medicines delivered for the first-time half year sales of over one
billion pounds to £1,017 million, up 72% at AER, 66% at CER,
representing 39% of the total HIV portfolio compared to 26% in H1
2021. Sales of the oral two drug regimens Dovato and Juluca were £577 million and
£285 million, respectively, with combined growth of 51% at
AER, 47% at CER. Cabenuva,
the first long-acting injectable for the treatment of HIV-1
infection, recorded sales of £110 million. Apretude, the first long-acting
injectable for the
prevention of HIV-1 delivered sales of £10
million.
Oncology
Oncology
sales were £281 million, up 23% at AER, 19% at CER.
Zejula sales of £218
million were up 17% at AER, 14% at CER with diagnosis and treatment
rates continuing to be impacted by the pandemic especially in the
US. Sales of Blenrep of
£55 million increased 31% at AER, 26% at CER, reflecting
ongoing launches and growth in launched markets.
Immuno-inflammation,
Respiratory and Other
Immuno-inflammation,
Respiratory and Other sales were £1,200 million up 26% at AER,
21% at CER. Benlysta sales
were £512 million, up 31% at AER, 24% at CER, representing
strong underlying demand worldwide. Nucala sales were £662 million, up
21% at AER, 18% at CER, including US sales of £413 million up
24% at AER, 16% at CER. The performance reflected continued strong
patient demand and the launch of several additional
indications.
Pandemic
Sales
of Xevudy were £1,773
million, compared to £16 million sales in the first half of
last year. Sales were delivered in all regions; £793 million
in the US, £434 million in Europe, and £546 million in
International.
Vaccines
Vaccines
turnover was £3,384 million, up 21% at AER, 17% at CER.
Excluding unrepeated 2021 pandemic adjuvant sales, vaccine sales
increased 33% at AER, 30% at CER. The performance reflected a
favourable comparator to H1 2021, which was impacted by
COVID-19 related disruptions in
several markets, and the strong commercial execution of
Shingrix, particularly in
the US and Europe.
Meningitis
Meningitis
vaccines sales grew 8% at AER, 6% at CER to £447 million
mainly driven by Bexsero
(10% at AER, 9% at CER to £328 million) resulting from higher
CDC purchasing and increased share in the US, partially offset by
phasing of tenders in Europe.
Shingles
Shingrix sales more than doubled to £1,429 million
primarily due to demand recovery, strong commercial execution aimed
at shifting the shingles vaccination season forward and
earlier-than-expected channel inventory build in the US, and higher
demand in Germany. All regions grew significantly in H1 2022, with
41% of the growth contributed from outside of the US. Shingrix is now available in 23
countries.
Established Vaccines
Established
Vaccines grew 1% AER but decreased 1% at CER to £1,458 million
mainly as a result of lower International tender demand and
unfavourable phasing for Synflorix, lower sales for Cervarix, and MMR/V vaccines in
International, and the negative impact of a CDC stockpile borrow
for Rotarix. This decrease
was partially offset by higher demand for hepatitis vaccines and
Boostrix in the US and
Europe.
General Medicines
General
Medicines sales in the half year were £4,896 million, up 3% at
AER, 2% at CER, with the impact of generic competition in US,
Europe and Japan offset by Trelegy growth in respiratory and the
post-pandemic rebound of the antibiotic market since H2 2021, in
Other General Medicines.
Respiratory
Respiratory
sales were £3,184 million, up 6% at AER, 3% at CER. The
performance was driven by Trelegy sales of £807 million, up
50% AER, 43% CER, including strong growth across all regions. The
performance also benefitted from prior period RAR adjustments in
the US. Advair/Seretide
sales of £564 million decreased 19% at AER, 20% at CER
predominately reflecting the adverse impact of generic competition;
growth in certain International markets due to targeted promotion
offset the decrease.
Other General
Medicines
Other
General Medicines sales were £1,712 million, and decreased 1%
at AER, stable at CER. Augmentin sales were £259 million,
up 42% at AER, 48% at CER, reflecting the post pandemic rebound of
the antibiotic market since Q3 2021 in the International and Europe
regions. This offsets the ongoing adverse impact of generic
competition and approximately two percentage points impact from the
divestment of cephalosporin products in Q4 2021.
By
Region
US
In the
US, sales were £6,903 million, up 38% at AER, 29% at CER,
including Xevudy sales of
£793 million contributing ten percentage points of
growth.
In
Specialty Medicines, HIV sales were £1,591 million up 21% at
AER, 13% at CER driven by strong patient demand from all new HIV
products with sales of £662 million up 73% at AER, 62% at CER,
and favourable channel inventory movements. HIV medicines,
Dovato delivered sales of
£309 million and Cabenuva £95 million. Nucala in respiratory and Benlysta in immunology both continued
to grow double-digit and reflected ongoing and strong patient
demand. Oncology sales increased 14% at AER, 7% at CER with
diagnosis and treatment rates continuing to be impacted by the
pandemic.
Vaccine
sales were £1,789 million, up 38% at AER, 29% at CER.
Excluding the impact of COVID-19 vaccine adjuvant sales during the
first half of 2021, sales increased 64% at AER, 53% at CER. The
performance was primarily driven by Shingrix and reflected demand recovery
and the benefit of a favourable comparator in the first half of
2021 when sales were impacted by COVID-19 related disruptions.
Meningitis, Hepatitis, Infanrix/Pediarix, and Boostrix sales all grew reflecting CDC
purchasing patterns and demand recovery.
General
Medicines sales were £1,744 million up 9% at AER, 2% at CER,
driven by strong respiratory sales of Trelegy, which increased 57% at AER,
47% at CER, and reflected increased patient demand and growth of
the single inhaler triple therapy market.
Europe
In
Europe, sales were £3,209 million, up 27% at AER, 30% at CER,
including Xevudy sales of
£434 million contributing 17 percentage points of
growth.
In
Specialty Medicines, HIV sales were £635 million up 10% at
AER, 13% at CER primarily driven by strong patient demand from two
drug regimens Dovato and Juluca.
Dovato delivered sales of £216 million and Juluca £63 million. Benlysta in immunology, Nucala in respiratory, and several
Oncology medicines continued to show strong double-digit
growth.
Vaccine
sales were £823 million, up 36% at AER, 40% at CER. The
performance was driven by Shingrix sales of £311 million,
>100% at AER, >100% at CER, particularly in
Germany.
General
Medicines sales were £1,025 million and decreased 5% at AER,
3% at CER, reflecting the ongoing and adverse impact of generic
competitive pressures on Seretide. This was partly offset,
however, by strong demand for Trelegy in respiratory and the growth
of Augmentin following the
post-pandemic rebound of the antibiotic market since H2
2021.
International
International
sales were £4,007 million, up 16% at AER, 17% at CER,
including Xevudy sales of
£546 million contributing 14 percentage points of
growth.
In
Specialty Medicines, HIV sales were £359 million and decreased
4% at AER, 5% at CER, primarily driven by tender phasing; strong
Dovato growth partially
offset the performance. Combined Tivicay and Triumeq sales were £278 million
decreasing 14% at AER, 15% at CER. Nucala in respiratory and Benlysta in immunology both continued
to grow strongly reflecting biologic market growth in Japan and
addition to China’s National Reimbursement Drug
List.
Vaccine
sales were £772 million and decreased 13% at AER, 14% at CER.
Vaccine sales excluding the impact of COVID-19 vaccine adjuvant
sales in H1 2021 decreased 8% at AER, 9% at CER, primarily
reflecting the phasing of public tenders and the lower sales of
divested brands.
General
Medicines sales were £2,127 million up 4% at AER, 5% at CER.
Respiratory sales of £935 million increased 4% at AER, 5% at
CER reflecting strong growth of Trelegy, particularly in Japan, China,
and Canada. This performance, however, was offset by the adverse
impact of generic competition and a lower allergy season in Japan.
Other General Medicines sales of £1,192 million increased 4%
at AER, 5% at CER, and reflected growth of Augmentin following the post-pandemic
rebound of the antibiotic market since H2 2021.
|
|
Operating performance
|
|
Cost of sales
Total
cost of sales as a percentage of turnover was 34.7%, 4.1 percentage
points higher at AER and 4.9 percentage points higher in CER terms
than H1 2021. This included lower write-downs on sites from major
restructuring programmes compared to 2021.
Excluding
these and other Adjusting items, Adjusted cost of sales as a
percentage of turnover was 31.9%, 5.0 percentage points higher at
AER and 5.7 percentage points higher at CER compared with H1 2021.
This primarily reflected higher sales of lower margin Xevudy compared to H1 2021 which
included higher margin pandemic adjuvant sales, increasing cost of
sales margin by 7.7 percentage points at AER and 7.6 percentage
points at CER, as well as the impact of increased commodity prices
and freight costs. This was partially offset by a favourable mix
primarily from increased sales of Shingrix in the US and Europe and
increased sales of HIV medicines in the US.
Selling, general and administration
Total
SG&A costs as a percentage of turnover were 27.5%, 1.6
percentage points lower at AER and 1.4 percentage points lower at
CER than in H1 2021 as the growth in sales outweighed SG&A
expenditure growth.
Adjusted
SG&A costs as a percentage of turnover were 26.4%, 1.9
percentage points lower at AER than in H1 2021 and 1.6 percentage
points lower at CER. Adjusted SG&A costs increased 20% at AER,
18% at CER which primarily reflected an increased level of launch
investment in Specialty Medicines particularly HIV and Vaccines
including Shingrix to drive
post-pandemic recovery demand and support market expansion. The
growth in Adjusted SG&A also reflected an unfavourable
comparison to a beneficial legal settlement in 2021, exchange
losses on the Vir Biotechnology, Inc. collaboration profit share
and impairment provisions relating to Ukraine. This growth, however
was partly offset by the continuing benefit of restructuring and
tight control of ongoing costs.
Research and development
Group
R&D expenditure was £2,345 million (16.6% of turnover), up
5% at AER and 3% at CER. Adjusted R&D expenditure in the
year-to-date was £2,243 million, up 5% at AER, 3% at CER. This
reflected continued efficiencies driven by the One R&D
restructuring programme, the completion of several late-stage
clinical development programmes, and a favourable comparator to H1
2021, which saw increased levels of R&D investment due to
COVID-19 pandemic solutions.
In the
half year, GSK increased investment across Vaccine clinical
development, including investments into its emerging mRNA
technology platform, continued investment in the late-stage
portfolio and accelerated several early discovery programmes. In
addition, in Specialty Medicines, the level of R&D investment
increased to support the early-stage HIV portfolio and in
respiratory, the phase III programme for depemokimab, a potential
new medicine to treat severe asthma. The expenditure in the year to
date does not reflect the impact of the acquisition of Sierra
Oncology, Inc. which completed on 1 July 2022.
Royalty income
Royalty
income was £297 million (H1 2021: £166 million), up 79%
at AER, 77% at CER, primarily reflecting royalty income from Gilead
under the settlement and licensing agreement with Gilead announced
on 1 February 2022 and higher sales of Gardasil.
|
|
Other operating income/(expense)
Net
other operating income was £74 million (H1 2021: £113
million) including £0.9 billion upfront income received from
the settlement with Gilead, partly offset by accounting charges of
£1,031 million (H1 2021: £208 million) arising from the
re-measurement of contingent consideration liabilities and the
liabilities for the Pfizer put option and Pfizer and Shionogi
preferential dividends in ViiV Healthcare. This included a
re-measurement charge of £841 million (H1 2021: £259
million) for the contingent consideration liability due to
Shionogi, including the unwinding of the discount for £196
million and a charge for £645 million primarily from changes
to exchange rates as well as adjustments to sales
forecasts.
|
|
Operating profit
Total
operating profit was £3,374 million compared with £2,485
million in H1 2021. This included the £0.9 billion upfront
income received from the settlement with Gilead and increased
profits on turnover growth of 25% at CER, partly offset by higher
re-measurement charges for contingent consideration liabilities.
Adjusted operating profit was £3,951 million, 33% higher at
AER and 26% at CER than H1 2021 on a turnover increase of 25% at
CER. The Adjusted operating margin of 28.0% was 1.0 percentage
points higher at AER and stable at CER compared to H1 2021. This
primarily reflected the impact from low margin COVID-19 solutions
sales (Xevudy), which reduced Adjusted Operating profit growth by
approximately 2% at AER, 1% at CER and reduced the Adjusted
operating margin by approximately 3.3 percentage points at AER and
CER. This was offset by operating leverage from strong sales
growth, mix benefit and higher royalty income.
Contingent
consideration cash payments made to Shionogi and other companies
reduce the balance sheet liability and hence are not recorded in
the income statement. Total contingent consideration cash payments
in H1 2022 amounted to £615 million (H1 2021: £426
million). These included cash payments made to Shionogi of
£603 million (H1 2021: £419 million).
Adjusted operating profit by business
Commercial
Operations operating profit was £6,421 million, up 21% at AER
and 16% at CER on a turnover increase of 25% at CER. The operating
margin of 45.5% was 2.8 percentage points lower at AER, 3.5
percentage points lower at CER than in H1 2021. This primarily
reflected strong sales of lower margin Xevudy in the period, increased
investment behind launches in Specialty Medicines including HIV and
Vaccines plus higher commodity, freight and distribution costs as
well as an adverse comparison to a favourable legal settlement in
H1 2021. This was partly offset by continued tight control of
ongoing costs, benefits from continued restructuring and increased
royalty income from Biktarvy sales following the settlement with
Gilead in February 2022 and Gardasil sales.
R&D
segment operating expenses were £2,247 million, up 5% at AER,
2% at CER, primarily reflecting increased investment in Vaccines
including priority investments for mRNA and late stage portfolio
and Specialty in early stage HIV and depemokimab. This was partly
offset by continued efficiencies driven by the R&D
restructuring programme, the completion of several late-stage
clinical development programmes, and a favourable comparator to H1
2021, which saw increased levels of R&D investment due to
COVID-19 pandemic solutions.
Net finance costs
Total
net finance costs were £381 million compared with £377
million in H1 2021. Adjusted net finance costs were £379
million compared with £375 million in H1 2021.
Share of after tax profits of associates and joint
ventures
The
share of after tax loss of associates and joint ventures was
£3 million (H1 2021: £32 million share of profit). In H1
2021, the Group also reported a net loss on disposal of interests
in associates of £36 million, primarily driven by a loss on
disposal of our interest in the associate Innoviva
Inc.
Taxation
The
charge of £473 million represented an effective tax rate on
Total results of 15.8% (H1 2021: 2.2% credit) and reflected the
different tax effects of the various Adjusting items. Included in
H1 2021 is a credit of £325 million resulting from the
revaluation of deferred tax assets following enactment of the
proposed change of UK corporation tax rates from 19% to 25%. Tax on
Adjusted profit amounted to £564 million and represented an
effective Adjusted tax rate of 15.8% (H1 2021: 16.7%).
Issues
related to taxation are described in Note 14,
‘Taxation’ in the Annual Report 2021. The Group
continues to believe it has made adequate provision for the
liabilities likely to arise from periods that are open and not yet
agreed by relevant tax authorities. The ultimate liability for such
matters may vary from the amounts provided and is dependent upon
the outcome of agreements with relevant tax
authorities.
Non-controlling interests
The
allocation of Total earnings to non-controlling interests amounted
to £315 million (H1 2021: £137 million). The increase was
primarily due to an increased allocation of ViiV Healthcare profits
of £268 million (H1 2021: £136 million), including the
Gilead upfront settlement income partly offset by increased credits
for re-measurement of contingent consideration liabilities, as well
as higher net profits in some of the Group’s other entities
with non-controlling interests.
The
allocation of Adjusted earnings to non-controlling interests
amounted to £311 million (Q2 2021: £211 million). The
increase in allocation primarily reflected an increased allocation
of ViiV Healthcare profits of £264 million (H1 2021: £210
million), as well as higher net profits in some of the
Group’s other entities with non-controlling
interests.
Earnings per share from continuing operations
Total
EPS from continuing operations was 54.8p compared with 50.3p in H1
2021. This primarily reflected the £0.9 billion upfront income
received from the settlement with Gilead and increased profits on
turnover growth of 25% at CER, partly offset by higher
re-measurement charges for contingent consideration liabilities as
well as an unfavourable comparison due to a credit of £325
million to Taxation in Q2 2021 resulting from the revaluation of
deferred tax assets.
Adjusted
EPS was 67.0p compared with 49.3p in H1 2021, up 36% at AER, 27% at
CER, on a 25% CER turnover increase. Adjusted operating profit
reflected higher COVID-19 solutions sales at low margin with the
reduction to growth from COVID-19 solutions being approximately 2%
at AER, 2% at CER. Operating leverage from growth in sales of
Specialty Medicines including HIV and Vaccines, beneficial mix,
higher royalty income and a lower effective tax rate was partly
offset by higher supply chain, freight and distribution costs and
higher non-controlling interests.
Profit and earnings per share from discontinued
operations
Discontinued
operations include the Consumer Healthcare business and certain
Corporate costs directly attributable to Consumer Healthcare.
Profit after taxation from discontinued operations amounted to
£625 million (H1 2021: £648 million) and EPS from
discontinued operations was 10.9p, compared with 11.4p in H1 2021.
The reduction in profit and EPS primarily reflected increased
separation costs and increased interest costs. For further details
see page 52, discontinued operations.
Currency impact on H1 2022 results
The
results for H1 2022 are based on average exchange rates,
principally £1/$1.30, £1/€1.19 and £1/Yen 159.
Comparative exchange rates are given on page 50. The period-end
exchange rates were £1/$1.21, £1/€1.16 and
£1/Yen 165.
In H1
2022, turnover was up 28% at AER and 25% at CER. Total EPS was
54.8p compared with 50.3p in H1 2021. Adjusted EPS was 67.0p
compared with 49.3p in H1 2021, up 36% at AER and 27% at CER. The
favourable currency impact reflected the weakening of Sterling
against the US Dollar, partly offset by strengthening in Sterling
against the Euro and Japanese Yen. Exchange gains or losses on the
settlement of intercompany transactions had a one percent
favourable impact on the nine percentage point favourable currency
impact on Adjusted EPS.
|
|
Adjusting items
The
reconciliations between Total results and Adjusted results for H1
2022 and H1 2021 are set out below.
|
|
Six months ended 30 June 2022
|
|
|
Total
results
£m
|
|
Profit from
discon-
tinued
operations
£m
|
|
Intangible
amort-
isation
£m
|
|
Intangible
impair-
ment
£m
|
|
Major
restruct-
uring
£m
|
|
Trans-
action-
related
£m
|
|
Divest-
ments,
significant
legal
and
other
items
£m
|
|
Adjusted
results
£m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Turnover
|
14,119
|
|
|
|
|
|
|
|
|
|
|
|
|
|
14,119
|
|
Cost of
sales
|
(4,893)
|
|
|
|
329
|
|
|
|
36
|
|
22
|
|
9
|
|
(4,497)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross
profit
|
9,226
|
|
|
|
329
|
|
|
|
36
|
|
22
|
|
9
|
|
9,622
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling,
general and
administration
|
(3,878)
|
|
|
|
|
|
|
|
135
|
|
|
|
18
|
|
(3,725)
|
|
Research
and development
|
(2,345)
|
|
|
|
49
|
|
39
|
|
14
|
|
|
|
|
|
(2,243)
|
|
Royalty
income
|
297
|
|
|
|
|
|
|
|
|
|
|
|
|
|
297
|
|
Other
operating
income/(expense)
|
74
|
|
|
|
|
|
|
|
|
|
1,010
|
|
(1,084)
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating profit
|
3,374
|
|
|
|
378
|
|
39
|
|
185
|
|
1,032
|
|
(1,057)
|
|
3,951
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
finance cost
|
(381)
|
|
|
|
|
|
|
|
1
|
|
|
|
1
|
|
(379)
|
|
Share
of after tax losses
of
associates and joint
ventures
|
(3)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(3)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit before taxation
|
2,990
|
|
|
|
378
|
|
39
|
|
186
|
|
1,032
|
|
(1,056)
|
|
3,569
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Taxation
|
(473)
|
|
|
|
(80)
|
|
(7)
|
|
(36)
|
|
(131)
|
|
163
|
|
(564)
|
|
Tax rate %
|
15.8%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15.8%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit after taxation from
continuing operations
|
2,517
|
|
|
|
298
|
|
32
|
|
150
|
|
901
|
|
(893)
|
|
3,005
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit after taxation from
discontinued operations
|
625
|
|
(625)
|
|
|
|
|
|
|
|
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total profit after taxation
for the period
|
3,142
|
|
(625)
|
|
298
|
|
32
|
|
150
|
|
901
|
|
(893)
|
|
3,005
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to non-
controlling
interest from
continuing
operations
|
315
|
|
|
|
|
|
|
|
|
|
(4)
|
|
|
|
311
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to
shareholders
from
continuing
operations
|
2,202
|
|
|
|
298
|
|
32
|
|
150
|
|
905
|
|
(893)
|
|
2,694
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to non-
controlling
interest from
discontinued
operations
|
187
|
|
(187)
|
|
|
|
|
|
|
|
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to
shareholders
from
discontinued
operations
|
438
|
|
(438)
|
|
|
|
|
|
|
|
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,142
|
|
(625)
|
|
298
|
|
32
|
|
150
|
|
901
|
|
(893)
|
|
3,005
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total profit attributable to
non-controlling interests
|
502
|
|
(187)
|
|
|
|
|
|
|
|
(4)
|
|
|
|
311
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total profit attributable to
shareholders
|
2,640
|
|
(438)
|
|
298
|
|
32
|
|
150
|
|
905
|
|
(893)
|
|
2,694
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,142
|
|
(625)
|
|
298
|
|
32
|
|
150
|
|
901
|
|
(893)
|
|
3,005
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings
per share from
continuing
operations
|
54.8p
|
|
|
|
7.4p
|
|
0.8p
|
|
3.7p
|
|
22.5p
|
|
(22.2)p
|
|
67.0p
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings
per share from
discontinued
operations
|
10.9p
|
|
(10.9)p
|
|
|
|
|
|
|
|
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total earnings per share
|
65.7p
|
|
(10.9)p
|
|
7.4p
|
|
0.8p
|
|
3.7p
|
|
22.5p
|
|
(22.2)p
|
|
67.0p
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
average number
of
shares (millions)
|
4,021
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,021
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six months ended 30 June 2021
|
|
|
Total
results
£m
|
|
Profit
from
discon-
tinued
operations
£m
|
|
Intangible
amort-
isation
£m
|
|
Intangible
impair-
ment
£m
|
|
Major
restruct-
uring
£m
|
|
Trans-
action-
related
£m
|
|
Divest-
ments,
significant
legal
and
other
items
£m
|
|
Adjusted
results
£m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Turnover
|
10,993
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10,993
|
|
Cost of
sales
|
(3,362)
|
|
|
|
326
|
|
|
|
38
|
|
14
|
|
27
|
|
(2,957)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross
profit
|
7,631
|
|
|
|
326
|
|
|
|
38
|
|
14
|
|
27
|
|
8,036
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling,
general and
administration
|
(3,198)
|
|
|
|
|
|
|
|
100
|
|
|
|
(10)
|
|
(3,108)
|
|
Research
and development
|
(2,227)
|
|
|
|
50
|
|
19
|
|
30
|
|
|
|
|
|
(2,128)
|
|
Royalty
income
|
166
|
|
|
|
|
|
|
|
|
|
|
|
|
|
166
|
|
Other
operating
income/(expense)
|
113
|
|
|
|
|
|
|
|
|
|
232
|
|
(345)
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating profit
|
2,485
|
|
|
|
376
|
|
19
|
|
168
|
|
246
|
|
(328)
|
|
2,966
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
finance cost
|
(377)
|
|
|
|
|
|
|
|
1
|
|
|
|
|
|
(375)
|
|
Loss on
disposal of interest
in
associates
|
(36)
|
|
|
|
|
|
|
|
|
|
|
|
36
|
|
-
|
|
Share
of after tax losses
of
associates and joint
ventures
|
32
|
|
|
|
|
|
|
|
|
|
|
|
|
|
32
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit before taxation
|
2,104
|
|
|
|
376
|
|
19
|
|
169
|
|
246
|
|
(291)
|
|
2,623
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Taxation
|
46
|
|
|
|
(73)
|
|
(4)
|
|
(36)
|
|
(64)
|
|
(308)
|
|
(439)
|
|
Tax rate %
|
(2.2%)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
16.7%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit after taxation from
continuing operations
|
2,150
|
|
|
|
303
|
|
15
|
|
133
|
|
182
|
|
(599)
|
|
2,184
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit after taxation from
discontinued operations
|
648
|
|
(648)
|
|
|
|
|
|
|
|
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total profit after taxation
for the period
|
2,798
|
|
(648)
|
|
303
|
|
15
|
|
133
|
|
182
|
|
(599)
|
|
2,184
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to non-
controlling
interest from
continuing
operations
|
137
|
|
|
|
|
|
|
|
|
|
74
|
|
|
|
211
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to
shareholders
from
continuing
operations
|
2,013
|
|
|
|
303
|
|
15
|
|
133
|
|
108
|
|
(599)
|
|
1,973
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to non-
controlling
interest from
discontinued
operations
|
193
|
|
(193)
|
|
|
|
|
|
|
|
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to
shareholders
from
discontinued
operations
|
455
|
|
(455)
|
|
|
|
|
|
|
|
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,798
|
|
(648)
|
|
303
|
|
15
|
|
133
|
|
182
|
|
(599)
|
|
2,184
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total profit attributable to
non-controlling interests
|
330
|
|
(193)
|
|
|
|
|
|
|
|
74
|
|
|
|
211
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total profit attributable to
shareholders
|
2,468
|
|
(455)
|
|
303
|
|
15
|
|
133
|
|
108
|
|
(599)
|
|
1,973
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,798
|
|
(648)
|
|
303
|
|
15
|
|
133
|
|
182
|
|
(599)
|
|
2,184
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings
per share from
continuing
operations
|
50.3p
|
|
|
|
7.6
|
|
0.4
|
|
3.3
|
|
2.7
|
|
(15.0)
|
|
49.3p
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings
per share from
discontinued
operations
|
11.4p
|
|
(11.4)p
|
|
|
|
|
|
|
|
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total earnings per share
|
61.7p
|
|
(11.4)p
|
|
7.6
|
|
0.4
|
|
3.3
|
|
2.7
|
|
(15.0)
|
|
49.3p
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
average number
of
shares (millions)
|
3,999
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,999
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Major restructuring and integration
|
|
Total
Major restructuring charges from continuing operations incurred in
H1 2022 were £185 million (H1 2021: £168 million),
analysed as follows:
|
|
|
H1 2022
|
|
H1
2021
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash
£m
|
|
Non-
cash
£m
|
|
Total
£m
|
|
Cash
£m
|
|
Non-
cash
£m
|
|
Total
£m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Separation
Preparation restructuring
programme
|
39
|
|
142
|
|
181
|
|
180
|
|
(1)
|
|
179
|
|
Legacy
programmes
|
1
|
|
3
|
|
4
|
|
19
|
|
(30)
|
|
(11)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
40
|
|
145
|
|
185
|
|
199
|
|
(31)
|
|
168
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash
charges of £39 million under the Separation Preparation
programme primarily arose from the restructuring of some
administrative functions as well as global Supply Chain and R&D
functions. The non-cash charges of £142 million primarily
reflected the write-down of assets in administrative locations and
impairment of IT assets.
Total
cash payments made in H1 2022 were £213 million (H1 2021:
£290 million), £189 million (H1 2021: £213 million)
relating to the Separation Preparation restructuring programme and
£24 million (H1 2021: £77 million) relating to other
legacy programmes including the settlement of certain charges
accrued in previous quarters.
|
|
The
analysis of Major restructuring charges by Income statement line
was as follows:
|
|
|
H1 2022
£m
|
|
H1
2021
£m
|
|
|
|
|
|
|
Cost of
sales
|
36
|
|
38
|
|
Selling,
general and administration
|
135
|
|
100
|
|
Research
and development
|
14
|
|
30
|
|
|
|
|
|
|
Total
Major restructuring costs from continuing operations
|
185
|
|
168
|
|
|
|
|
|
|
The
benefit in H1 2022 from restructuring programmes was £0.2
billion, primarily relating to the Separation Preparation
restructuring programme.
The
Group initiated in Q1 2020 a two-year Separation Preparation
programme to prepare for the separation of GSK into two companies.
The programme aims to:
|
|
●
|
Drive a
common approach to R&D with improved capital
allocation
|
|
●
|
Align
and improve the capabilities and efficiency of global support
functions to support new GSK
|
|
●
|
Further
optimise the supply chain and product portfolio, including the
divestment of non-core assets
|
|
●
|
Prepare
Consumer Healthcare to operate as a standalone company
|
|
The
programme continues to target delivery of £0.8 billion of
annual savings by 2022 and £1.0 billion by 2023, with total
costs estimated at £2.4 billion, of which £1.6 billion is
expected to be cash costs. The proceeds of divestments have largely
covered the cash costs of the programme.
|
|
Materially
all of the Separation Preparation restructuring programme has been
included as part of continuing operations. The legacy Consumer
Healthcare Joint Venture integration programme is now included as
part of discontinued operations.
|
|
Transaction-related adjustments
Transaction-related
adjustments from continuing operations resulted in a net charge of
£1,032 million (H1 2021: £246 million). This included a
net £1,031 million accounting charge for the re-measurement of
contingent consideration liabilities and the liabilities for the
Pfizer put option and Pfizer and Shionogi preferential dividends in
ViiV Healthcare.
|
|
Charge/(credit)
|
H1 2022
£m
|
|
H1
2021
£m
|
|
|
|
|
|
|
Contingent
consideration on former Shionogi-ViiV Healthcare joint
Venture
(including
Shionogi preferential dividends)
|
841
|
|
259
|
|
ViiV
Healthcare put options and Pfizer preferential
dividends
|
150
|
|
(90)
|
|
Contingent
consideration on former Novartis Vaccines business
|
40
|
|
39
|
|
Other
adjustments
|
1
|
|
38
|
|
|
|
|
|
|
Total
transaction-related charges
|
1,032
|
|
246
|
|
|
|
|
|
|
The £841 million charge relating to the contingent
consideration for the former Shionogi-ViiV Healthcare joint venture
represented an increase in the valuation of the contingent
consideration due to Shionogi, as a result of the unwind of the
discount for £196 million and a charge of £645 million
primarily from exchange rates as well as adjustments to sales
forecasts. The £150 million charge relating to the ViiV
Healthcare put option and Pfizer preferential dividends represented
an increase in the valuation of the put option primarily as a
result of updated exchange rates as well as adjustments to sales
forecasts.
The
ViiV Healthcare contingent consideration liability is fair valued
under IFRS. An explanation of the accounting for the
non-controlling interests in ViiV Healthcare is set out on page
38.
Divestments, significant legal charges, and other
items
Divestments,
significant legal charges and other items primarily included the
£929 million upfront settlement income received from Gilead,
as well as milestone income and gains from a number of asset
disposals and certain other Adjusting items.
Discontinued operations
From Q2
2020, the Group started to report additional costs to prepare for
establishment of the Consumer Healthcare business as an independent
entity (“Separation costs”). These are now presented as
part of discontinued operations. Total separation costs incurred in
H1 2022 were £302 million (H1 2021: £109 million). This
includes £52 million relating to transaction costs incurred in
connection with the demerger and preparatory admission costs
related to the listing of Haleon.
Total
separation costs to date are £684 million including £90
million relating to transaction costs.
|
|
Cash
generation
|
|
Cash flow
|
|
|
Q2 2022
£m
|
|
H1
2022
£m
|
|
H1
2021
£m
|
|
|
|
|
|
|
|
|
Cash
generated from operations attributable to continuing
operations
(£m)
|
1,584
|
|
3,936
|
|
1,759
|
|
Cash
generated from operations attributable to discontinued
operations
(£m)
|
515
|
|
918
|
|
564
|
|
|
|
|
|
|
|
|
Total
cash generated from operations (£m)
|
2,099
|
|
4,854
|
|
2,323
|
|
|
|
|
|
|
|
|
Net
cash inflow from operating activities from continuing
operations
|
1,196
|
|
3,402
|
|
1,217
|
|
Net
cash inflow from operating activities from
discontinued
operations
|
439
|
|
775
|
|
406
|
|
|
|
|
|
|
|
|
Total
net cash generated from operating activities (£m)
|
1,635
|
|
4,177
|
|
1,623
|
|
|
|
|
|
|
|
|
Free
cash inflow from continuing operations** (£m)
|
264
|
|
1,741
|
|
137
|
|
Free
cash flow from continuing operations growth (%)
|
>100%
|
|
>100%
|
|
N/A
|
|
Free
cash flow conversion from continuing operations* (%)
|
37%
|
|
79%
|
|
7%
|
|
Total
net debt (**) (£m)
|
21,458
|
|
21,458
|
|
21,921
|
|
|
|
|
|
|
|
|
*
|
Free
cash flow from continuing operations and free cash flow conversion
are defined on page 68.
|
|
**
|
Net
debt is analysed on page 58.
|
|
Q2 2022
Cash generated from operations attributable to continuing
operations for the quarter was £1,584 million Q2 2021:
£1,357 million). The increase primarily reflected the increase
in operating profit including beneficial exchange and favourable
timing of collections partly offset by increased contingent
consideration payments reflecting the Gilead settlement in February
2022, adverse timing of profit share payments for
Xevudy
sales, a higher seasonal increase in
inventory and adverse timing of returns and
rebates.
Cash generated from operations attributable to discontinued
operations for the quarter was £515 million (Q2 2021:
£482 million).
Total cash payments to Shionogi in relation to the ViiV Healthcare
contingent consideration liability in the quarter were £395
million (Q2 2021: £203 million), of which £351 million
was recognised in cash flows from operating activities and £44
million was recognised in contingent consideration paid within
investing cash flows. These payments are deductible for tax
purposes.
Free
cash inflow from continued operations was £264 million for the
quarter (Q2 2021: £20 million outflow). The increase primarily
reflected the increase in operating profit including beneficial
exchange and favourable timing of collections and reduced purchases
of intangible assets partly offset by increased contingent
consideration payments reflecting the Gilead settlement in February
2022, adverse timing of profit share payments for Xevudy sales, a higher seasonal
increase in inventory, higher capital expenditure and adverse
timing of returns and rebates.
|
|
H1 2022
Cash generated from operations attributable to continuing
operations for H1 was £3,936 million (H1 2021: £1,759
million). The increase primarily reflected a significant increase
in operating profit including the upfront income from the
settlement with Gilead, favourable exchange, favourable timing of
collections and profit share payments for Xevudy sales, partly offset by increased contingent
consideration payments reflecting the Gilead settlement in February
2022 and a higher seasonal increase in
inventory.
Cash generated from operations attributable to discontinued
operations for H1 2022 was £918 million (H1 2021: £564
million).
Total cash payments to Shionogi in relation to the ViiV Healthcare
contingent consideration liability in the half year were £603
million (H1 2021: £419 million), of which £534 million
was recognised in cash flows from operating activities and £69
million was recognised in contingent consideration paid within
investing cash flows. These payments are deductible for tax
purposes.
Free
cash inflow from continuing operations was £1,741 million for
the six months (H1 2021: £137 million). The increase primarily
reflected the significant increase in operating profit including
the upfront income from the settlement with Gilead, favourable
exchange and favourable timing of collections and profit share
payments for Xevudy sales.
This was partially offset by lower proceeds from disposals,
increased contingent consideration payments reflecting the Gilead
settlement in February 2022, higher capital expenditure and a
higher seasonal increase in inventory.
|
|
Total Net debt
At 30
June 2022, net debt was £21.5 billion, compared with
£19.8 billion at 31 December 2021, comprising gross debt of
£32.4 billion which increased primarily due to the debt
issuance for Consumer Healthcare, cash and liquid investments of
£8.0 billion and cash advances and a short-term loan to a
subsidiary of Pfizer Inc. of £2.9 billion, reflecting an
on-lend of a portion of the cash received from the proceeds of the
Consumer Healthcare bond issuance in line with Pfizer’s
shareholding of the Consumer Healthcare Joint Venture.
Net
debt increased by £1.6 billion due to dividends paid to
shareholders of £2.1 billion, £1.6 billion of net adverse
exchange impacts from the translation of non-Sterling denominated
debt and exchange on other financing items and £0.3 billion
dividends to non-controlling interests from discontinued operations
and £0.1 billion capital expenditure for discontinued
operations partly offset by £1.7 billion free cash flow from
continuing operations and £0.8 billion net cash inflow from
discontinued operating activities.
At 30
June 2022, GSK had short-term borrowings (including overdrafts and
lease liabilities) repayable within 12 months of £3,327
billion with loans of £2.3 billion repayable in the subsequent
year.
|
|
Returns to
shareholders
|
|
Quarterly dividends
The
Board has declared a second dividend for 2022 of 16.25p per share
(Q2 2021: 23.75p per share) retrospectively adjusted for the Share
Consolidation.
On 23
June 2021, at the new GSK Investor Update, GSK set out that from
2022 a progressive dividend policy will be implemented guided by a
40 to 60 percent pay-out ratio through the investment cycle. The
dividend policy, the total expected cash distribution, and the
respective dividend pay-out ratios for GSK remain
unchanged.
GSK has
previously stated that it expected to declare a 27p per share
dividend for the first half of 2022, a 22p per share dividend for
the second half of 2022 and a 45p per share dividend for 2023, but
that these targeted dividends per share would increase in step with
the Share Consolidation to maintain the same aggregate dividend
pay-out in absolute Pound Sterling terms. Accordingly, using the
consolidation ratio, GSK’s expected dividend for the second
quarter of 2022 converts to 16.25p per new ordinary share. The
expected dividend for the second half of 2022 converts to 27.5p per
new ordinary share and the expected dividend for 2023 converts to
56.5p per new ordinary share, rounded-up from 56.25p.
Payment of dividends
The
equivalent interim dividend receivable by ADR holders will be
calculated based on the exchange rate on 4 October 2022. An annual
fee of $0.03 per ADS (or $0.0075 per ADS per quarter) is charged by
the Depositary. The ex-dividend date will be 18 August 2022, with a
record date of 19 August 2022 and a payment date of 6 October
2022.
|
|
|
Paid/
Payable
|
|
Pence
per
share/
pre
share
consolidation
|
|
Pence
per
share/
post
share
consolidation
|
|
£m
|
|
|
|
|
|
|
|
|
|
|
2022
|
|
|
|
|
|
|
|
|
First
interim
|
1 July
2022
|
|
14
|
|
17.50
|
|
704
|
|
Second
interim
|
6
October 2022
|
|
13
|
|
16.25
|
|
654
|
|
|
|
|
|
|
|
|
|
|
|
Paid/
Payable
|
|
Pence
per
share/
pre
share
consolidation
|
|
Pence
per
share/
post
share
consolidation
|
|
£m
|
|
|
|
|
|
|
|
|
|
|
2021
|
|
|
|
|
|
|
|
|
First
interim
|
8 July
2021
|
|
19
|
|
23.75
|
|
951
|
|
Second
interim
|
7
October 2021
|
|
19
|
|
23.75
|
|
951
|
|
Third
interim
|
13
January 2022
|
|
19
|
|
23.75
|
|
952
|
|
Fourth
interim
|
7 April
2022
|
|
23
|
|
28.75
|
|
1,157
|
|
|
|
|
|
|
|
|
|
|
|
|
|
80
|
|
100
|
|
4,011
|
|
|
|
|
|
|
|
|
|
|
For
details of the Share Consolidation see page 53.
|
|
Weighted average number of shares
|
|||||
|
|
|
|
Q2 2022
millions
|
|
Q2
2021
millions(a)
|
|
|
|
|
|
|
|
|
Weighted
average number of shares – basic
|
|
|
4,025
|
|
4,003
|
|
Dilutive
effect of share options and share awards
|
|
|
39
|
|
35
|
|
|
|
|
|
|
|
|
Weighted
average number of shares – diluted
|
|
|
4,064
|
|
4,038
|
|
|
|
|
|
|
|
|
Weighted average number of shares
|
|||||
|
|
|
|
H1 2022
millions
|
|
H1
2021
millions(a)
|
|
|
|
|
|
|
|
|
Weighted
average number of shares – basic
|
|
|
4,021
|
|
3,999
|
|
Dilutive
effect of share options and share awards
|
|
|
38
|
|
35
|
|
|
|
|
|
|
|
|
Weighted
average number of shares – diluted
|
|
|
4,059
|
|
4,034
|
|
|
|
|
|
|
|
|
(a)
|
See
page 53 for details of the Share Consolidation.
|
|
At 30
June 2022, 4,026 million shares (Q2 2021: 4,004 million) were in
free issue (excluding Treasury shares and shares held by the ESOP
Trusts), after taking into account the Share Consolidation on 18
July 2022. GSK made no share repurchases during the period. The
company issued 0.3 million shares under employee share schemes in
the period for proceeds of £3 million (Q2 2021: £4
million).
|
|
At 30
June 2022 , the ESOP Trust held 50.0 million GSK shares (before the
Share Consolidation on 18 July 2022) against the future exercise of
share options and share awards. The carrying value of £371
million has been deducted from other reserves. The market value of
these shares was £925 million.
At 30
June 2022, the company held 243.9 million Treasury shares after
taking into account the Share Consolidation on 18 July 2022 at a
cost of £4,265 million which has been deducted from retained
earnings.
|
|
Total and Adjusted
results
|
|
Total
reported results represent the Group’s overall
performance.
GSK
also uses a number of adjusted, non-IFRS, measures to report the
performance of its business. Adjusted results and other non-IFRS
measures may be considered in addition to, but not as a substitute
for or superior to, information presented in accordance with IFRS.
Adjusted results are defined below and other non-IFRS measures are
defined on page 68.
GSK
believes that Adjusted results, when considered together with Total
results, provide investors, analysts and other stakeholders with
helpful complementary information to understand better the
financial performance and position of the Group from period to
period, and allow the Group’s performance to be more easily
compared against the majority of its peer companies. These measures
are also used by management for planning and reporting purposes.
They may not be directly comparable with similarly described
measures used by other companies.
GSK
encourages investors and analysts not to rely on any single
financial measure but to review GSK’s quarterly results
announcements, including the financial statements and notes, in
their entirety.
GSK is
committed to continuously improving its financial reporting, in
line with evolving regulatory requirements and best practice. In
line with this practice, GSK expects to continue to review and
refine its reporting framework.
Adjusted
results exclude the profits from discontinued operations from the
Consumer Healthcare business (see details on page 20 and the
following items in relation to our continuing operations from Total
results, together with the tax effects of all of these
items:
|
|
●
|
amortisation
of intangible assets (excluding computer software and capitalised
development costs)
|
|
●
|
impairment
of intangible assets (excluding computer software) and
goodwill
|
|
●
|
Major
restructuring costs, which include impairments of tangible assets
and computer software, (under specific Board approved programmes
that are structural, of a significant scale and where the costs of
individual or related projects exceed £25 million), including
integration costs following material acquisitions
|
|
●
|
transaction-related
accounting or other adjustments related to significant
acquisitions
|
|
●
|
proceeds
and costs of disposal of associates, products and businesses;
significant settlement income; significant legal charges (net of
insurance recoveries) and expenses on the settlement of litigation
and government investigations; other operating income other than
royalty income, and other items
|
|
Costs
for all other ordinary course smaller scale restructuring and legal
charges and expenses from continuing operations are retained within
both Total and Adjusted results.
As
Adjusted results include the benefits of Major restructuring
programmes but exclude significant costs (such as significant
legal, major restructuring and transaction items) they should not
be regarded as a complete picture of the Group’s financial
performance, which is presented in Total results. The exclusion of
other Adjusting items may result in Adjusted earnings being
materially higher or lower than Total earnings. In particular, when
significant impairments, restructuring charges and legal costs are
excluded, Adjusted earnings will be higher than Total
earnings.
GSK has
undertaken a number of Major restructuring programmes in response
to significant changes in the Group’s trading environment or
overall strategy, or following material acquisitions. Within the
Pharmaceuticals sector, the highly regulated manufacturing
operations and supply chains and long lifecycle of the business
mean that restructuring programmes, particularly those that involve
the rationalisation or closure of manufacturing or R&D sites
are likely to take several years to complete. Costs, both cash and
non-cash, of these programmes are provided for as individual
elements are approved and meet the accounting recognition criteria.
As a result, charges may be incurred over a number of years
following the initiation of a Major restructuring
programme.
Significant
legal charges and expenses are those arising from the settlement of
litigation or government investigations that are not in the normal
course and materially larger than more regularly occurring
individual matters. They also include certain major legacy
matters.
Reconciliations
between Total and Adjusted results, providing further information
on the key Adjusting items, are set out on pages 17, 18, 29 and
30.
GSK
provides earnings guidance to the investor community on the basis
of Adjusted results. This is in line with peer companies and
expectations of the investor community, supporting easier
comparison of the Group’s performance with its peers. GSK is
not able to give guidance for Total results as it cannot reliably
forecast certain material elements of the Total results,
particularly the future fair value movements on contingent
consideration and put options that can and have given rise to
significant adjustments driven by external factors such as currency
and other movements in capital markets.
|
|
ViiV Healthcare
ViiV
Healthcare is a subsidiary of the Group and 100% of its operating
results (turnover, operating profit, profit after tax) are included
within the Group income statement.
Earnings
are allocated to the three shareholders of ViiV Healthcare on the
basis of their respective equity shareholdings (GSK 78.3%, Pfizer
11.7% and Shionogi 10%) and their entitlement to preferential
dividends, which are determined by the performance of certain
products that each shareholder contributed. As the relative
performance of these products changes over time, the proportion of
the overall earnings allocated to each shareholder also changes. In
particular, the increasing proportion of sales of dolutegravir and
cabotegravir-containing products has a favourable impact on the
proportion of the preferential dividends that is allocated to GSK.
Adjusting items are allocated to shareholders based on their equity
interests. GSK was entitled to approximately 86% of the Total
earnings and 83% of the Adjusted earnings of ViiV Healthcare for
2021.
As
consideration for the acquisition of Shionogi’s interest in
the former Shionogi-ViiV Healthcare joint venture in 2012, Shionogi
received the 10% equity stake in ViiV Healthcare and ViiV
Healthcare also agreed to pay additional future cash consideration
to Shionogi, contingent on the future sales performance of the
products being developed by that joint venture, dolutegravir and
cabotegravir. Under IFRS 3 ‘Business combinations’, GSK
was required to provide for the estimated fair value of this
contingent consideration at the time of acquisition and is required
to update the liability to the latest estimate of fair value at
each subsequent period end. The liability for the contingent
consideration recognised in the balance sheet at the date of
acquisition was £659 million. Subsequent re-measurements are
reflected within other operating income/(expense) and within
Adjusting items in the income statement in each
period.
On 1
February 2022, ViiV Healthcare reached agreement with Gilead to
settle the global patent infringement litigation relating to the
commercialisation of Gilead’s Biktarvy. Under the terms of the global settlement and
licensing agreement, Gilead made an upfront payment of $1.25
billion to ViiV Healthcare in February
2022. In addition, Gilead will also pay a 3% royalty on all future
US sales of Biktarvy and in respect of the bictegravir component of
any other future bictegravir-containing products sold in the US.
These royalties will be payable by Gilead to ViiV Healthcare from 1
February 2022 until the expiry of ViiV Healthcare's US
Patent No. 8,129,385 on 5 October
2027. Gilead's obligation to pay royalties does not extend into any
period of regulatory paediatric exclusivity, if
awarded.
Cash
payments to settle the contingent consideration are made to
Shionogi by ViiV Healthcare each quarter, based on the actual sales
performance and other income of the relevant products in the
previous quarter. These payments reduce the balance sheet liability
and hence are not recorded in the income statement. The cash
payments made to Shionogi by ViiV Healthcare in H1 2022 were
£603 million.
As the
liability is required to be recorded at the fair value of estimated
future payments, there is a significant timing difference between
the charges that are recorded in the Total income statement to
reflect movements in the fair value of the liability and the actual
cash payments made to settle the liability.
Further
explanation of the acquisition-related arrangements with ViiV
Healthcare are set out on pages 57 and 58 of the Annual Report
2021.
|
|
Financial information
|
|
Income
statements
|
|
|
Q2 2022
£m
|
|
Q2
2021(a)
£m
|
|
H1 2022
£m
|
|
H1
2021(a)
£m
|
|
|
|
|
|
|
|
|
|
|
TURNOVER
|
6,929
|
|
5,838
|
|
14,119
|
|
10,993
|
|
|
|
|
|
|
|
|
|
|
Cost of
sales
|
(2,176)
|
|
(1,708)
|
|
(4,893)
|
|
(3,362)
|
|
|
|
|
|
|
|
|
|
|
Gross
profit
|
4,753
|
|
4,130
|
|
9,226
|
|
7,631
|
|
|
|
|
|
|
|
|
|
|
Selling,
general and administration
|
(2,066)
|
|
(1,689)
|
|
(3,878)
|
|
(3,198)
|
|
Research
and development
|
(1,242)
|
|
(1,167)
|
|
(2,345)
|
|
(2,227)
|
|
Royalty income
|
159
|
|
77
|
|
297
|
|
166
|
|
Other
operating income/(expense)
|
(523)
|
|
(76)
|
|
74
|
|
113
|
|
|
|
|
|
|
|
|
|
|
OPERATING PROFIT
|
1,081
|
|
1,275
|
|
3,374
|
|
2,485
|
|
|
|
|
|
|
|
|
|
|
Finance
income
|
21
|
|
4
|
|
28
|
|
10
|
|
Finance
expense
|
(204)
|
|
(189)
|
|
(409)
|
|
(387)
|
|
Loss on
disposal of interests in associates
|
-
|
|
(36)
|
|
-
|
|
(36)
|
|
Share
of after tax (losses)/profits of associates
and
joint ventures
|
(2)
|
|
16
|
|
(3)
|
|
32
|
|
|
|
|
|
|
|
|
|
|
PROFIT BEFORE TAXATION
|
896
|
|
1,070
|
|
2,990
|
|
2,104
|
|
|
|
|
|
|
|
|
|
|
Taxation
|
(150)
|
|
201
|
|
(473)
|
|
46
|
|
Tax rate %
|
16.7%
|
|
(18.8)%
|
|
15.8%
|
|
(2.2)%
|
|
|
|
|
|
|
|
|
|
|
PROFIT AFTER TAXATION FROM
CONTINUING OPERATIONS
|
746
|
|
1,271
|
|
2,517
|
|
2,150
|
|
|
|
|
|
|
|
|
|
|
PROFIT AFTER TAXATION FROM
DISCONTINUED OPERATIONS
|
229
|
|
267
|
|
625
|
|
648
|
|
|
|
|
|
|
|
|
|
|
PROFIT AFTER TAXATION FROM THE PERIOD
|
975
|
|
1,538
|
|
3,142
|
|
2,798
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to non-controlling interests
from
continuing operations
|
40
|
|
57
|
|
315
|
|
137
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to shareholders from
continuing
operations
|
706
|
|
1,214
|
|
2,202
|
|
2,013
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to non-controlling interests
from
discontinued operations
|
97
|
|
86
|
|
187
|
|
193
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to shareholders from
discontinued
operations
|
132
|
|
181
|
|
438
|
|
455
|
|
|
|
|
|
|
|
|
|
|
|
975
|
|
1,538
|
|
3,142
|
|
2,798
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to non-controlling interests
|
137
|
|
143
|
|
502
|
|
330
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to shareholders
|
838
|
|
1,395
|
|
2,640
|
|
2,468
|
|
|
|
|
|
|
|
|
|
|
|
975
|
|
1,538
|
|
3,142
|
|
2,798
|
|
|
|
|
|
|
|
|
|
|
EARNINGS PER SHARE FROM CONTINUING OPERATIONS
|
17.5p
|
|
30.3p
|
|
54.8p
|
|
50.3p
|
|
|
|
|
|
|
|
|
|
|
EARNINGS PER SHARE FROM DISCONTINUED OPERATIONS
|
3.3p
|
|
4.5p
|
|
10.9p
|
|
11.4p
|
|
|
|
|
|
|
|
|
|
|
TOTAL EARNINGS PER SHARE
|
20.8p
|
|
34.8p
|
|
65.7p
|
|
61.7p
|
|
|
|
|
|
|
|
|
|
|
Diluted
earnings per share from continuing
operations
|
17.4p
|
|
30.1p
|
|
54.3p
|
|
49.9p
|
|
|
|
|
|
|
|
|
|
|
Diluted
earnings per share from discontinued
operations
|
3.2p
|
|
4.4p
|
|
10.7p
|
|
11.3p
|
|
|
|
|
|
|
|
|
|
|
Total
diluted earnings per share
|
20.6p
|
|
34.5p
|
|
65.0p
|
|
61.2p
|
|
|
|
|
|
|
|
|
|
|
(a)
|
The
2021 comparative results have been restated on a consistent basis
from those previously published to reflect the classification of
the Consumer Healthcare business as a discontinued operation (see
page 20) and the impact of Share Consolidation implemented on 18
July 2022 (see page 53).
|
|
Statement of comprehensive
income
|
|
|
Q2 2022
£m
|
|
Q2
2021(a)
£m
|
|
H1 2022
£m
|
|
H1
2021(a)
£m
|
|
|
|
|
|
|
|
|
|
|
Total
profit for the period
|
975
|
|
1,538
|
|
3,142
|
|
2,798
|
|
|
|
|
|
|
|
|
|
|
Items that may be reclassified subsequently to continuing
operations income statement:
|
|
|
|
|
|
|
|
|
Exchange
movements on overseas net assets
and
net investment hedges
|
(179)
|
|
70
|
|
(198)
|
|
(40)
|
|
Reclassification
of exchange movements on
liquidation
or disposal of overseas subsidiaries
and
associates
|
9
|
|
(10)
|
|
9
|
|
(10)
|
|
Fair
value movements on cash flow hedges
|
-
|
|
9
|
|
2
|
|
(2)
|
|
Reclassification
of cash flow hedges to income
statement
|
14
|
|
2
|
|
13
|
|
16
|
|
Deferred
tax on fair value movements on cash
flow
hedges
|
-
|
|
(3)
|
|
-
|
|
(3)
|
|
|
|
|
|
|
|
|
|
|
|
(156)
|
|
68
|
|
(174)
|
|
(39)
|
|
|
|
|
|
|
|
|
|
|
Items that will not be reclassified to continuing operations income
statement:
|
|
|
|
|
|
|
|
|
Exchange
movements on overseas net assets
of
non-controlling interests
|
(3)
|
|
(2)
|
|
-
|
|
(7)
|
|
Fair
value movements on equity investments
|
(81)
|
|
(78)
|
|
(624)
|
|
158
|
|
Tax on
fair value movements on equity
investments
|
10
|
|
(16)
|
|
57
|
|
38
|
|
Re-measurement
gains on defined benefit plans
|
200
|
|
257
|
|
513
|
|
285
|
|
Tax on
re-measurement losses on defined
benefit
plans
|
(53)
|
|
(40)
|
|
(126)
|
|
(52)
|
|
|
|
|
|
|
|
|
|
|
|
73
|
|
121
|
|
(180)
|
|
422
|
|
|
|
|
|
|
|
|
|
|
Other
comprehensive (expense)/income for the
period
from continuing operations
|
(83)
|
|
189
|
|
(354)
|
|
383
|
|
|
|
|
|
|
|
|
|
|
Other
comprehensive income/(expense) for the
period
from discontinued operations
|
493
|
|
(10)
|
|
928
|
|
(201)
|
|
|
|
|
|
|
|
|
|
|
Total
comprehensive income for the period
|
1,385
|
|
1,717
|
|
3,716
|
|
2,980
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
comprehensive income for the period
attributable
to:
|
|
|
|
|
|
|
|
|
Shareholders
|
1,277
|
|
1,577
|
|
3,239
|
|
2,687
|
|
Non-controlling
interests
|
108
|
|
140
|
|
477
|
|
293
|
|
|
|
|
|
|
|
|
|
|
|
1,385
|
|
1,717
|
|
3,716
|
|
2,980
|
|
|
|
|
|
|
|
|
|
|
(a)
|
The
2021 comparative results have been restated on a consistent basis
from those previously published to reflect the classification of
the Consumer Healthcare business as a discontinued operation (see
page 20) and the impact of Share Consolidation implemented on 18
July 2022 (see page 53).
|
|
Specialty Medicines turnover – three months ended 30 June
2022
|
|
|
Total
|
|
US
|
|
Europe
|
|
International
|
||||||||||||||||
|
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
||||||||
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HIV
|
1,404
|
|
14
|
|
7
|
|
894
|
|
25
|
|
13
|
|
336
|
|
15
|
|
17
|
|
174
|
|
(23)
|
|
(27)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dolutegravir
products
|
1,279
|
|
8
|
|
1
|
|
796
|
|
15
|
|
5
|
|
320
|
|
14
|
|
16
|
|
163
|
|
(25)
|
|
(30)
|
|
Tivicay
|
346
|
|
(15)
|
|
(21)
|
|
201
|
|
3
|
|
(7)
|
|
72
|
|
-
|
|
3
|
|
73
|
|
(47)
|
|
(53)
|
|
Triumeq
|
461
|
|
(1)
|
|
(7)
|
|
307
|
|
5
|
|
(5)
|
|
97
|
|
(13)
|
|
(12)
|
|
57
|
|
(8)
|
|
(10)
|
|
Juluca
|
152
|
|
15
|
|
7
|
|
116
|
|
15
|
|
4
|
|
33
|
|
22
|
|
22
|
|
3
|
|
(25)
|
|
(25)
|
|
Dovato
|
320
|
|
74
|
|
66
|
|
172
|
|
69
|
|
54
|
|
118
|
|
71
|
|
74
|
|
30
|
|
>100
|
|
>100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Rukobia
|
19
|
|
90
|
|
70
|
|
18
|
|
80
|
|
70
|
|
-
|
|
-
|
|
-
|
|
1
|
|
>100
|
|
>(100)
|
|
Cabenuva
|
72
|
|
>100
|
|
>100
|
|
63
|
|
>100
|
|
>100
|
|
8
|
|
>100
|
|
>100
|
|
1
|
|
>100
|
|
>100
|
|
Apretude
|
8
|
|
-
|
|
-
|
|
8
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
Other
|
26
|
|
(19)
|
|
(25)
|
|
9
|
|
(25)
|
|
(50)
|
|
8
|
|
(27)
|
|
(36)
|
|
9
|
|
-
|
|
22
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Oncology
|
154
|
|
29
|
|
23
|
|
83
|
|
22
|
|
10
|
|
62
|
|
27
|
|
29
|
|
9
|
|
>100
|
|
>100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Zejula
|
120
|
|
22
|
|
16
|
|
63
|
|
17
|
|
6
|
|
48
|
|
17
|
|
20
|
|
9
|
|
>100
|
|
>100
|
|
Blenrep
|
30
|
|
43
|
|
33
|
|
19
|
|
36
|
|
21
|
|
11
|
|
37
|
|
37
|
|
-
|
|
-
|
|
-
|
|
Jemperli
|
4
|
|
>100
|
|
>100
|
|
1
|
|
>100
|
|
>100
|
|
3
|
|
>100
|
|
100
|
|
-
|
|
-
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Immuno-
inflammation,
respiratory and other
|
680
|
|
32
|
|
24
|
|
487
|
|
35
|
|
23
|
|
92
|
|
12
|
|
12
|
|
101
|
|
42
|
|
46
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Benlysta
|
297
|
|
39
|
|
29
|
|
251
|
|
40
|
|
27
|
|
20
|
|
18
|
|
24
|
|
26
|
|
44
|
|
44
|
|
Nucala
|
367
|
|
26
|
|
19
|
|
236
|
|
30
|
|
18
|
|
74
|
|
14
|
|
15
|
|
57
|
|
27
|
|
29
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Speciality Medicines
excluding pandemic
|
2,238
|
|
20
|
|
13
|
|
1,464
|
|
28
|
|
16
|
|
490
|
|
16
|
|
17
|
|
284
|
|
(5)
|
|
(8)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pandemic
|
466
|
|
>100
|
|
>100
|
|
23
|
|
>100
|
|
>100
|
|
123
|
|
-
|
|
-
|
|
320
|
|
>100
|
|
>100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Xevudy
|
466
|
|
>100
|
|
>100
|
|
23
|
|
>100
|
|
>100
|
|
123
|
|
-
|
|
-
|
|
320
|
|
>100
|
|
>100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Specialty Medicines
|
2,704
|
|
44
|
|
35
|
|
1,487
|
|
30
|
|
16
|
|
613
|
|
45
|
|
47
|
|
604
|
|
91
|
|
90
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Specialty Medicines turnover – six months ended 30 June
2022
|
|
|
Total
|
|
US
|
|
Europe
|
|
International
|
||||||||||||||||
|
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
||||||||
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HIV
|
2,585
|
|
14
|
|
10
|
|
1,591
|
|
21
|
|
13
|
|
635
|
|
10
|
|
13
|
|
359
|
|
(4)
|
|
(5)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dolutegravir
products
|
2,381
|
|
9
|
|
6
|
|
1,437
|
|
13
|
|
6
|
|
607
|
|
8
|
|
11
|
|
337
|
|
(4)
|
|
(6)
|
|
Tivicay
|
666
|
|
(6)
|
|
(9)
|
|
361
|
|
1
|
|
(6)
|
|
137
|
|
(7)
|
|
(4)
|
|
168
|
|
(17)
|
|
(19)
|
|
Triumeq
|
853
|
|
(5)
|
|
(9)
|
|
552
|
|
1
|
|
(6)
|
|
191
|
|
(18)
|
|
(16)
|
|
110
|
|
(9)
|
|
(9)
|
|
Juluca
|
285
|
|
17
|
|
12
|
|
215
|
|
17
|
|
9
|
|
63
|
|
19
|
|
23
|
|
7
|
|
-
|
|
-
|
|
Dovato
|
577
|
|
78
|
|
73
|
|
309
|
|
76
|
|
64
|
|
216
|
|
70
|
|
75
|
|
52
|
|
>100
|
|
>100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Rukobia
|
35
|
|
>100
|
|
88
|
|
33
|
|
94
|
|
82
|
|
1
|
|
>100
|
|
>100
|
|
1
|
|
>100
|
|
>(100)
|
|
Cabenuva
|
110
|
|
>100
|
|
>100
|
|
95
|
|
>100
|
|
>100
|
|
14
|
|
>100
|
|
>100
|
|
1
|
|
>100
|
|
>100
|
|
Apretude
|
10
|
|
-
|
|
-
|
|
10
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
Other
|
49
|
|
(23)
|
|
(22)
|
|
16
|
|
(33)
|
|
(42)
|
|
13
|
|
(28)
|
|
(28)
|
|
20
|
|
(9)
|
|
5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Oncology
|
281
|
|
23
|
|
19
|
|
152
|
|
14
|
|
7
|
|
116
|
|
26
|
|
29
|
|
13
|
|
>100
|
|
>100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Zejula
|
218
|
|
17
|
|
14
|
|
114
|
|
9
|
|
1
|
|
91
|
|
18
|
|
21
|
|
13
|
|
>100
|
|
>100
|
|
Blenrep
|
55
|
|
31
|
|
26
|
|
35
|
|
25
|
|
18
|
|
20
|
|
33
|
|
33
|
|
-
|
|
-
|
|
-
|
|
Jemperli
|
8
|
|
>100
|
|
>100
|
|
3
|
|
>100
|
|
>100
|
|
5
|
|
>100
|
|
>100
|
|
-
|
|
-
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Immuno-
inflammation,
respiratory and other
|
1,200
|
|
26
|
|
21
|
|
834
|
|
27
|
|
19
|
|
176
|
|
10
|
|
13
|
|
190
|
|
39
|
|
42
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Benlysta
|
512
|
|
31
|
|
24
|
|
421
|
|
30
|
|
21
|
|
39
|
|
18
|
|
21
|
|
52
|
|
49
|
|
49
|
|
Nucala
|
662
|
|
21
|
|
18
|
|
413
|
|
24
|
|
16
|
|
139
|
|
9
|
|
13
|
|
110
|
|
26
|
|
30
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Speciality Medicines
excluding pandemic
|
4,066
|
|
18
|
|
14
|
|
2,577
|
|
23
|
|
15
|
|
927
|
|
12
|
|
15
|
|
562
|
|
9
|
|
9
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pandemic
|
1,773
|
|
>100
|
|
>100
|
|
793
|
|
>100
|
|
>100
|
|
434
|
|
-
|
|
-
|
|
546
|
|
>100
|
|
>100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Xevudy
|
1,773
|
|
>100
|
|
>100
|
|
793
|
|
>100
|
|
>100
|
|
434
|
|
-
|
|
-
|
|
546
|
|
>100
|
|
>100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Specialty Medicines
|
5,839
|
|
69
|
|
63
|
|
3,370
|
|
60
|
|
50
|
|
1,361
|
|
64
|
|
67
|
|
1,108
|
|
>100
|
|
>100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vaccines turnover – three months ended 30 June
2022
|
|
|
Total
|
|
US
|
|
Europe
|
|
International
|
||||||||||||||||
|
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
||||||||
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Meningitis
|
235
|
|
4
|
|
-
|
|
120
|
|
10
|
|
(1)
|
|
87
|
|
(9)
|
|
(6)
|
|
28
|
|
40
|
|
40
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Bexsero
|
165
|
|
-
|
|
(3)
|
|
65
|
|
8
|
|
(3)
|
|
81
|
|
(9)
|
|
(7)
|
|
19
|
|
19
|
|
19
|
|
Menveo
|
69
|
|
17
|
|
10
|
|
55
|
|
12
|
|
2
|
|
5
|
|
-
|
|
-
|
|
9
|
|
80
|
|
>100
|
|
Other
|
1
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
1
|
|
(50)
|
|
-
|
|
-
|
|
-
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Influenza
|
32
|
|
(3)
|
|
(9)
|
|
1
|
|
>100
|
|
>100
|
|
-
|
|
-
|
|
-
|
|
31
|
|
(6)
|
|
(12)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fluarix, FluLaval
|
32
|
|
(3)
|
|
(9)
|
|
1
|
|
>100
|
|
>100
|
|
-
|
|
-
|
|
-
|
|
31
|
|
(6)
|
|
(12)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shingles
|
731
|
|
>100
|
|
>100
|
|
519
|
|
>100
|
|
97
|
|
151
|
|
>100
|
|
>100
|
|
61
|
|
>100
|
|
>100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shingrix
|
731
|
|
>100
|
|
>100
|
|
519
|
|
>100
|
|
97
|
|
151
|
|
>100
|
|
>100
|
|
61
|
|
>100
|
|
>100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Established
Vaccines
|
717
|
|
(5)
|
|
(9)
|
|
257
|
|
8
|
|
(3)
|
|
176
|
|
12
|
|
13
|
|
284
|
|
(22)
|
|
(23)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Infanrix, Pediarix
|
120
|
|
(12)
|
|
(19)
|
|
51
|
|
(35)
|
|
(45)
|
|
31
|
|
15
|
|
15
|
|
38
|
|
23
|
|
16
|
|
Boostrix
|
158
|
|
8
|
|
3
|
|
95
|
|
44
|
|
30
|
|
38
|
|
9
|
|
11
|
|
25
|
|
(44)
|
|
(44)
|
|
Hepatitis
|
159
|
|
45
|
|
35
|
|
98
|
|
53
|
|
39
|
|
39
|
|
56
|
|
56
|
|
22
|
|
5
|
|
-
|
|
Rotarix
|
120
|
|
(9)
|
|
(8)
|
|
14
|
|
(46)
|
|
(54)
|
|
29
|
|
7
|
|
11
|
|
77
|
|
(3)
|
|
-
|
|
Synflorix
|
84
|
|
(13)
|
|
(14)
|
|
-
|
|
-
|
|
-
|
|
10
|
|
11
|
|
-
|
|
74
|
|
(16)
|
|
(16)
|
|
Priorix, Priorix
Tetra, Varilrix
|
40
|
|
(26)
|
|
(26)
|
|
-
|
|
-
|
|
-
|
|
23
|
|
(4)
|
|
(8)
|
|
17
|
|
(43)
|
|
(40)
|
|
Cervarix
|
22
|
|
(39)
|
|
(44)
|
|
-
|
|
-
|
|
-
|
|
4
|
|
(43)
|
|
(43)
|
|
18
|
|
(38)
|
|
(45)
|
|
Other
|
14
|
|
(70)
|
|
(70)
|
|
(1)
|
|
>(100)
|
|
(60)
|
|
2
|
|
(33)
|
|
33
|
|
13
|
|
(67)
|
|
(79)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vaccines excluding
pandemic
|
1,715
|
|
31
|
|
24
|
|
897
|
|
53
|
|
38
|
|
414
|
|
39
|
|
42
|
|
404
|
|
(6)
|
|
(8)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pandemic vaccines
|
-
|
|
(100)
|
|
(100)
|
|
-
|
|
(100)
|
|
(100)
|
|
-
|
|
-
|
|
-
|
|
-
|
|
(100)
|
|
(100)
|
|
Pandemic
adjuvant
|
-
|
|
(100)
|
|
(100)
|
|
-
|
|
(100)
|
|
(100)
|
|
-
|
|
-
|
|
-
|
|
-
|
|
(100)
|
|
(100)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vaccines
|
1,715
|
|
9
|
|
3
|
|
897
|
|
13
|
|
2
|
|
414
|
|
39
|
|
42
|
|
404
|
|
(15)
|
|
(18)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vaccines turnover – six months ended 30 June
2022
|
|
|
Total
|
|
US
|
|
Europe
|
|
International
|
||||||||||||||||
|
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
||||||||
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Meningitis
|
447
|
|
8
|
|
6
|
|
219
|
|
34
|
|
24
|
|
170
|
|
(9)
|
|
(6)
|
|
58
|
|
(11)
|
|
(8)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Bexsero
|
328
|
|
10
|
|
9
|
|
131
|
|
44
|
|
34
|
|
160
|
|
(8)
|
|
(6)
|
|
37
|
|
9
|
|
15
|
|
Menveo
|
111
|
|
13
|
|
8
|
|
88
|
|
21
|
|
12
|
|
8
|
|
(11)
|
|
(11)
|
|
15
|
|
(6)
|
|
-
|
|
Other
|
8
|
|
(56)
|
|
(56)
|
|
-
|
|
-
|
|
-
|
|
2
|
|
(33)
|
|
-
|
|
6
|
|
(60)
|
|
(67)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Influenza
|
50
|
|
(2)
|
|
(6)
|
|
2
|
|
>100
|
|
>100
|
|
-
|
|
-
|
|
-
|
|
48
|
|
(6)
|
|
(10)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fluarix, FluLaval
|
50
|
|
(2)
|
|
(6)
|
|
2
|
|
>100
|
|
>100
|
|
-
|
|
-
|
|
-
|
|
48
|
|
(6)
|
|
(10)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shingles
|
1,429
|
|
>100
|
|
>100
|
|
1,009
|
|
99
|
|
86
|
|
311
|
|
>100
|
|
>100
|
|
109
|
|
>100
|
|
>100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shingrix
|
1,429
|
|
>100
|
|
>100
|
|
1,009
|
|
99
|
|
86
|
|
311
|
|
>100
|
|
>100
|
|
109
|
|
>100
|
|
>100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Established
Vaccines
|
1,458
|
|
1
|
|
(1)
|
|
559
|
|
33
|
|
25
|
|
342
|
|
-
|
|
2
|
|
557
|
|
(19)
|
|
(19)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Infanrix, Pediarix
|
295
|
|
8
|
|
4
|
|
163
|
|
15
|
|
7
|
|
60
|
|
(10)
|
|
(9)
|
|
72
|
|
14
|
|
11
|
|
Boostrix
|
284
|
|
18
|
|
15
|
|
165
|
|
51
|
|
41
|
|
71
|
|
-
|
|
3
|
|
48
|
|
(20)
|
|
(20)
|
|
Hepatitis
|
281
|
|
37
|
|
32
|
|
176
|
|
53
|
|
43
|
|
68
|
|
39
|
|
41
|
|
37
|
|
(10)
|
|
(10)
|
|
Rotarix
|
237
|
|
(4)
|
|
(2)
|
|
49
|
|
2
|
|
(4)
|
|
61
|
|
7
|
|
11
|
|
127
|
|
(10)
|
|
(6)
|
|
Synflorix
|
165
|
|
(17)
|
|
(17)
|
|
-
|
|
-
|
|
-
|
|
16
|
|
(24)
|
|
(24)
|
|
149
|
|
(16)
|
|
(16)
|
|
Priorix, Priorix
Tetra, Varilrix
|
87
|
|
(26)
|
|
(26)
|
|
-
|
|
-
|
|
-
|
|
51
|
|
(9)
|
|
(9)
|
|
36
|
|
(41)
|
|
(41)
|
|
Cervarix
|
51
|
|
(37)
|
|
(41)
|
|
-
|
|
-
|
|
-
|
|
8
|
|
(47)
|
|
(47)
|
|
43
|
|
(35)
|
|
(39)
|
|
Other
|
58
|
|
(33)
|
|
(32)
|
|
6
|
|
-
|
|
33
|
|
7
|
|
-
|
|
29
|
|
45
|
|
(39)
|
|
(43)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vaccines excluding
pandemic
|
3,384
|
|
33
|
|
30
|
|
1,789
|
|
64
|
|
53
|
|
823
|
|
36
|
|
40
|
|
772
|
|
(8)
|
|
(9)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pandemic vaccines
|
-
|
|
(100)
|
|
(100)
|
|
-
|
|
(100)
|
|
(100)
|
|
-
|
|
-
|
|
-
|
|
-
|
|
(100)
|
|
(100)
|
|
Pandemic
adjuvant
|
-
|
|
(100)
|
|
(100)
|
|
-
|
|
(100)
|
|
(100)
|
|
-
|
|
-
|
|
-
|
|
-
|
|
(100)
|
|
(100)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vaccines
|
3,384
|
|
21
|
|
17
|
|
1,789
|
|
38
|
|
29
|
|
823
|
|
36
|
|
40
|
|
772
|
|
(13)
|
|
(14)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General Medicines turnover – three months ended 30 June
2022
|
|
|
Total
|
|
US
|
|
Europe
|
|
International
|
||||||||||||||||
|
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
||||||||
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Respiratory
|
1,649
|
|
9
|
|
4
|
|
846
|
|
11
|
|
1
|
|
348
|
|
4
|
|
5
|
|
455
|
|
8
|
|
7
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Arnuity Ellipta
|
13
|
|
30
|
|
20
|
|
11
|
|
22
|
|
22
|
|
-
|
|
-
|
|
-
|
|
2
|
|
100
|
|
-
|
|
Anoro Ellipta
|
118
|
|
(12)
|
|
(16)
|
|
59
|
|
(23)
|
|
(31)
|
|
39
|
|
8
|
|
11
|
|
20
|
|
(5)
|
|
(5)
|
|
Avamys/Veramyst
|
74
|
|
17
|
|
14
|
|
-
|
|
-
|
|
-
|
|
20
|
|
-
|
|
-
|
|
54
|
|
26
|
|
21
|
|
Flixotide/Flovent
|
143
|
|
36
|
|
28
|
|
98
|
|
44
|
|
31
|
|
18
|
|
20
|
|
27
|
|
27
|
|
23
|
|
18
|
|
Incruse Ellipta
|
51
|
|
(4)
|
|
(8)
|
|
29
|
|
-
|
|
(14)
|
|
17
|
|
(11)
|
|
(16)
|
|
5
|
|
-
|
|
60
|
|
Relvar/Breo Ellipta
|
309
|
|
(1)
|
|
(4)
|
|
150
|
|
(2)
|
|
(11)
|
|
87
|
|
4
|
|
5
|
|
72
|
|
(4)
|
|
(1)
|
|
Seretide/Advair
|
262
|
|
(24)
|
|
(27)
|
|
61
|
|
(54)
|
|
(60)
|
|
73
|
|
(8)
|
|
(6)
|
|
128
|
|
(6)
|
|
(7)
|
|
Trelegy Ellipta
|
467
|
|
60
|
|
50
|
|
354
|
|
74
|
|
58
|
|
58
|
|
18
|
|
20
|
|
55
|
|
45
|
|
47
|
|
Ventolin
|
174
|
|
4
|
|
(2)
|
|
85
|
|
(4)
|
|
(15)
|
|
27
|
|
8
|
|
12
|
|
62
|
|
17
|
|
11
|
|
Other
Respiratory
|
38
|
|
19
|
|
16
|
|
(1)
|
|
50
|
|
>100
|
|
9
|
|
12
|
|
-
|
|
30
|
|
11
|
|
4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other General Medicines
|
861
|
|
(1)
|
|
(2)
|
|
87
|
|
6
|
|
(6)
|
|
174
|
|
(15)
|
|
(14)
|
|
600
|
|
4
|
|
4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dermatology
|
91
|
|
(11)
|
|
(11)
|
|
-
|
|
-
|
|
-
|
|
28
|
|
(20)
|
|
(20)
|
|
63
|
|
(6)
|
|
(6)
|
|
Augmentin
|
130
|
|
43
|
|
45
|
|
-
|
|
-
|
|
-
|
|
37
|
|
28
|
|
31
|
|
93
|
|
50
|
|
52
|
|
Avodart
|
81
|
|
(5)
|
|
(6)
|
|
-
|
|
-
|
|
-
|
|
27
|
|
(10)
|
|
(7)
|
|
54
|
|
(2)
|
|
(5)
|
|
Lamictal
|
127
|
|
9
|
|
3
|
|
65
|
|
18
|
|
7
|
|
27
|
|
(4)
|
|
(4)
|
|
35
|
|
6
|
|
-
|
|
Other
|
399
|
|
(9)
|
|
(9)
|
|
22
|
|
(19)
|
|
(33)
|
|
55
|
|
(34)
|
|
(34)
|
|
322
|
|
-
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General Medicines
|
2,510
|
|
5
|
|
2
|
|
933
|
|
11
|
|
-
|
|
522
|
|
(3)
|
|
(2)
|
|
1,055
|
|
6
|
|
5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General Medicines turnover – six months ended 30 June
2022
|
|
|
Total
|
|
US
|
|
Europe
|
|
International
|
||||||||||||||||
|
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
||||||||
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Respiratory
|
3,184
|
|
6
|
|
3
|
|
1,568
|
|
9
|
|
2
|
|
681
|
|
1
|
|
3
|
|
935
|
|
4
|
|
5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Arnuity Ellipta
|
26
|
|
62
|
|
50
|
|
22
|
|
69
|
|
62
|
|
-
|
|
-
|
|
-
|
|
4
|
|
33
|
|
-
|
|
Anoro Ellipta
|
216
|
|
(14)
|
|
(16)
|
|
100
|
|
(29)
|
|
(34)
|
|
77
|
|
7
|
|
10
|
|
39
|
|
-
|
|
3
|
|
Avamys/Veramyst
|
168
|
|
1
|
|
2
|
|
-
|
|
-
|
|
-
|
|
36
|
|
-
|
|
3
|
|
132
|
|
2
|
|
2
|
|
Flixotide/Flovent
|
270
|
|
22
|
|
17
|
|
183
|
|
33
|
|
24
|
|
36
|
|
16
|
|
19
|
|
51
|
|
(4)
|
|
(2)
|
|
Incruse Ellipta
|
101
|
|
(4)
|
|
(7)
|
|
55
|
|
(2)
|
|
(9)
|
|
33
|
|
(11)
|
|
(11)
|
|
13
|
|
8
|
|
17
|
|
Relvar/Breo Ellipta
|
584
|
|
1
|
|
(1)
|
|
270
|
|
2
|
|
(5)
|
|
170
|
|
2
|
|
5
|
|
144
|
|
(3)
|
|
(1)
|
|
Seretide/Advair
|
564
|
|
(19)
|
|
(20)
|
|
145
|
|
(42)
|
|
(46)
|
|
146
|
|
(16)
|
|
(14)
|
|
273
|
|
(1)
|
|
(1)
|
|
Trelegy Ellipta
|
807
|
|
50
|
|
43
|
|
592
|
|
57
|
|
47
|
|
111
|
|
18
|
|
20
|
|
104
|
|
53
|
|
57
|
|
Ventolin
|
375
|
|
5
|
|
2
|
|
202
|
|
-
|
|
(6)
|
|
57
|
|
14
|
|
18
|
|
116
|
|
10
|
|
10
|
|
Other
Respiratory
|
73
|
|
-
|
|
2
|
|
(1)
|
|
50
|
|
100
|
|
15
|
|
7
|
|
7
|
|
59
|
|
(5)
|
|
(5)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other General Medicines
|
1,712
|
|
(1)
|
|
-
|
|
176
|
|
10
|
|
3
|
|
344
|
|
(16)
|
|
(14)
|
|
1,192
|
|
4
|
|
5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dermatology
|
183
|
|
(9)
|
|
(8)
|
|
-
|
|
-
|
|
-
|
|
-
|
|
(20)
|
|
(19)
|
|
128
|
|
(4)
|
|
(2)
|
|
Augmentin
|
259
|
|
42
|
|
48
|
|
-
|
|
-
|
|
-
|
|
73
|
|
40
|
|
46
|
|
186
|
|
43
|
|
48
|
|
Avodart
|
162
|
|
(4)
|
|
(4)
|
|
-
|
|
-
|
|
-
|
|
54
|
|
(10)
|
|
(8)
|
|
108
|
|
1
|
|
-
|
|
Lamictal
|
247
|
|
6
|
|
3
|
|
124
|
|
13
|
|
5
|
|
53
|
|
(5)
|
|
(4)
|
|
70
|
|
6
|
|
5
|
|
Other
|
785
|
|
(8)
|
|
(7)
|
|
52
|
|
6
|
|
(2)
|
|
109
|
|
(36)
|
|
(35)
|
|
624
|
|
(1)
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General Medicines
|
4,896
|
|
3
|
|
2
|
|
1,744
|
|
9
|
|
2
|
|
1,025
|
|
(5)
|
|
(3)
|
|
2,127
|
|
4
|
|
5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Commercial Operations turnover
|
|
|
Total
|
|
US
|
|
Europe
|
|
International
|
||||||||||||||||
|
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
||||||||
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended 30 June 2022
|
6,929
|
|
19
|
|
13
|
|
3,317
|
|
19
|
|
7
|
|
1,549
|
|
23
|
|
25
|
|
2,063
|
|
15
|
|
14
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six months ended
30 June 2022
|
14,119
|
|
28
|
|
25
|
|
6,903
|
|
38
|
|
29
|
|
3,209
|
|
27
|
|
30
|
|
4,007
|
|
16
|
|
17
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance
sheet
|
|
|
30 June 2022
£m
|
|
31
December 2021
£m
|
|
ASSETS
|
|
|
|
|
Non-current assets
|
|
|
|
|
Property,
plant and equipment
|
8,503
|
|
9,932
|
|
Right
of use assets
|
650
|
|
740
|
|
Goodwill
|
5,906
|
|
10,552
|
|
Other
intangible assets
|
11,371
|
|
30,079
|
|
Investments
in associates and joint ventures
|
77
|
|
88
|
|
Other
investments
|
1,651
|
|
2,126
|
|
Deferred
tax assets
|
4,952
|
|
5,218
|
|
Derivative
financial instruments
|
11
|
|
18
|
|
Other
non-current assets
|
1,736
|
|
1,676
|
|
|
|
|
|
|
Total non-current assets
|
34,857
|
|
60,429
|
|
|
|
|
|
|
Current assets
|
|
|
|
|
Inventories
|
4,664
|
|
5,783
|
|
Current
tax recoverable
|
413
|
|
486
|
|
Trade
and other receivables
|
6,457
|
|
7,860
|
|
Derivative
financial instruments
|
105
|
|
188
|
|
Liquid
investments
|
67
|
|
61
|
|
Cash
and cash equivalents
|
6,465
|
|
4,274
|
|
Assets
held for sale/distribution
|
36,017
|
|
22
|
|
|
|
|
|
|
Total current assets
|
54,188
|
|
18,674
|
|
|
|
|
|
|
TOTAL ASSETS
|
89,045
|
|
79,103
|
|
|
|
|
|
|
LIABILITIES
|
|
|
|
|
Current liabilities
|
|
|
|
|
Short-term
borrowings
|
(3,327)
|
|
(3,601)
|
|
Contingent
consideration liabilities
|
(888)
|
|
(958)
|
|
Trade
and other payables
|
(14,806)
|
|
(17,554)
|
|
Derivative
financial instruments
|
(70)
|
|
(227)
|
|
Current
tax payable
|
(295)
|
|
(489)
|
|
Short-term
provisions
|
(599)
|
|
(841)
|
|
Liabilities
held for distribution
|
(17,850)
|
|
-
|
|
|
|
|
|
|
Total current liabilities
|
(37,835)
|
|
(23,670)
|
|
|
|
|
|
|
Non-current liabilities
|
|
|
|
|
Long-term
borrowings
|
(18,784)
|
|
(20,572)
|
|
Corporation
tax payable
|
(200)
|
|
(180)
|
|
Deferred
tax liabilities
|
(149)
|
|
(3,556)
|
|
Pensions
and other post-employment benefits
|
(2,526)
|
|
(3,113)
|
|
Other
provisions
|
(557)
|
|
(630)
|
|
Derivative
financial instruments
|
(1)
|
|
(1)
|
|
Contingent
consideration liabilities
|
(5,472)
|
|
(5,118)
|
|
Other
non-current liabilities
|
(881)
|
|
(921)
|
|
|
|
|
|
|
Total non-current liabilities
|
(28,570)
|
|
(34,091)
|
|
|
|
|
|
|
TOTAL LIABILITIES
|
(66,405)
|
|
(57,761)
|
|
|
|
|
|
|
NET ASSETS
|
22,640
|
|
21,342
|
|
|
|
|
|
|
EQUITY
|
|
|
|
|
Share
capital
|
1,347
|
|
1,347
|
|
Share
premium account
|
3,439
|
|
3,301
|
|
Retained
earnings
|
9,824
|
|
7,944
|
|
Other
reserves
|
1,764
|
|
2,463
|
|
|
|
|
|
|
Shareholders’ equity
|
16,374
|
|
15,055
|
|
|
|
|
|
|
Non-controlling
interests
|
6,266
|
|
6,287
|
|
|
|
|
|
|
TOTAL EQUITY
|
22,640
|
|
21,342
|
|
|
|
|
|
|
Statement of changes in
equity
|
|
|
Share
capital
£m
|
|
Share
premium
£m
|
|
Retained
earnings
£m
|
|
Other
reserves
£m
|
|
Share-
holder’s
equity
£m
|
|
Non-
controlling
interests
£m
|
|
Total
equity
£m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At 1
January 2022
|
1,347
|
|
3,301
|
|
7,944
|
|
2,463
|
|
15,055
|
|
6,287
|
|
21,342
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
for the period
|
|
|
|
|
2,640
|
|
|
|
2,640
|
|
502
|
|
3,142
|
|
Other
comprehensive
income/(expense)
for the period
|
|
|
|
|
1,010
|
|
(411)
|
|
599
|
|
(25)
|
|
574
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
comprehensive income/(expense)
for
the period
|
|
|
|
|
3,650
|
|
(411)
|
|
3,239
|
|
477
|
|
3,716
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Distributions
to non-controlling interests
|
|
|
|
|
|
|
|
|
|
|
(506)
|
|
(506)
|
|
Contributions
from non-controlling
interests
|
|
|
|
|
|
|
|
|
|
|
8
|
|
8
|
|
Dividends
to shareholders
|
|
|
|
|
(2,108)
|
|
|
|
(2,108)
|
|
|
|
(2,108)
|
|
Shares
issued
|
|
|
20
|
|
|
|
|
|
20
|
|
|
|
20
|
|
Shares
acquired by ESOP Trusts
|
|
|
118
|
|
704
|
|
(822)
|
|
-
|
|
|
|
-
|
|
Share
of associates and joint ventures
realised
profits on disposal of equity
investments
|
|
|
|
|
(1)
|
|
1
|
|
-
|
|
|
|
-
|
|
Realised
after tax losses on disposal
or
liquidation of equity investments
|
|
|
|
|
(23)
|
|
23
|
|
-
|
|
|
|
-
|
|
Write-down
on shares held by ESOP
Trusts
|
|
|
|
|
(510)
|
|
510
|
|
-
|
|
|
|
-
|
|
Share-based
incentive plans
|
|
|
|
|
168
|
|
|
|
168
|
|
|
|
168
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At 30 June 2022
|
1,347
|
|
3,439
|
|
9,824
|
|
1,764
|
|
16,374
|
|
6,266
|
|
22,640
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At 1
January 2021
|
1,346
|
|
3,281
|
|
6,755
|
|
3,205
|
|
14,587
|
|
6,221
|
|
20,808
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
for the period
|
|
|
|
|
2,468
|
|
|
|
2,468
|
|
330
|
|
2,798
|
|
Other
comprehensive (expense)/
income
for the period
|
|
|
|
|
14
|
|
205
|
|
219
|
|
(37)
|
|
182
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
comprehensive income for the
period
|
|
|
|
|
2,482
|
|
205
|
|
2,687
|
|
293
|
|
2,980
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Distributions
to non-controlling interests
|
|
|
|
|
|
|
|
|
|
|
(320)
|
|
(320)
|
|
Contributions
from non-controlling
interests
|
|
|
|
|
|
|
|
|
|
|
7
|
|
7
|
|
Dividends
to shareholders
|
|
|
|
|
(2,097)
|
|
|
|
(2,097)
|
|
|
|
(2,097)
|
|
Shares
issued
|
1
|
|
18
|
|
|
|
|
|
19
|
|
|
|
19
|
|
Realised
after tax profits on disposal
of
equity investments
|
|
|
|
|
145
|
|
(145)
|
|
-
|
|
|
|
-
|
|
Share
of associates and joint ventures
realised
profits on disposal of equity
investments
|
|
|
|
|
9
|
|
(9)
|
|
-
|
|
|
|
-
|
|
Write-down
on shares held by ESOP
Trusts
|
|
|
|
|
(96)
|
|
96
|
|
-
|
|
|
|
-
|
|
Share-based
incentive plans
|
|
|
|
|
181
|
|
|
|
181
|
|
|
|
181
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At 30
June 2021
|
1,347
|
|
3,299
|
|
7,379
|
|
3,352
|
|
15,377
|
|
6,201
|
|
21,578
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flow statement
– six months ended 30 June 2022
(amounts presented are from continuing operations unless otherwise
specified)
|
|
|
H1 2022
£m
|
|
H1
2021(a)
£m
|
|
|
|
|
|
|
|
|
Profit after tax from continuing operations
|
2,517
|
|
2,150
|
|
|
Tax on
profits
|
473
|
|
(46)
|
|
|
Share
of after tax losses/(profits) of associates and joint
ventures
|
3
|
|
(32)
|
|
|
Loss on
disposal of interests in associates
|
-
|
|
36
|
|
|
Net
finance expense
|
381
|
|
377
|
|
|
Depreciation,
amortisation and other adjusting items
|
1,335
|
|
906
|
|
|
Increase
in working capital
|
(198)
|
|
(809)
|
|
|
Contingent
consideration paid
|
(542)
|
|
(371)
|
|
|
Decrease
in other net liabilities (excluding contingent consideration
paid)
|
(33)
|
|
(452)
|
|
|
|
|
|
|
|
|
Cash generated from operations attributable to continuing
operations
|
3,936
|
|
1,759
|
|
|
Taxation
paid
|
(534)
|
|
(542)
|
|
|
|
|
|
|
|
|
Net cash inflow from continuing operating activities
|
3,402
|
|
1,217
|
|
|
Cash
generated from operations attributable to discontinued
operations
|
918
|
|
564
|
|
|
Taxation
paid from discontinued operations
|
(143)
|
|
(158)
|
|
|
Net operating cash flows attributable to discontinued
operations
|
775
|
|
406
|
|
|
|
|
|
|
|
|
Total net cash inflows from operating activities
|
4,177
|
|
1,623
|
|
|
|
|
|
|
|
|
Cash flow from investing activities
|
|
|
|
|
|
Purchase
of property, plant and equipment
|
(430)
|
|
(352)
|
|
|
Proceeds
from sale of property, plant and equipment
|
6
|
|
95
|
|
|
Purchase
of intangible assets
|
(597)
|
|
(556)
|
|
|
Proceeds
from sale of intangible assets
|
13
|
|
314
|
|
|
Purchase
of equity investments
|
(59)
|
|
(122)
|
|
|
Proceeds
from sale of equity investments
|
-
|
|
171
|
|
|
Share
transaction with minority shareholders
|
1
|
|
1
|
|
|
Contingent
consideration paid
|
(73)
|
|
(55)
|
|
|
Disposal
of businesses
|
(12)
|
|
(19)
|
|
|
Investment
in associates and joint ventures
|
-
|
|
(1)
|
|
|
Proceeds
from disposal of associates and joint ventures
|
-
|
|
277
|
|
|
Interest
received
|
26
|
|
10
|
|
|
Decrease
in liquid investments
|
-
|
|
18
|
|
|
Dividends
from associates and joint ventures
|
-
|
|
9
|
|
|
|
|
|
|
|
|
Net cash outflow from continuing investing activities
|
(1,125)
|
|
(210)
|
|
|
Net
investing cash flows attributable to discontinued
operations
|
(3,013)
|
|
(23)
|
|
|
|
|
|
|
|
|
Total net cash outflow from investing activities
|
(4,138)
|
|
(233)
|
|
|
|
|
|
|
|
|
Cash flow from financing activities
|
|
|
|
|
|
Issue
of share capital
|
20
|
|
19
|
|
|
Shares
acquired by ESOP trust
|
(3)
|
|
-
|
|
|
Decrease
in long-term loans
|
(3)
|
|
(2)
|
|
|
Repayment
of short-term loans
|
(3,062)
|
|
(352)
|
|
|
Repayment
of lease liabilities
|
(99)
|
|
(94)
|
|
|
Interest
paid
|
(437)
|
|
(431)
|
|
|
Dividends
paid to shareholders
|
(2,108)
|
|
(2,097)
|
|
|
Distributions
to non-controlling interests
|
(177)
|
|
(121)
|
|
|
Contributions
from non-controlling interests
|
8
|
|
7
|
|
|
Other
financing items
|
264
|
|
(99)
|
|
|
|
|
|
|
|
|
Net cash outflow from continuing financing activities
|
(5,597)
|
|
(3,170)
|
|
|
Net
financing cash flows attributable to discontinued
operations
|
9,084
|
|
(251)
|
|
|
|
|
|
|
|
|
Total net cash inflow/(outflow) from financing
activities
|
3,487
|
|
(3,421)
|
|
|
|
|
|
|
|
|
Increase/(decrease) in cash and bank overdrafts in the
period
|
3,526
|
|
(2,031)
|
|
|
|
|
|
|
|
|
Cash
and bank overdrafts at beginning of the period
|
3,817
|
|
5,261
|
|
|
Exchange
adjustments
|
83
|
|
(34)
|
|
|
Increase/(decrease)
in cash and bank overdrafts
|
3,526
|
|
(2,031)
|
|
|
|
|
|
|
|
|
Cash and bank overdrafts at end of the period
|
7,426
|
|
3,196
|
|
|
|
|
|
|
|
|
Cash
and bank overdrafts at end of the period comprise:
|
|
|
|
|
|
|
Cash
and cash equivalents
|
6,465
|
|
3,503
|
|
|
Cash
and cash equivalents reported in assets held for
sale/distribution
|
1,421
|
|
-
|
|
|
|
|
|
|
|
|
|
7,886
|
|
3,503
|
|
|
Overdrafts
|
(460)
|
|
(307)
|
|
|
|
|
|
|
|
|
7,426
|
|
3,196
|
|
|
|
|
|
|
|
|
(a)
|
The
2021 comparative results have been restated on a consistent basis
from those previously published to reflect the classification of
the Consumer Healthcare business as a discontinued operation (see
page 20) and the impact of Share Consolidation implemented on 18
July 2022 (see page 53).
|
|
Segment
information
|
|
Operating
segments are reported based on the financial information provided
to the Chief Executive Officer and the responsibilities of the GSK
Leadership Team (GLT). GSK has revised its operating segments from
Q1 2022 and from Q2 2022. Previously, GSK reported results under
four segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines
and Consumer Healthcare. For the first quarter 2022, GSK reported
results under three segments: Commercial Operations; Total R&D
and Consumer Healthcare. From Q2 2022, GSK reports results under
two segments from continuing operations as the demerger of the
Consumer Healthcare segment was completed on 18 July 2022. Members
of the GLT are responsible for each segment. Comparative
information in this announcement has been retrospectively restated
on a consistent basis. The Consumer Healthcare segment is presented
entirely as discontinued operations and therefore no segment
information is presented.
R&D
investment is essential for the sustainability of the business.
However for segment reporting the Commercial operating profits
exclude allocations of globally funded R&D.
The
Total R&D segment is the responsibility of the Chief Scientific
Officer and President, R&D and is reported as a separate
segment. The operating profit of this segment includes R&D
activities across Specialty Medicines, including HIV and Vaccines.
It includes R&D and some SG&A costs relating to regulatory
and other functions.
The
Group’s management reporting process allocates intra-Group
profit on a product sale to the market in which that sale is
recorded, and the profit analyses below have been presented on that
basis.
|
|
Turnover by segment
|
|||||||
|
|
Q2 2022
£m
|
|
Q2
2021
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
|
|
Commercial
Operations (total turnover)
|
6,929
|
|
5,838
|
|
19
|
|
13
|
|
|
|
|
|
|
|
|
|
|
Operating profit by segment
|
|||||||
|
|
Q2 2022
£m
|
|
Q2
2021
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
|
|
Commercial
Operations
|
3,304
|
|
2,869
|
|
15
|
|
6
|
|
Research
and Development
|
(1,152)
|
|
(1,119)
|
|
3
|
|
(2)
|
|
|
|
|
|
|
|
|
|
|
Segment
profit
|
2,152
|
|
1,750
|
|
23
|
|
10
|
|
Corporate
and other unallocated costs
|
(144)
|
|
(109)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted
operating profit
|
2,008
|
|
1,641
|
|
22
|
|
7
|
|
Adjusting
items
|
(927)
|
|
(366)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
operating profit
|
1,081
|
|
1,275
|
|
(15)
|
|
(35)
|
|
|
|
|
|
|
|
|
|
|
Finance
income
|
21
|
|
4
|
|
|
|
|
|
Finance
costs
|
(204)
|
|
(189)
|
|
|
|
|
|
Loss on
disposal of interests in associates
|
-
|
|
(36)
|
|
|
|
|
|
Share
of after tax (losses)/profits of
associates
and joint ventures
|
(2)
|
|
16
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
before taxation from continuing operations
|
896
|
|
1,070
|
|
(16)
|
|
(40)
|
|
|
|
|
|
|
|
|
|
|
Adjusting items reconciling Q2 2022 and H1 2022 segment profit and
operating profit comprise items not specifically allocated to
segment profit. These include impairment and amortisation of
intangible assets; major restructuring costs, which include
impairments of tangible assets and computer software;
transaction-related adjustments related to significant
acquisitions; proceeds and costs of disposals of associates,
products and businesses, significant legal charges and expenses on
the settlement of litigation and government investigations, other
operating income other than royalty income and other
items.
|
|
Turnover by segment
|
|||||||
|
|
H1 2022
£m
|
|
H1
2021
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
|
|
Commercial
Operations (total turnover)
|
14,119
|
|
10,993
|
|
28
|
|
25
|
|
|
|
|
|
|
|
|
|
|
Operating profit by segment
|
|||||||
|
|
H1 2022
£m
|
|
H1
2021
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
|
|
Commercial
Operations
|
6,421
|
|
5,312
|
|
21
|
|
16
|
|
Research
and Development
|
(2,247)
|
|
(2,148)
|
|
5
|
|
2
|
|
|
|
|
|
|
|
|
|
|
Segment
profit
|
4,174
|
|
3,164
|
|
32
|
|
26
|
|
Corporate
and other unallocated costs
|
(223)
|
|
(198)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted
operating profit
|
3,951
|
|
2,966
|
|
33
|
|
26
|
|
Adjusting
items
|
(577)
|
|
(481)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
operating profit
|
3,374
|
|
2,485
|
|
36
|
|
26
|
|
|
|
|
|
|
|
|
|
|
Finance
income
|
28
|
|
10
|
|
|
|
|
|
Finance
costs
|
(409)
|
|
(387)
|
|
|
|
|
|
Loss on
disposal of interests in associates
|
-
|
|
(36)
|
|
|
|
|
|
Share
of after tax (losses)/profits of
associates
and joint ventures
|
(3)
|
|
32
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
before taxation from continuing operations
|
2,990
|
|
2,104
|
|
42
|
|
32
|
|
|
|
|
|
|
|
|
|
|
Legal
matters
The
Group is involved in significant legal and administrative
proceedings, principally product liability, intellectual property,
tax, anti-trust, consumer fraud and governmental investigations,
which are more fully described in the ‘Legal
Proceedings’ note in the Annual Report 2021. At 30 June 2022,
the Group’s aggregate provision for legal and other disputes
(not including tax matters described on page 27 was £0.2
billion (31 December 2021: £ 0.2 billion).
The
Group may become involved in significant legal proceedings in
respect of which it is not possible to meaningfully assess whether
the outcome will result in a probable outflow, or to quantify or
reliably estimate the liability, if any, that could result from
ultimate resolution of the proceedings. In these cases, the Group
would provide appropriate disclosures about such cases, but no
provision would be made.
The
ultimate liability for legal claims may vary from the amounts
provided and is dependent upon the outcome of litigation
proceedings, investigations and possible settlement negotiations.
The Group’s position could change over time, and, therefore,
there can be no assurance that any losses that result from the
outcome of any legal proceedings will not exceed by a material
amount the amount of the provisions reported in the Group’s
financial accounts.
There
have been no significant legal developments this
quarter.
|
|
Additional
information
|
|
Disposal group and discontinued operations accounting
policy
Disposal
groups are classified as held for distribution if their carrying
amount will be recovered principally through a distribution to
shareholders rather than through continuing use, they are available
for distribution in their present condition and the distribution is
considered highly probable. They are measured at the lower of their
carrying amount and fair value less costs to
distribute.
Non-current
assets included as part of a disposal group are not depreciated or
amortised while they are classified as held for distribution. The
assets and liabilities of a disposal group classified as held for
distribution are presented separately from the other assets and
liabilities in the balance sheet.
A
discontinued operation is a component of the entity that has been
disposed of or distributed or is classified as held for
distribution and that represents a separate major line of business.
The results of discontinued operations are presented separately in
the statement of profit or loss and comparatives are restated on a
consistent basis.
Accounting policies and basis of preparation
This
unaudited Results Announcement contains condensed financial
information for the three and six months ended 30 June 2022, and should be read in
conjunction with the Annual Report 2021, which was prepared
in accordance with United Kingdom adopted
International Financial Reporting Standards. This Results
Announcement has been prepared applying consistent accounting
policies to those applied by the Group in the Annual Report
2021.
The
Group has not identified any changes to its key sources of
accounting judgements or estimations of uncertainty compared with
those disclosed in the Annual Report 2021.
|
|
This
Results Announcement does not constitute statutory accounts of the
Group within the meaning of sections 434(3) and 435(3) of the
Companies Act 2006. The full Group accounts for 2021 were published
in the Annual Report 2021, which has been delivered to the
Registrar of Companies and on which the report of the independent
auditor was unqualified and did not contain a statement under
section 498 of the Companies Act 2006.
COVID-19 pandemic
The
potential impact of the COVID-19 pandemic on GSK’s trading
performance and all its principal risks is continually assessed,
with appropriate mitigation plans put in place. GSK is encouraged
by the uptake in demand in the second quarter for its medicines and
vaccines, particularly Shingrix. The Company remains confident
in the underlying demand for its vaccines and medicines, given the
number of COVID-19 vaccinations and boosters administered
worldwide. The pandemic continues to be challenging to predict and
remains a dynamic situation with the worldwide rate of community
infections presently increasing due to Omicron subvariants BA.5 and
BA.4; these variants of concern and future variants of concern
could potentially impact GSK’s trading results, clinical
trials, supply continuity and its employees
materially.
|
|
Exchange rates
|
|
GSK
operates in many countries and earns revenues and incurs costs in
many currencies. The results of the Group, as reported in Sterling,
are affected by movements in exchange rates between Sterling and
other currencies. Average exchange rates, as modified by specific
transaction rates for large transactions, prevailing during the
period, are used to translate the results and cash flows of
overseas subsidiaries, associates and joint ventures into Sterling.
Period-end rates are used to translate the net assets of those
entities. The currencies which most influenced these translations
and the relevant exchange rates were:
|
|
|
Q2 2022
|
|
Q2
2021
|
|
H1 2022
|
|
H1
2021
|
|
2021
|
||
|
|
|
|
|
|
|
|
|
|
|
||
|
Average
rates:
|
|
|
|
|
|
|
|
|
|
||
|
|
|
US$/£
|
1.26
|
|
1.40
|
|
1.30
|
|
1.39
|
|
1.38
|
|
|
|
Euro/£
|
1.18
|
|
1.16
|
|
1.19
|
|
1.15
|
|
1.16
|
|
|
|
Yen/£
|
162
|
|
152
|
|
159
|
|
149
|
|
151
|
|
|
|
|
|
|
|
|
|
|
|
||
|
Period-end
rates:
|
|
|
|
|
|
|
|
|
|
||
|
|
|
US$/£
|
1.21
|
|
1.39
|
|
1.21
|
|
1.39
|
|
1.35
|
|
|
|
Euro/£
|
1.16
|
|
1.17
|
|
1.16
|
|
1.17
|
|
1.19
|
|
|
|
Yen/£
|
165
|
|
153
|
|
165
|
|
153
|
|
155
|
|
During Q2 2022 average Sterling exchange rates were stronger
against the Yen and the Euro but weaker against the US Dollar
compared with the same period in 2021. Period-end Sterling exchange
rates were stronger against the Yen but weaker against the US
Dollar and the Euro compared with the 2021 period-end
rates.
|
|
Net assets
|
|
The
book value of net assets increased by £1,298 million from
£21,342 million at 31 December 2021 to £22,640 million at
30 June 2022. This primarily reflected the Total profit for the
period and the re-measurement gains on the defined benefit plans.
These increases were partially offset by a decrease in fair value
of Other investments and by dividends paid during the
period.
The
carrying value of investments in associates and joint ventures at
30 June 2022 was £77 million (31 December 2021: £88
million), with a market value of £77 million (31 December
2021: £88 million).
At 30
June 2022, the net deficit on the Group’s pension plans was
£651 million compared with £1,129 million at 31 December
2021. This decrease in the net deficit is primarily related to
increases in the long term UK discount rate (3.9% Q2 2022, 2.0% Q4
2021), the US discount rate (4.7% Q2 2022, 2.7% Q4 2021) and
Euro-zone discount rates (3.4% Q2 2022, 1.3% Q4 2021), partially
offset by increases in the US cash balance credit rate (3.0% Q2
2022; 2.0% Q4 2021), Euro-zone inflation rates (2.2% Q2 2022; 2.1%
Q4 2021) and, lower UK and Euro-zone asset values. The net deficit
balance at 30 June 2022 excludes £25 million relating to the
discontinued Consumer Healthcare business.
The
estimated present value of the potential redemption amount of the
Pfizer put option related to ViiV Healthcare, recorded in Other
payables in Current liabilities, was £1,158 million (31
December 2021: £1,008 million).
Contingent
consideration amounted to £6,360 million at 30 June 2022 (31
December 2021: £6,076 million), of which £5,797 million
(31 December 2021: £5,559 million) represented the estimated
present value of amounts payable to Shionogi relating to ViiV
Healthcare and £546 million (31 December 2021: £479
million) represented the estimated present value of contingent
consideration payable to Novartis related to the Vaccines
acquisition.
Of the
contingent consideration payable (on a post-tax basis) to Shionogi
at 30 June 2022, £857 million (31 December 2021: £937
million) is expected to be paid within one year.
|
|
Movements in contingent consideration are as follows:
|
|
H1
2022
|
ViiV
Healthcare
£m
|
|
Group
£m
|
|
|
|
|
|
|
Contingent
consideration at beginning of the period
|
5,559
|
|
6,076
|
|
Re-measurement
through income statement
|
841
|
|
899
|
|
Cash
payments: operating cash flows
|
(534)
|
|
(542)
|
|
Cash
payments: investing activities
|
(69)
|
|
(73)
|
|
|
|
|
|
|
Contingent
consideration at end of the period
|
5,797
|
|
6,360
|
|
|
|
|
|
|
H1 2021
|
ViiV
Healthcare
£m
|
|
Group
£m
|
|
|
|
|
|
|
Contingent
consideration at beginning of the period
|
5,359
|
|
5,869
|
|
Re-measurement
through income statement
|
259
|
|
317
|
|
Cash
payments: operating cash flows
|
(366)
|
|
(371)
|
|
Cash
payments: investing activities
|
(53)
|
|
(55)
|
|
|
|
|
|
|
Contingent
consideration at end of the period
|
5,199
|
|
5,760
|
|
|
|
|
|
|
Contingent liabilities
|
|
There
were contingent liabilities at 30 June 2022 in respect of
guarantees and indemnities entered into as part of the ordinary
course of the Group’s business. No material losses are
expected to arise from such contingent liabilities. Provision is
made for the outcome of legal and tax disputes where it is both
probable that the Group will suffer an outflow of funds and it is
possible to make a reliable estimate of that outflow. Descriptions
of the significant legal disputes to which the Group is a party are
set out on page 49.
|
|
Discontinued operations
|
|
Consumer
Healthcare has been presented as a discontinued operation at the
end of Q2 2022. The demerger of Haleon was completed on 18 July.
Financial information relating to the operations of Consumer
Healthcare for the period is set out below. The Group Income
Statement and Group Cash Flow Statement distinguish discontinued
operations from continuing operations. Comparative figures have
been restated on a consistent basis.
This
financial information differs both in purpose and basis of
preparation from the Historical Financial Information and the
Interim Financial Information included in the Haleon prospectus and
from that which will be published by Haleon plc on 19 September
2022. As a result, whilst the two sets of financial information are
similar, they are not the same because of certain differences in
accounting and disclosure under IFRS.
|
|
Total
Results
|
H1 2022
£m
|
|
H1
2021
£m
|
|
|
|
|
|
|
Turnover
|
5,115
|
|
4,517
|
|
Expenses
|
(4,271)
|
|
(3,633)
|
|
Profit
before tax
|
844
|
|
884
|
|
Taxation
|
(219)
|
|
(236)
|
|
Tax
rate%
|
25.9%
|
|
26.7%
|
|
Profit
after Tax from discontinued operations
|
625
|
|
648
|
|
Non-controlling
interest in discontinued operations
|
187
|
|
193
|
|
Earnings
attributable to shareholders from discontinued
operations
|
438
|
|
455
|
|
Earnings
per share from discontinued operations
|
10.9p
|
|
11.4p
|
|
|
|
|
|
|
|
Q2 2022
£m
|
|
Q2
2021
£m
|
|
|
|
|
|
|
Turnover
|
2,525
|
|
2,254
|
|
Expenses
|
(2,185)
|
|
(1,854)
|
|
Profit
before tax
|
340
|
|
400
|
|
Taxation
|
(111)
|
|
(133)
|
|
Tax
rate%
|
32.6%
|
|
33.4%
|
|
Profit
after Tax from discontinued operations
|
229
|
|
267
|
|
Non-controlling
interest in discontinued operations
|
97
|
|
86
|
|
Earnings
attributable to shareholders from discontinued
operations
|
132
|
|
181
|
|
Earnings
per share from discontinued operations
|
3.3p
|
|
4.5p
|
|
|
|
|
|
|
Assets and liabilities held for sale/distribution
|
|
Haleon
has been presented as a disposal group at the end of Q2 2022.
Non-current assets and disposal groups are transferred to Assets
held for sale/distribution when it is expected that their carrying
amounts will be recovered principally through disposal or a
distribution, they are available for sale/distribution in their
present condition and sale/distribution is considered highly
probable. They are held at the lower of carrying amount and fair
value less costs to sell/distribute. No impairment was recorded as
fair value was in excess of carrying value.
|
|
Assets held for sale/distribution
|
30 June 2022
Haleon
£m
|
|
30 June 2022
Other
£m
|
|
30 June 2022
Total
£m
|
|
31
December 2021
Total
£m
|
|
|
|
|
|
|
|
|
|
|
Property,
plant and equipment
|
1,649
|
|
104
|
|
1,753
|
|
22
|
|
Goodwill
|
5,207
|
|
-
|
|
5,207
|
|
-
|
|
Other
intangibles
|
19,951
|
|
6
|
|
19,957
|
|
-
|
|
Inventories
|
1,775
|
|
-
|
|
1,775
|
|
-
|
|
Trade
and other receivables
|
1,955
|
|
-
|
|
1,955
|
|
-
|
|
Short
term loans to third parties
|
2,948
|
|
-
|
|
2,948
|
|
-
|
|
Cash
and cash equivalents
|
1,421
|
|
-
|
|
1,421
|
|
-
|
|
Other
|
987
|
|
14
|
|
1,001
|
|
-
|
|
|
|
|
|
|
|
|
|
|
Total
assets held for sale/distribution
|
35,893
|
|
124
|
|
36,017
|
|
22
|
|
|
|
|
|
|
|
|
|
|
Liabilities held for distribution
|
30 June 2022
Haleon
£m
|
|
31
December 2021
Total
£m
|
|
|
|
|
|
|
Borrowings
|
(10,248)
|
|
-
|
|
Trade
payables and other liabilities
|
(3,880)
|
|
-
|
|
Deferred
tax liability
|
(3,722)
|
|
-
|
|
|
|
|
|
|
Total
liabilities held for distribution
|
(17,850)
|
|
-
|
|
|
|
|
|
|
Post balance sheet events:
|
|
Business acquisitions
|
|
On 1 July 2022, GSK completed the acquisition of 100% of Sierra
Oncology, Inc. a California-based, late-stage biopharmaceutical
company focused on targeted therapies for the treatment of rare
forms of cancer, for $1.9 billion (£1.6 billion). The main
asset is momelotinib which targets the medical needs of
myelofibrosis patients with anaemia. The initial acquisition
accounting will be reflected in the third quarter of
2022, and it is not completed
at this date.
On 31
May 2022, GSK announced that it has entered into a definitive
agreement to acquire 100% of Affinivax, Inc. (Affinivax), a
clinical-stage biopharmaceutical company based in Cambridge,
Boston, Massachusetts focused on pneumococcal vaccine candidates.
Under the terms of the
agreement, GSK will acquire 100% of the outstanding shares of
Affinivax. The consideration for the acquisition comprises an
upfront payment of $2.1 billion (£1.7 billion)
to be paid upon closing and
two potential milestone payments of $0.6 billion (£0.5
billion) to be paid upon
the achievement of certain paediatric clinical development
milestones. The transaction is subject to customary closing
conditions, including the expiration or early termination of the
waiting period under the Hart-Scott-Rodino Anti-Trust Improvements
Act of 1976. The transaction is expected to close in the third
quarter of 2022.
Divestments
On 18 July 2022, GSK plc separated its Consumer Healthcare business
from the GSK Group to form Haleon, an independent listed company.
The separation was effected by way of a demerger of 80.1% of
GSK’s 68% holding in the Consumer Healthcare business to GSK
shareholders. Following the demerger, 54.5% of Haleon is held in
aggregate by GSK Shareholders, 6.0% is held by GSK (including
shares received by GSK’s consolidated ESOT trusts) and 7.5%
is held by certain Scottish limited partnerships (SLPs) set up to
provide a funding mechanism pursuant to which GSK will provide
additional funding for GSK’s UK Pension Schemes. The
aggregate ownership by GSK (including ownership by the ESOT trusts
and SLPs) after the demerger of 13.5% will be initially measured at
fair value with changes through profit or loss. Pfizer continues to
hold 32% of Haleon after the demerger.
Under IFRIC 17 ‘Distributions of
Non-cash Assets to Owners’ a liability and an equity distribution
are measured at the fair value of the assets to be distributed when
the dividend is appropriately authorised and it is no longer at the
entity’s discretion. The liability and equity movement, and
associated gain, will be recognised in Q3 2022 when the demerger
distribution was authorised and occurred.
The asset distributed was the 54.5% ownership of the Consumer
Healthcare business. The net carrying value of the Consumer
Healthcare business, including the retained 13.5% and net of the
amount attributable to the non-controlling interest, was
approximately £11.5 billion at the end of June. The assets
distributed were reduced by Consumer Healthcare transactions up to
18 July that included pre-separation dividends declared and settled
after the end of Q2 2022 and before 18 July 2022. Those dividends
included: £10.4 billion (£7.1 billion attributable to
GSK) of dividends funded by Consumer Healthcare debt that was
partially on-lent during Q1 2022 and dividends of £0.6 billion
(£0.4 billion attributable to GSK) from available cash
balances. GSK’s share of the pre-separation dividends and
loans are eliminated in the consolidated financial
statements.
The fair value of the 54.5% ownership of the Consumer Healthcare
business distributed was £15.5 billion. This was measured by
reference to the quoted average Haleon share price over the first
five days of trading, this being a fair value measured with
observable inputs which is considered to be representative of the
fair value at the distribution date. A gain on distribution of this
fair value less 54.5% of the book value of the net assets of the
Consumer Healthcare business will be recorded in the Income
Statement in Q3 2022. There will be an additional gain to remeasure
the retained 13.5% from its book value to fair value of £3.9
billion using the same fair value methodology as used for the
distributed shares. In addition, there will be a reclassification
of the Group’s share of cumulative exchange differences
arising on translation of the foreign currency net assets of the
divested subsidiaries and offsetting net investment hedges from
Retained Earnings into the Income Statement. All these transactions
will be presented in profit from discontinued operations (adjusting
results) in Q3 2022.
Share Consolidation
Following
completion of the Consumer Healthcare business demerger on 18 July
2022, GSK plc Ordinary shares were consolidated to maintain share
price comparability before and after demerger. The consolidation
was approved by GSK shareholders at a General Meeting held on 6
July 2022. Shareholders received 4 new Ordinary shares with a
nominal value of 31¼ pence each for every 5 existing Ordinary
share which had a nominal value of 25 pence each. Earnings per
share, diluted earnings per share, adjusted earnings per share and
dividends per share were retrospectively adjusted to reflect the
Share Consolidation in all the periods presented.
|
|
Related party transactions
|
|
Details of GSK’s related party transactions are disclosed on
page 221 of our 2021 Annual Report and Accounts.
|
|
Financial instruments fair value disclosures
|
|
The following tables categorise the Group’s financial assets
and liabilities held at fair value by the valuation methodology
applied in determining their fair value. Where possible, quoted
prices in active markets are used (Level 1). Where such prices are
not available, the asset or liability is classified as Level 2,
provided all significant inputs to the valuation model used are
based on observable market data. If one or more of the significant
inputs to the valuation model is not based on observable market
data, the instrument is classified as Level 3. Other investments
classified as Level 3 in the tables below comprise equity
investments in unlisted entities with which the Group has entered
into research collaborations and also investments in emerging life
science companies.
|
|
At 30 June 2022
|
Level 1
£m
|
|
Level 2
£m
|
|
Level 3
£m
|
|
Total
£m
|
|
|
|
|
|
|
|
|
|
|
Financial assets at fair value
|
|
|
|
|
|
|
|
|
Financial
assets at fair value through other comprehensive income
(FVTOCI):
|
|
|
|
|
|
|
|
|
Other investments designated at FVTOCI
|
1,183
|
|
-
|
|
208
|
|
1,391
|
|
Trade and other receivables
|
-
|
|
2,119
|
|
-
|
|
2,119
|
|
Financial
assets mandatorily at fair value through profit or loss
(FVTPL):
|
|
|
|
|
|
|
|
|
Other investments
|
-
|
|
-
|
|
260
|
|
260
|
|
Other non-current assets
|
-
|
|
-
|
|
25
|
|
25
|
|
Trade and other receivables
|
-
|
|
55
|
|
-
|
|
55
|
|
Held for trading derivatives that are not in
a
designated and effective hedging
relationship
|
-
|
|
102
|
|
11
|
|
113
|
|
Cash and cash equivalents
|
5,230
|
|
-
|
|
-
|
|
5,230
|
|
Derivatives designated and effective as hedging
instruments (FVTOCI)
|
-
|
|
3
|
|
-
|
|
3
|
|
Financial assets classified as assets held
for distribution
|
424
|
|
160
|
|
-
|
|
584
|
|
|
|
|
|
|
|
|
|
|
|
6,837
|
|
2,439
|
|
504
|
|
9,780
|
|
|
|
|
|
|
|
|
|
|
Financial liabilities at fair value
|
|
|
|
|
|
|
|
|
Financial
liabilities mandatorily at fair value through profit or loss
(FVTPL):
|
|
|
|
|
|
|
|
|
Contingent consideration liabilities
|
-
|
|
-
|
|
(6,360)
|
|
(6,360)
|
|
Held for trading derivatives that are not in
a
designated and effective hedging
relationship
|
-
|
|
(41)
|
|
(1)
|
|
(42)
|
|
Derivatives designated and effective as hedging
instruments (FVTOCI)
|
-
|
|
(29)
|
|
-
|
|
(29)
|
|
Financial liabilities classified as liabilities held
for distribution
|
-
|
|
(57)
|
|
-
|
|
(57)
|
|
|
|
|
|
|
|
|
|
|
|
-
|
|
(127)
|
|
(6,361)
|
|
(6,488)
|
|
|
|
|
|
|
|
|
|
|
At 31 December 2021
|
Level 1
£m
|
|
Level 2
£m
|
|
Level 3
£m
|
|
Total
£m
|
|
|
|
|
|
|
|
|
|
|
Financial assets at fair value
|
|
|
|
|
|
|
|
|
Financial
assets at fair value through other comprehensive income
(FVTOCI):
|
|
|
|
|
|
|
|
|
Other investments designated at FVTOCI
|
1,736
|
|
-
|
|
191
|
|
1,927
|
|
Trade and other receivables
|
-
|
|
1,943
|
|
-
|
|
1,943
|
|
Financial
assets mandatorily at fair value through profit or loss
(FVTPL):
|
|
|
|
|
|
|
|
|
Other investments
|
-
|
|
-
|
|
199
|
|
199
|
|
Other non-current assets
|
-
|
|
-
|
|
23
|
|
23
|
|
Trade and other receivables
|
-
|
|
59
|
|
-
|
|
59
|
|
Held for trading derivatives that are not in
a
designated and effective hedging
relationship
|
-
|
|
77
|
|
6
|
|
83
|
|
Cash and cash equivalents
|
1,449
|
|
-
|
|
-
|
|
1,449
|
|
Derivatives designated and effective as hedging
instruments (FVTOCI)
|
-
|
|
123
|
|
-
|
|
123
|
|
|
|
|
|
|
|
|
|
|
|
3,185
|
|
2,202
|
|
419
|
|
5,806
|
|
|
|
|
|
|
|
|
|
|
Financial liabilities at fair value
|
|
|
|
|
|
|
|
|
Financial
liabilities mandatorily at fair value through profit or loss
(FVTPL):
|
|
|
|
|
|
|
|
|
Contingent consideration liabilities
|
-
|
|
-
|
|
(6,076)
|
|
(6,076)
|
|
Held for trading derivatives that are not in
a
designated and effective hedging relationship
|
-
|
|
(171)
|
|
-
|
|
(171)
|
|
Derivatives designated and effective as hedging
instruments (FVTOCI)
|
-
|
|
(57)
|
|
-
|
|
(57)
|
|
|
|
|
|
|
|
|
|
|
|
-
|
|
(228)
|
|
(6,076)
|
|
(6,304)
|
|
|
|
|
|
|
|
|
|
|
Movements in the six months to 30 June 2022 and the six months to
30 June 2021 for financial instruments measured using Level 3
valuation methods are presented below:
|
|
|
Financial
assets
£m
|
|
Financial
liabilities
£m
|
|
|
|
|
|
|
At 1 January 2022
|
419
|
|
(6,076)
|
|
Gains/(losses) recognised in the income statement
|
(7)
|
|
(900)
|
|
Gains recognised in other comprehensive income
|
32
|
|
-
|
|
Additions
|
60
|
|
-
|
|
Disposals
|
-
|
|
-
|
|
Transfer from Level 3
|
-
|
|
-
|
|
Payments in the period
|
-
|
|
615
|
|
|
|
|
|
|
At 30 June 2022
|
504
|
|
(6,361)
|
|
|
|
|
|
|
At 1 January 2021
|
814
|
|
(5,878)
|
|
Gains/(losses) recognised in the income statement
|
47
|
|
(313)
|
|
Gains recognised in other comprehensive income
|
90
|
|
-
|
|
Additions
|
51
|
|
-
|
|
Disposals
|
(10)
|
|
-
|
|
Transfer from Level 3
|
(595)
|
|
-
|
|
Payments in the period
|
-
|
|
426
|
|
|
|
|
|
|
At 30 June 2021
|
397
|
|
(5,765)
|
|
|
|
|
|
|
Net losses of £907 million (H1 2021: net losses of £267
million) reported in other operating income were attributable to
Level 3 financial instruments held at the end of the period. There
were no transfers from Level 3 as a result of listing of equity
investments on a recognised stock exchange during the period. In H1
2021, net gains of £99m arose prior to transfer from Level 3
on equity investments which transferred to a Level 1 valuation
methodology as a result of such listings. Net gains and losses
include the impact of exchange movements.
Financial liabilities measured using Level 3 valuation methods at
30 June included £5,797 million (H1 2021: £5,199 million)
of contingent consideration for the acquisition in 2012 of the
former Shionogi-ViiV Healthcare joint venture and £546 million
(H1 2021: £504 million) of contingent consideration for the
acquisition of the Novartis Vaccines business in 2015. Contingent
consideration is expected to be paid over a number of years and
will vary in line with the future performance of specified
products, the achievement of certain milestone targets and
movements in certain foreign currencies. The financial liabilities
are measured at the present value of expected future cash flows,
the most significant inputs to the valuation models being future
sales forecasts, the discount rate, the Sterling/US Dollar exchange
rate and the Sterling/Euro exchange rate.
|
|
The table below shows, on an indicative basis, the income statement
and balance sheet sensitivity to reasonably possible changes in key
inputs to the valuation of the largest contingent consideration
liabilities.
|
|
|
Shionogi-
ViiV Healthcare
£m
|
|
Novartis
Vaccines
£m
|
|
|
|
|
|
|
Increase/(decrease) in financial liability
|
|
|
|
|
10% increase in sales forecasts
|
571
|
|
64
|
|
10% decrease in sales forecasts
|
(571)
|
|
(62)
|
|
1% (100 basis points) increase in discount rate
|
(211)
|
|
(40)
|
|
1% (100 basis points) decrease in discount rate
|
227
|
|
47
|
|
10 cent appreciation of US Dollar
|
397
|
|
7
|
|
10 cent depreciation of US Dollar
|
(338)
|
|
(5)
|
|
10 cent appreciation of Euro
|
103
|
|
20
|
|
10 cent depreciation of Euro
|
(86)
|
|
(17)
|
|
|
|
|
|
|
The Group transfers financial instruments between different levels
in the fair value hierarchy when, as a result of an event or change
in circumstances, the valuation methodology applied in determining
their fair values alters in such a way that it meets the definition
of a different level. There were no transfers between the Level 1
and Level 2 fair value measurement categories. Transfers from Level
3 during H1 2021 relate to equity investments in companies which
were listed on stock exchanges during the period.
|
|
The following methods and assumptions were used to measure the fair
value of the significant financial instruments carried at fair
value on the balance sheet:
|
|
|
|
|
|
●
|
Other
investments – equity investments traded in an active market
determined by reference to the relevant stock exchange quoted bid
price; other equity investments determined by reference to the
current market value of similar instruments, recent financing
rounds or the discounted cash flows of the underlying net
assets
|
|
|
|
|
●
|
Trade
receivables carried at fair value – based on invoiced
amount
|
|
|
|
|
●
|
Interest
rate swaps, foreign exchange forward contracts, swaps and options
– based on the present value of contractual cash flows or
option valuation models using market-sourced data (exchange rates
or interest rates) at the balance sheet date
|
|
|
|
|
●
|
Cash
and cash equivalents carried at fair value – based on net
asset value of the funds
|
|
|
|
|
●
|
Contingent consideration for business acquisitions and divestments
– based on present values of expected future cash
flows
|
|
There are no material differences between the carrying value of the
Group's other financial assets and liabilities and their estimated
fair values, with the exception of bonds, for which the carrying
values and fair values are set out in the table below:
|
|
|
30 June 2022
|
|
31 December 2021
|
||||
|
|
|
|
|
|
|
|
|
|
|
Carrying
value
£m
|
|
Fair
value
£m
|
|
Carrying
value
£m
|
|
Fair
value
£m
|
|
|
|
|
|
|
|
|
|
|
Bonds in a designated hedging relationship
|
(5,096)
|
|
(5,008)
|
|
(4,982)
|
|
(5,311)
|
|
Other bonds
|
(15,830)
|
|
(16,688)
|
|
(17,373)
|
|
(20,746)
|
|
Bonds classified as liabilities held for distribution
|
(9,823)
|
|
(9,341)
|
|
-
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
(30,749)
|
|
(31,037)
|
|
(22,355)
|
|
(26,057)
|
|
|
|
|
|
|
|
|
|
|
The following methods and assumptions are used to estimate the fair
values of financial assets and liabilities which are not measured
at fair value on the balance sheet:
|
|
|
|
|
|
|
|
|
●
|
Receivables
and payables, including put options, carried at amortised cost
– approximates to the carrying amount
|
|
|
|
|
●
|
Liquid
investments – approximates to the carrying
amount
|
|
|
|
|
●
|
Cash
and cash equivalents carried at amortised cost – approximates
to the carrying amount
|
|
|
|
|
●
|
Short-term
loans, overdrafts and commercial paper – approximates to the
carrying amount because of the short maturity of these
instruments
|
|
|
|
|
●
|
Long-term
loans – based on quoted market prices (a Level 1 fair value
measurement) in the case of European and US Medium Term Notes;
approximates to the carrying amount in the case of other
fixed rate borrowings and floating rate bank loans
|
|
Put option
Other
payables in Current liabilities includes the present value of the
expected redemption amount of the Pfizer put option over its
non-controlling interest in ViiV Healthcare of £1,158 million.
This reflects a number of assumptions around future sales, profit
forecasts and forecast exchange rates. The forecast exchange rates
used are consistent with market rates at 30 June 2022.
The table below shows on an indicative basis the income statement
and balance sheet sensitivity to reasonably possible changes in the
key inputs to the measurement of this liability.
|
|
Increase/(decrease) in financial liability
|
|
|
ViiV
Healthcare
put
option
£m
|
|
|
|
|
|
|
10%
increase in sales forecasts
|
|
|
107
|
|
10%
decrease in sales forecasts
|
|
|
(107)
|
|
1% (100
basis points) increase in discount rate
|
|
|
(38)
|
|
1% (100
basis points) decrease in discount rate
|
|
|
42
|
|
10 cent appreciation of US Dollar
|
|
|
73
|
|
10 cent depreciation of US Dollar
|
|
|
(61)
|
|
10 cent appreciation of Euro
|
|
|
32
|
|
10 cent depreciation of Euro
|
|
|
(27)
|
|
|
|
|
|
|
Reconciliation of cash
flow to movements in net debt
|
|
|
H1 2022
£m
|
|
H1
2021
£m
|
|
|
|
|
|
|
Total
Net debt at beginning of the period
|
(19,838)
|
|
(20,780)
|
|
|
|
|
|
|
Increase/(decrease)
in cash and bank overdrafts
|
3,526
|
|
(2,031)
|
|
Increase/(decrease)
in liquid investments and short-term loans to third
parties
|
2,948
|
|
(18)
|
|
Net
decrease in short-term loans
|
3,073
|
|
352
|
|
Net
increase in long-term loans
|
(9,232)
|
|
-
|
|
Repayment
of lease liabilities
|
116
|
|
108
|
|
Exchange
adjustments
|
(1,999)
|
|
525
|
|
Other
non-cash movements
|
(52)
|
|
(77)
|
|
|
|
|
|
|
Increase
in net debt
|
(1,620)
|
|
(1,141)
|
|
|
|
|
|
|
Total
Net debt at end of the period
|
(21,458)
|
|
(21,921)
|
|
|
|
|
|
|
Net debt
analysis
|
|
|
30 June 2022
£m
|
|
30 June
2021
£m
|
|
31
December
2021
£m
|
|
|
|
|
|
|
|
|
Liquid
investments
|
67
|
|
59
|
|
61
|
|
Cash
and cash equivalents
|
6,465
|
|
3,503
|
|
4,274
|
|
Short-term
borrowings
|
(3,327)
|
|
(5,041)
|
|
(3,601)
|
|
Long-term
borrowings
|
(18,784)
|
|
(20,442)
|
|
(20,572)
|
|
|
|
|
|
|
|
|
Short-term
loans to third parties held for distribution
|
2,948
|
|
-
|
|
-
|
|
Cash
and cash equivalents held for distribution
|
1,421
|
|
-
|
|
-
|
|
Borrowings
held for distribution
|
(10,248)
|
|
-
|
|
-
|
|
|
|
|
|
|
|
|
Total
Net debt at the end of the period
|
(21,458)
|
|
(21,921)
|
|
(19,838)
|
|
|
|
|
|
|
|
|
Free cash flow
reconciliation from continuing operations
|
|
|
Q2 2022
£m
|
|
H1 2022
£m
|
|
H1
2021
£m
|
|
|
|
|
|
|
|
|
Net
cash inflow from continuing operating activities
|
1,196
|
|
3,402
|
|
1,217
|
|
Purchase
of property, plant and equipment
|
(237)
|
|
(430)
|
|
(352)
|
|
Proceeds
from sale of property, plant and equipment
|
-
|
|
6
|
|
95
|
|
Purchase
of intangible assets
|
(220)
|
|
(597)
|
|
(556)
|
|
Proceeds
from disposals of intangible assets
|
8
|
|
13
|
|
314
|
|
Net
finance costs
|
(337)
|
|
(411)
|
|
(421)
|
|
Dividends
from joint ventures and associates
|
-
|
|
-
|
|
9
|
|
Contingent
consideration paid (reported in investing activities)
|
(47)
|
|
(73)
|
|
(55)
|
|
Distributions
to non-controlling interests
|
(99)
|
|
(177)
|
|
(121)
|
|
Contributions
from non-controlling interests
|
-
|
|
8
|
|
7
|
|
|
|
|
|
|
|
|
Free
cash inflow from continuing operations
|
264
|
|
1,741
|
|
137
|
|
|
|
|
|
|
|
|
R&D
commentary
|
|
Pipeline overview
|
|
Medicines
and vaccines in phase III development (including major lifecycle
innovation or under regulatory review)
|
21
|
Infectious Diseases (10)
|
|
|
●
|
Bexsero infants vaccine (US)
|
||
|
●
|
COVID-19
(Medicago) vaccine candidate
|
||
|
●
|
COVID-19
(Sanofi) vaccine candidate
|
||
|
●
|
COVID-19
(SK Bioscience) vaccine candidate
|
||
|
●
|
MenABCWY
(1st gen) vaccine candidate
|
||
|
●
|
Menveo liquid vaccine
|
||
|
●
|
Rotarix liquid (US) vaccine
|
||
|
●
|
RSV
older adult vaccine candidate
|
||
|
●
|
gepotidacin
(bacterial topoisomerase inhibitor) uUTI and GC
|
||
|
●
|
Xevudy (sotrovimab/VIR-7831) COVID-19
|
||
|
|
|
||
|
Oncology (5)
|
|||
|
●
|
Blenrep (anti-BCMA ADC) multiple myeloma
|
||
|
●
|
Jemperli (anti-PD-1) 1L endometrial cancer
|
||
|
●
|
Zejula (PARP inhibitor) 1L ovarian, lung and breast
cancer
|
||
|
●
|
letetresgene-autoleucel
(NY-ESO-1 TCR) synovial
sarcoma/myxoid/round
cell liposarcoma
|
||
|
●
|
momelotinib
(JAK1/2 and ACVR1/ALK2 inhibitor) myelofibrosis with
anaemia
|
||
|
|
|
||
|
Immunology (4)
|
|||
|
●
|
latozinemab
(AL001, anti-sortilin) frontotemporal dementia
|
||
|
●
|
depemokimab
(long acting anti-IL5) asthma, eosinophilic granulomatosis with
polyangiitis, chronic rhinosinusitis with nasal polyps
|
||
|
●
|
Nucala chronic obstructive pulmonary disease
|
||
|
●
|
otilimab
(anti-GM-CSF) rheumatoid arthritis
|
||
|
|
|
||
|
Opportunity driven (2)
|
|||
|
●
|
daprodustat
(HIF-PHI) anaemia of chronic kidney disease
|
||
|
●
|
linerixibat
(IBATi) cholestatic pruritus in primary biliary
cholangitis
|
||
|
Total
vaccines and medicines in all phases of clinical
development
|
68
|
|
|
|
Total
projects in clinical development (inclusive of all phases and
indications)
|
86
|
|
|
|
Our key growth assets by
therapy area
|
|
The following outlines several key vaccines and medicines by
therapy area that will help drive growth for GSK to meet its
outlooks and ambition for 2021-2026 and beyond.
|
|
Infectious Diseases
|
|
bepirovirsen (HBV ASO)
|
|
Bepirovirsen is a potential new treatment option for people with
chronic hepatitis B as either a monotherapy (B-Clear) or
combination therapy with both existing (B-Together) and novel
treatments to explore additional combinations in the future. In
June 2022, GSK announced promising interim results from the B-Clear
phase IIb trial showing that bepirovirsen reduced levels of
hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA
after 24 weeks’ treatment in people with chronic hepatitis B
(CHB). These data were presented in an oral late-breaker session at
the European Association for the Study of the Liver’s
International Liver Congress (ILC) in June 2022 in London, UK. The
final results from the trial will be submitted for presentation at
a scientific congress later this year and published in a
peer-reviewed journal. GSK also presented an abstract at ILC
showing preclinical evidence that bepirovirsen harbours intrinsic
immunostimulatory activity via Toll-like receptor 8 (TLR8),
correlating with clinical efficacy from the phase IIa
trial.
GSK announced that a phase III trial evaluating bepirovirsen as a
monotherapy treating people with CHB is anticipated to start in the
first half of 2023.
|
|
Key
trials for bepirovirsen:
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
B-Clear bepirovirsen monotherapy (chronic hepatitis B)
NCT04449029
|
IIb
|
A multi-centre, randomised, partial-blind parallel cohort trial to
assess the efficacy and safety of treatment with bepirovirsen in
participants with chronic hepatitis B virus
|
Trial start:
Q3 2020
|
Complete; interim results presented; full data anticipated H2
2022
|
|
B-Together bepirovirsen sequential combination therapy with
Peg-interferon phase II (chronic hepatitis B)
NCT04676724
|
II
|
A multi-centre, randomised, open label trial to assess the efficacy
and safety of sequential treatment with bepirovirsen followed by
Pegylated Interferon Alpha 2a in participants with chronic
hepatitis B virus
|
Trial start:
Q1 2021
|
Active, not recruiting
|
|
bepirovirsen sequential combination therapy with targeted
immunotherapy (chronic hepatitis B)
NCT05276297
|
II
|
A trial on the safety, efficacy and immune response following
sequential treatment with an anti-sense oligonucleotide against
chronic hepatitis B (CHB) and chronic hepatitis B targeted
immunotherapy (CHB-TI) in CHB patients receiving nucleos(t)ide
analogue (NA) therapy
|
Trial start:
Q2 2022
|
Recruiting
|
|
gepotidacin (bacterial topoisomerase inhibitor)
|
|
First in class novel antibiotic for the treatment of uncomplicated
urinary tract infections (uUTI) and gonorrhoea. Interim analysis
for EAGLE-2 and 3 are scheduled for the second half of
2022.
|
|
Key
phase III trials for gepotidacin:
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
EAGLE-1 (uncomplicated urogenital gonorrhoea)
NCT04010539
|
III
|
A randomised, multi-centre, open-label trial in adolescent and
adult participants comparing the efficacy and safety of gepotidacin
to ceftriaxone plus azithromycin in the treatment of uncomplicated
urogenital gonorrhoea caused by Neisseria gonorrhoeae
|
Trial start:
Q4 2019
|
Recruiting
|
|
EAGLE-2 (females with uUTI / acute cystitis)
NCT04020341
|
III
|
A randomised, multi-centre, parallel-group, double-blind,
double-dummy trial in adolescent and adult female participants
comparing the efficacy and safety of gepotidacin to nitrofurantoin
in the treatment of uncomplicated urinary tract infection (acute
cystitis)
|
Trial start:
Q4 2019
|
Recruiting
|
|
EAGLE-3 (females with uUTI / acute cystitis)
NCT04187144
|
III
|
A randomised, multi-centre, parallel-group, double-blind,
double-dummy trial in adolescent and adult female participants
comparing the efficacy and safety of gepotidacin to nitrofurantoin
in the treatment of uncomplicated urinary tract infection (acute
cystitis)
|
Trial start:
Q2 2020
|
Recruiting
|
|
MenABCWY vaccine candidate
|
|
GSK is
developing two MenABCWY pentavalent (5-in-1) vaccines. The first
generation is in late-stage development and the second generation
is in an earlier stage. The goal is to help protect against all
five major disease-causing serogroups. Phase III pivotal results
from the first-generation MenABCWY vaccine are anticipated in the
second half of this year.
|
|
Key
trials for MenABCWY vaccine candidate:
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
MenABCWY – 019
NCT04707391
|
IIIb
|
A randomised, controlled, observer-blind trial to evaluate safety
and immunogenicity of GSK’s meningococcal ABCWY vaccine when
administered in healthy adolescents and adults, previously primed
with meningococcal ACWY vaccine
|
Trial start:
Q1 2021
|
Active, not recruiting
|
|
MenABCWY – V72 72
NCT04502693
|
III
|
A randomised, controlled, observer-blind trial to demonstrate
effectiveness, immunogenicity, and safety of GSK's meningococcal
Group B and combined ABCWY vaccines when administered to healthy
adolescents and young adults
|
Trial
start:
Q3
2020
|
Active, not recruiting
|
|
RSV vaccine candidates
|
|
In June
2022, GSK announced positive headline results from a pre-specified
efficacy interim analysis of the AReSVi 006 phase III trial for its
RSV older adult (OA) vaccine candidate. An Independent Data
Monitoring Committee reviewed the interim analysis, and the primary
endpoint was exceeded with no unexpected safety concerns observed.
Results from this phase III trial will be presented in a
peer-reviewed publication and at an upcoming scientific meeting.
The AReSVi 006 trial will continue to evaluate an annual
revaccination schedule and longer-term protection over multiple
seasons following one dose of the RSV OA vaccine
candidate.
|
|
Key
phase III trials for RSV older adult and maternal vaccine
candidates:
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
RSV OA=ADJ-004
(Adults ≥ 60 years old)
NCT04732871
|
III
|
A randomised, open-label, multi-country trial to evaluate the
immunogenicity, safety, reactogenicity and persistence of a single
dose of the RSVPreF3 OA investigational vaccine and different
revaccination schedules in adults aged 60 years and
above
|
Trial start:
Q1 2021
|
Active, not recruiting; results anticipated to be shared in H2
2022
|
|
RSV OA=ADJ-006
(ARESVI-006; Adults ≥ 60 years old)
NCT04886596
|
III
|
A randomised, placebo-controlled, observer-blind, multi-country
trial to demonstrate the efficacy of a single dose of GSK’s
RSVPreF3 OA investigational vaccine in adults aged 60 years and
above
|
Trial start:
Q2 2021
|
Active, not recruiting; primary endpoint met; results anticipated
to be shared in H2 2022
|
|
RSV OA=ADJ-007
(Adults ≥ 60 years old)
NCT04841577
|
III
|
An open-label, randomised, controlled, multi-country trial to
evaluate the immune response, safety and reactogenicity of RSVPreF3
OA investigational vaccine when co-administered with FLU-QIV
vaccine in adults aged 60 years and above
|
Trial start:
Q2 2021
|
Complete; results anticipated to be shared in H2 2022
|
|
RSV OA=ADJ-009
(Adults ≥ 60 years old)
NCT05059301
|
III
|
A randomised, double-blind, multi-country trial to evaluate
consistency, safety, and reactogenicity of 3 lots of RSVPreF3 OA
investigational vaccine administrated as a single dose in adults
aged 60 years and above
|
Trial start:
Q4 2021
|
Active, not recruiting; primary endpoint met
|
|
GRACE (pregnant women aged 18-49 years old)
NCT04605159
|
III
|
A randomised, double-blind, placebo-controlled multi-country trial
to demonstrate efficacy of a single dose of unadjuvanted RSV
maternal vaccine, administered IM to pregnant women 18 to 49 years
of age, for prevention of RSV associated LRTIs in their infants up
to 6 months of age
|
Trial start:
Q4 2020
Trial stopped enrolment and vaccination:
Q1 2022
|
Stopped enrolment and vaccination
|
|
HIV
|
|
cabotegravir
|
|
In June 2022, the Ministry of Health, Labour and
Welfare (MHLW) in Japan approved Vocabria
(cabotegravir
injection and tablets) used in combination with Janssen
Pharmaceutical Companies of Johnson & Johnson’s
Rekambys
(rilpivirine
long-acting injectable suspension) and Edurant
(rilpivirine tablets
taken as an oral lead-in before initiating injections), the first
and only complete long-acting treatment for
HIV.
|
|
Key
phase III trials for cabotegravir:
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
HPTN 083
(HIV uninfected cisgender men and transgender women who have sex
with men)
NCT02720094
|
IIb/III
|
A double-blind safety and efficacy trial of injectable cabotegravir
compared to daily oral tenofovir disoproxil fumarate/emtricitabine
(TDF/FTC), for Pre-Exposure Prophylaxis in HIV-uninfected cisgender
men and transgender women who have sex with men
|
Trial start:
Q4 2016
|
Active; not recruiting; primary endpoint met
(superiority)
|
|
HPTN 084
(HIV uninfected women who are at high risk of acquiring
HIV)
NCT03164564
|
III
|
A double-blind safety and efficacy trial of long-acting injectable
cabotegravir compared to daily oral TDF/FTC for Pre-Exposure
Prophylaxis in HIV-Uninfected women
|
Trial start:
Q4 2017
|
Active; not recruiting; primary endpoint met
(superiority)
|
|
ATLAS
NCT02951052
|
III
|
A randomised, multi-centre, parallel-group, non-inferiority,
open-label trial evaluating the efficacy, safety, and tolerability
of switching to long-acting cabotegravir plus long-acting
rilpivirine from current INI- NNRTI-, or PI-based antiretroviral
regimen in HIV-1-infected adults who are virologically
suppressed
|
Trial start:
Q4 2016
|
Active; not recruiting; primary endpoint met
(non-inferiority)
|
|
ATLAS-2M
NCT03299049
|
IIIb
|
A randomised, multi-centre, parallel-group, non-inferiority,
open-label trial evaluating the efficacy, safety, and tolerability
of long-acting cabotegravir plus long-acting rilpivirine
administered every 8 weeks or every 4 weeks in HIV-1-infected
adults who are virologically suppressed
|
Trial start:
Q4 2017
|
Active; not recruiting; primary endpoint met
(non-inferiority)
|
|
FLAIR
NCT02938520
|
III
|
A randomised, multi-centre, parallel-group, open-label trial
evaluating the efficacy, safety, and tolerability of long-acting
intramuscular cabotegravir and rilpivirine for maintenance of
virologic suppression following switch from an integrase inhibitor
single tablet regimen in HIV-1 infected antiretroviral therapy
naïve adult participants
|
Trial
start:
Q4
2016
|
Active; not recruiting; primary endpoint met
(non-inferiority)
|
|
Oncology
|
|
Blenrep
(belantamab mafodotin)
|
|
Updated
data from the DREAMM (DRiving Excellence in Approaches to Multiple
Myeloma) clinical trial programme evaluating Blenrep were presented at the 2022
American Society of Clinical Oncology (ASCO) Annual Meeting, held
3-7 June in Chicago, and the European Haematology Association (EHA)
2022 Hybrid Congress, held 9-12 June in Vienna,
Austria.
At
ASCO, preliminary data from DREAMM-5 sub-study 3 of low-dose
Blenrep in combination with
nirogacestat in patients with relapsed/refractory multiple myeloma
were presented. Nirogacestat, an investigational gamma-secretase
inhibitor, has been shown to increase target density and reduce
levels of soluble BCMA. As such, the potential to enhance the
activity of BCMA-targeted therapies like Blenrep is under investigation.
Additionally, the DREAMM-6 data showcased outcomes from several
dose cohorts of Blenrep in
combination with lenalidomide and dexamethasone in patients with
relapsed/refractory multiple myeloma who have received one or more
prior lines of treatment.
At EHA,
data from DREAMM-9 evaluating a quadruplet combination treatment
regimen of Blenrep with the
standard of care (bortezomib, lenalidomide and dexamethasone) in
patients with newly diagnosed multiple myeloma who are transplant
ineligible was presented. Additionally, an oral presentation on
updated results from a supported collaborative trial evaluated the
safety and efficacy of Blenrep plus lenalidomide and
dexamethasone in transplant-ineligible patients with newly
diagnosed multiple myeloma.
Collectively,
the data from these trials will be used to help inform additional
studies evaluating the potential of Blenrep in multiple myeloma, including
the earlier line setting.
DREAMM-3
phase III pivotal results are anticipated in the second half of
this year.
|
|
Key
phase III trials for Blenrep:
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
DREAMM-3 (3L/4L+ MM pts who have failed Len + PI)
NCT04162210
|
III
|
An open-label, randomised trial to evaluate the efficacy and safety
of single-agent belantamab mafodotin compared to pomalidomide plus
low dose dexamethasone (pom/dex) in participants with
relapsed/refractory multiple myeloma
|
Trial start:
Q2 2020
|
Recruiting
|
|
DREAMM-7 (2L+ MM pts)
NCT04246047
|
III
|
A multi-centre, open-label, randomised trial to evaluate the
efficacy and safety of the combination of belantamab mafodotin,
bortezomib, and dexamethasone (B-Vd) compared with the combination
of daratumumab, bortezomib and dexamethasone (D-Vd) in participants
with relapsed/refractory multiple myeloma
|
Trial start:
Q2 2020
|
Active, not recruiting
|
|
DREAMM-8 (2L+ MM pts)
NCT04484623
|
III
|
A multi-centre, open-label, randomised trial to evaluate the
efficacy and safety of belantamab mafodotin in combination with
pomalidomide and dexamethasone (B-Pd) versus pomalidomide plus
bortezomib and dexamethasone (P-Vd) in participants with
relapsed/refractory multiple myeloma
|
Trial start:
Q4 2020
|
Recruiting
|
|
Jemperli
(dostarlimab)
|
|
At
ASCO, updated data from an investigator-sponsored trial from
Memorial Sloan Kettering Cancer Center (MSKCC) was presented in a
late-breaking oral presentation. The data showed 14 consecutive clinical
complete responses in patients who received Jemperli
as a
first-line treatment for mismatch repair-deficient (dMMR) locally
advanced rectal cancer. The research was also published in
The New England Journal of
Medicine, and initial data were presented earlier this year
at the ASCO Gastrointestinal Cancers Symposium. GSK continues to closely collaborate with MSKCC to
advance this research and expand the trial for patients with rectal
cancer.
Also,
at ASCO, results from the GARNET trial Cohorts A1 and A2 in
advanced/recurrent dMMR/microsatellite instability-high or
proficient/stable endometrial cancer was presented, which will
inform long-term use of Jemperli in this patient population. In
addition, long-term outcomes from the GARNET trial Cohorts A1 and F
were shared, covering the efficacy and safety profile of
Jemperli in certain
patients with dMMR recurrent or advanced solid tumours, including
endometrial cancer.
RUBY
phase III pivotal results are anticipated in the second half of
this year.
|
|
Key
trials for Jemperli:
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
RUBY
ENGOT-EN6
GOG-3031 (1L Stage III or IV endometrial cancer)
NCT03981796
|
III
|
A randomised, double-blind, multi-centre trial of dostarlimab
(TSR-042) plus carboplatin-paclitaxel with and without niraparib
maintenance versus placebo plus carboplatin-paclitaxel in patients
with recurrent or primary advanced endometrial cancer
|
Trial start:
Q3 2019
|
Recruiting
|
|
PERLA (1L metastatic non-small cell lung cancer)
NCT04581824
|
II
|
A randomised, double-blind study to evaluate the efficacy of
dostarlimab plus chemotherapy versus pembrolizumab plus
chemotherapy in metastatic non-squamous non-small cell lung
cancer
|
Trial start:
Q4 2020
|
Active, not recruiting
|
|
momelotinib (JAK1/2 and ACVR1/ALK2 inhibitor)
|
|
On July
1, GSK announced that it had completed the acquisition of Sierra
Oncology, Inc. (Sierra Oncology), a California-based
biopharmaceutical company focused on targeted therapies for the
treatment of rare forms of cancer. The acquisition includes
momelotinib, a potential new medicine with a unique dual mechanism
of action that may address the critical unmet medical needs of
myelofibrosis patients with anaemia.
The
full MOMENTUM phase III data were presented in an oral presentation
at ASCO, in addition to a poster presentation of a subset analysis
from the trial evaluating safety and efficacy for patients with low
platelet counts, which was presented as a poster. Together, these
data demonstrate the potential use of momelotinib in symptomatic
and anaemic myelofibrosis patients.
In June
2022, Sierra Oncology announced the regulatory submission of a New
Drug Application (NDA) for momelotinib with the US Food and Drug
Administration (FDA). A filing with the European Medicines Agency
(EMA) is expected in H2 2022.
|
|
Key
phase III trials for momelotinib:
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
MOMENTUM (myelofibrosis)
NCT04173494
|
III
|
A randomised, double-blind, active control phase III trial intended
to confirm the differentiated clinical benefits of the
investigational drug momelotinib (MMB) versus danazol (DAN) in
symptomatic and anaemic subjects who have previously received an
approved Janus kinase inhibitor (JAKi) therapy for myelofibrosis
(MF)
|
Trial start:
Q1 2020
|
Active, not recruiting; primary endpoint met
|
|
Zejula
(niraparib)
|
|
At ASCO, GSK presented real-world analyses from four studies
in patients with advanced ovarian cancer, including real-world data
evaluating outcomes in patients with advanced ovarian cancer who
receive poly (ADP-ribose) polymerase (PARP) inhibitor monotherapy
as maintenance compared to those who receive active surveillance.
Insights from the presentations will deepen the understanding of
the use of PARP inhibitors for maintenance therapy in advanced
ovarian cancer and shed light on differences in treatment practice
across geographic locations.
|
|
Key
phase III trials for Zejula:
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
ZEAL-1L (maintenance for 1L advanced NSCLC)
NCT04475939
|
III
|
A randomised, double-blind, placebo-controlled, multi-centre trial
comparing niraparib plus pembrolizumab versus placebo plus
pembrolizumab as maintenance therapy in participants whose disease
has remained stable or responded to first-line platinum-based
chemotherapy with pembrolizumab for Stage IIIB/IIIC or IV non-small
cell lung cancer
|
Trial start:
Q4 2020
|
Recruiting
|
|
ZEST (Her2- with BRCA-mutation, or TNBC)
NCT04915755
|
III
|
A randomised double-blinded trial comparing the efficacy and safety
of niraparib to placebo in participants with either HER2-negative
BRCA-mutated or triple-negative breast cancer with molecular
disease based on presence of circulating tumour DNA after
definitive therapy
|
Trial start:
Q2 2021
|
Recruiting
|
|
FIRST (1L ovarian cancer maintenance)
NCT03602859
|
III
|
A randomised, double-blind, comparison of platinum-based therapy
with dostarlimab (TSR-042) and niraparib versus standard of care
platinum-based therapy as first-line treatment of stage III or IV
non-mucinous epithelial ovarian cancer
|
Trial start:
Q4 2018
|
Active, not recruiting
|
|
Immunology
|
|
depemokimab (long-acting anti-IL5)
|
|
In Q2 2022, GSK began recruiting for three additional phase III
programmes. This includes a screening of patients in two trials for
chronic rhinosinusitis with nasal polyps (CRSwNP) and site
initiation activities for trials in eosinophilic granulomatosis
with polyangiitis (EGPA) and hyper-eosinophilic syndrome (HES).
Recruitment of patients into all three programmes is
ongoing.
|
|
Key
phase III trials for depemokimab:
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
SWIFT-1 (severe eosinophilic asthma; SEA)
NCT04719832
|
III
|
A 52-week, randomised, double-blind, placebo-controlled,
parallel-group, multi-centre trial of the efficacy and safety of
depemokimab adjunctive therapy in adult and adolescent participants
with severe uncontrolled asthma with an eosinophilic
phenotype
|
Trial start:
Q1 2021
|
Recruiting
|
|
SWIFT-2 (SEA)
NCT04718103
|
III
|
A 52-week, randomised, double-blind, placebo-controlled,
parallel-group, multi-centre trial of the efficacy and safety of
depemokimab adjunctive therapy in adult and adolescent participants
with severe uncontrolled asthma with an eosinophilic
phenotype
|
Trial start:
Q1 2021
|
Recruiting
|
|
NIMBLE (SEA)
NCT04718389
|
III
|
A 52-week, randomised, double-blind, double-dummy, parallel group,
multi-centre, non-inferiority trial assessing exacerbation rate,
additional measures of asthma control and safety in adult and
adolescent severe asthmatic participants with an eosinophilic
phenotype treated with depemokimab compared with mepolizumab or
benralizumab
|
Trial start:
Q1 2021
|
Recruiting
|
|
ANCHOR-1 (CRSwNP)
NCT05274750
|
III
|
Efficacy and safety of depemokimab in participants with
CRSwNP
|
Trial start:
Q2 2022
|
Recruiting
|
|
ANCHOR-2 (CRSwNP)
NCT05281523
|
III
|
Efficacy and safety of depemokimab in participants with
CRSwNP
|
Trial start:
Q2 2022
|
Recruiting
|
|
OCEAN (EGPA)
NCT05263934
|
III
|
Efficacy and safety of depemokimab compared with mepolizumab in
adults with relapsing or refractory EGPA
|
Trial site initiations underway
|
Recruiting
|
|
DESTINY (HES)
NCT05334368
|
III
|
A 52-week, randomised, placebo-controlled, double-blind, parallel
group, multicentre trial of depemokimab in adults with uncontrolled
HES receiving standard of care (SoC) therapy
|
Trial site initiations underway
|
Recruiting
|
|
otilimab (anti-GM-CSF)
|
|
GSK is
investigating otilimab, an anti-GM-CSF monoclonal antibody, as a
potential new treatment for rheumatoid arthritis (RA). We expect to
report results from three phase III studies by the end of
2022.
|
|
Key
phase III trials for otilimab:
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
contRAst-1
(Moderate to severe RA MTX-IR patients)
NCT03980483
|
III
|
A 52-week, multi-centre, randomised, double blind, efficacy, and
safety trial comparing otilimab with placebo and with tofacitinib,
in combination with methotrexate in participants with moderately to
severely active rheumatoid arthritis who have an inadequate
response to methotrexate
|
Trial start:
Q2 2019
|
Active, not recruiting
|
|
contRAst-2 (Moderate to severe RA DMARD-IR patients)
NCT03970837
|
III
|
A 52-week, multi-centre, randomised, double blind, efficacy, and
safety trial, comparing otilimab with placebo and with tofacitinib
in combination with conventional synthetic DMARDs, in participants
with moderately to severely active rheumatoid arthritis who have an
inadequate response to conventional synthetic DMARDs or
biologic
|
Trial start:
Q2 2019
|
Active, not recruiting
|
|
contRAst-3 (Moderate to severe RA patients IR to biologic DMARD
and/or JAKs)
NCT04134728
|
III
|
A 24-week, multi-centre, randomised, double-blind, efficacy and
safety trial, comparing otilimab with placebo and with sarilumab,
in combination with conventional synthetic DMARDs, in participants
with moderately to severely active rheumatoid arthritis who have an
inadequate response to biological DMARDs and/or Janus Kinase
inhibitors
|
Trial start:
Q4 2019
|
Complete; results anticipated to be shared
H2 2022
|
|
Opportunity driven
|
|
daprodustat (oral hypoxia-inducible factor prolyl hydroxylase
inhibitor)
|
|
Earlier
this year, the EMA validated the marketing authorisation
application (MAA), and the US FDA accepted the NDA for daprodustat
based on the positive data from the ASCEND phase III clinical trial
programme. The programme included five pivotal trials assessing the
efficacy and safety of daprodustat for the treatment of anaemia of
chronic kidney disease (CKD) in both non-dialysis and dialysis
settings. GSK has also submitted MAAs in both Australia and
Switzerland.
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
ASCEND-D (Dialysis subjects with anaemia of CKD)
NCT02879305
|
III
|
A randomised, open-label (sponsor-blind), active-controlled,
parallel-group, multi-centre, event driven trial in dialysis
subjects with anaemia associated with chronic kidney disease to
evaluate the safety and efficacy of daprodustat compared to
recombinant human erythropoietin, following a switch from
erythropoietin-stimulating agents
|
Reported
|
Complete; primary endpoint met
|
|
ASCEND-ID (Incident Dialysis subjects with anaemia of
CKD)
NCT03029208
|
III
|
A 52-week open-label (sponsor-blind), randomised,
active-controlled, parallel-group, multi-centre trial to evaluate
the efficacy and safety of daprodustat compared to recombinant
human erythropoietin in subjects with anaemia of chronic kidney
disease who are initiating dialysis
|
Reported
|
Complete; primary endpoint met
|
|
ASCEND-TD (Dialysis subjects with anaemia of CKD)
NCT03400033
|
III
|
A randomised, double-blind, active-controlled, parallel-group,
multi-centre trial in haemodialysis participants with anaemia of
chronic kidney disease to evaluate the efficacy, safety, and
pharmacokinetics of three-times weekly dosing of daprodustat
compared to recombinant human erythropoietin, following a switch
from recombinant human erythropoietin or its analogues
|
Reported
|
Complete; primary endpoint met
|
|
ASCEND-ND (Non-dialysis subjects with anaemia of CKD)
NCT02876835
|
III
|
A randomised, open-label (sponsor-blind), active-controlled,
parallel-group, multi-centre, event driven trial in non-dialysis
subjects with anaemia of chronic kidney disease to evaluate the
safety and efficacy of daprodustat compared to darbepoetin
alfa
|
Reported
|
Complete; primary endpoint met
|
|
ASCEND-NHQ (Non-dialysis subjects with anaemia of CKD)
NCT03409107
|
III
|
A 28-week, randomised, double-blind, placebo-controlled,
parallel-group, multi-centre, trial in recombinant human
erythropoietin (rhEPO) naïve non-dialysis participants with
anaemia of chronic kidney disease to evaluate the efficacy, safety,
and effects on quality of life of daprodustat compared to
placebo
|
Reported
|
Complete; primary endpoint met
|
|
Principal risks and
uncertainties
The
principal risks and uncertainties affecting the Group for 2022 are
those described under the headings below. In our November 2021
annual risk review, the Board agreed our principal risks for 2022,
which remain largely unchanged, with the evolution of Privacy to
Data Ethics and Privacy, Non-Promotional Engagement to Scientific
and Patient Engagement and Transformation and Separation to
Separation. Additionally, we agreed that Environmental
Sustainability, the risks relating to which are described on pages
284 to 285 of our Annual Report, will be managed under our ESG
areas of focus.
We
describe our risk management process on page 46 of our 2021 Annual
Report, along with more detailed information on our risks,
including definitions, trends, potential impact, context and
mitigation activities as set out on pages 47 to 48 and pages 275 to
287 of our 2021 Annual Report. Additionally, we include risks and
uncertainties relating to the COVID-19 pandemic in our Annual
Report (see page 54).
|
|
2022 Principal Risks
|
||
|
Risk Title
|
Risk Definition
|
|
|
Patient
safety
|
Failure
to appropriately collect, review, follow up, or report human safety
information (HSI), including adverse events from all potential
sources, and to act on any relevant findings in a timely
manner.
|
|
|
Product
quality
|
Failure
by GSK, its contractors or suppliers to ensure:
|
|
|
●
|
Appropriate
controls and governance of quality in product
development;
|
|
|
●
|
Compliance
with good manufacturing practice or good distribution practice
regulations in commercial or clinical trials manufacture and
distribution activities;
|
|
|
●
|
Compliance
with the terms of GSK product licences and supporting regulatory
activities.
|
|
|
Financial
controls and reporting
|
Failure
to comply with current tax laws or incurring significant losses due
to treasury activities; failure to report accurate financial
information in compliance with accounting standards and applicable
legislation.
|
|
|
Anti-bribery
and anti-corruption (ABAC)
|
Failure
of GSK employees and third parties to comply with our anti-bribery
& anti-corruption (ABAC) principles, standards and controls, as
well as all applicable legislation.
|
|
|
Commercial
practices
|
Failure
to engage in commercial activities that are consistent with the
letter and spirit of the law, industry regulations, or the Group's
requirements relating to sales and promotion of our medicines and
vaccines; appropriate interactions with healthcare professionals/
organizations and patients; legitimate and transparent transfers of
value; and competition (or antitrust) regulations in commercial
practices, including trade channel activities and tendering
business.
|
|
|
Scientific
and patient engagement
|
We
engage externally with HCPs, HCOs, payers, governments,
patients/general public and others, to gain insights, educate and
communicate the science of our medicines and/or associated disease
areas to inform patient care decisions. These interactions must be
legitimate, conducted appropriately and transparently in compliance
with local laws, regulations, Industry Codes, GSK business and
ethics standards.
|
|
|
Data
ethics and privacy
|
With
increasing ease and opportunities for use and re-use of data
through artificial intelligence, data analytics and automation in
business decisions and processes, complex ethical dilemmas emerge
irrespective of legal compliance, particularly around its
application to personal data. Unethical use of data or the failure
to collect, secure, use, share and destroy Personal Information in
accordance with data privacy laws can lead to harm to individuals
and GSK.
|
|
|
Research
practices
|
Potential
failure to adequately conduct ethical and credible pre-clinical and
clinical research. In addition, it is the failure to engage in
scientific activities that are consistent with relevant laws,
industry practices, and GSK values and expectations. It comprises
the following sub-risks: Data Governance; Laboratory Research; and
Human Subject Research.
|
|
|
Environment,
health and safety (EHS)
|
Failure
in management of:
|
|
|
●
|
Execution
of hazardous activities;
|
|
|
●
|
GSK's
physical assets and infrastructure;
|
|
|
●
|
Handling
and processing of hazardous chemicals and biological
agents;
|
|
|
●
|
Control
of releases of substances harmful to the environment in both the
short and long term;
|
|
|
leading
to incidents which could disrupt our R&D and Supply activities,
harm employees, harm the communities and harm the local
environments in which we operate.
|
||
|
Information
security
|
Information
Security risk is characterized as the unauthorised disclosure,
theft, unavailability or corruption of GSK’s Information or
key information systems that may lead to harm to our patients,
partners, workforce and/or customers, disruption to our business
and/or loss of commercial or strategic advantage, regulatory
sanction, or damage to our reputation.
|
|
|
Supply
continuity
|
Failure
to deliver a continuous supply of compliant finished product;
inability to respond effectively to a crisis incident in a timely
manner to recover and sustain critical operations.
|
|
|
Separation
|
Failure
to deliver the plan for successful separation of GSK into two new,
leading companies: new GSK and Haleon.
|
|
|
Reporting
definitions
|
|
Total, Continuing and Adjusted results
Total
reported results represent the Group’s overall performance
including discontinued operations. Continuing results represents
performance excluding discontinued operations.
GSK
also uses a number of adjusted, non-IFRS, measures to report the
performance of its business. Adjusted results and other non-IFRS
measures may be considered in addition to, but not as a substitute
for or superior to, information presented in accordance with IFRS.
Adjusted results are defined on page 37 and other non-IFRS measures
are defined below and are based on continuing
operations.
Free cash flow from continuing operations
Free
cash flow is defined as the net cash inflow/outflow from continuing
operating activities less capital expenditure on property, plant
and equipment and intangible assets, contingent consideration
payments, net finance costs, and dividends paid to non-controlling
interests plus proceeds from the sale of property, plant and
equipment and intangible assets, and dividends received from joint
ventures and associates (all attributable to continuing
operations). It is used by management for planning and reporting
purposes and in discussions with and presentations to investment
analysts and rating agencies. Free cash flow growth is calculated
on a reported basis. A reconciliation of net cash inflow from
continuing operations to free cash flow from continuing operations
is set out on page 58.
Free cash flow conversion
Free
cash flow conversion is free cash flow from continuing operations
as a percentage of earnings attributable to shareholders from
continuing operations.
Working capital
Working
capital represents inventory and trade receivables less trade
payables.
CER and AER growth
In
order to illustrate underlying performance, it is the Group’s
practice to discuss its results in terms of constant exchange rate
(CER) growth. This represents growth calculated as if the exchange
rates used to determine the results of overseas companies in
Sterling had remained unchanged from those used in the comparative
period. CER% represents growth at constant exchange rates. £%
or AER% represents growth at actual exchange rates.
Total Net debt
Net debt is defined as total borrowings less cash, cash
equivalents, liquid investments, and short-term loans to third
parties that are subject to an insignificant risk of change in
value (including those classified as assets and liabilities held
for distribution).
COVID-19 solutions
COVID-19
solutions include the sales of pandemic adjuvant and other COVID-19
solutions including vaccine manufacturing and Xevudy and the associated costs but
does not include reinvestment in R&D. This categorisation is
used by management and we believe is helpful to investors through
providing clarity on the results of the Group by showing the
contribution to growth from COVID-19 solutions.
New GSK
New GSK
refers to the current GSK group excluding the Haleon business that
has been demerged.
General Medicines
General
Medicines are usually prescribed in the primary care or community
settings by general healthcare practitioners. For GSK, this
includes medicines in inhaled respiratory, dermatology, antibiotics
and other diseases.
Specialty Medicines
Specialty
Medicines are typically prescription medicines used to treat
complex or rare chronic conditions. For GSK, this comprises
medicines in infectious diseases, HIV, oncology, immunology and
respiratory.
Biopharma
Biopharma
refers to sales in Commercial Operations.
Share Consolidation
Shareholders
received 4 new Ordinary shares with a nominal value of 31¼
pence each for every 5 existing Ordinary share which had a nominal
value of 25 pence each. Earnings per share, diluted earnings per
share, adjusted earnings per share and dividends per share were
retrospectively adjusted to reflect the Share Consolidation in all
the periods presented.
Earnings per share
Earnings
per share has been retrospectively adjusted for the Share
Consolidation on 18 July 2022, applying a ratio of 4 new Ordinary
shares for every 5 existing Ordinary shares.
|
|
Brand names and partner acknowledgements
Brand
names appearing in italics throughout this document are trademarks
of GSK or associated companies or used under licence by the
Group.
The MAPS trademark is a registered Trademark of Affinivax,
Inc.
|
|
Guidance, assumptions and
cautionary statements
|
|
2022 guidance
GSK now
expects 2022 sales to increase between 6 to 8 per cent and Adjusted
operating profit to increase between 13 to 15 per cent. Adjusted
Earnings per share is expected to grow around 1 per cent lower than
Operating Profit. This guidance is provided at CER and excludes the
commercial benefit of COVID-19 solutions.
Assumptions related to 2022 guidance
In
outlining the guidance for 2022, the Group has made certain
assumptions about the healthcare sector, the different markets in
which the Group operates and the delivery of revenues and financial
benefits from its current portfolio, pipeline and restructuring
programmes. This guidance relates only to GSK. With the momentum
from the business performance to date, GSK now expects 2022 sales
to increase between 6 to 8 per cent and Adjusted operating profit
to increase between 13 to 15 per cent, excluding any contributions
from COVID-19 solutions. Adjusted Earnings per share is expected to
grow around 1 per cent lower than Operating Profit. We have
delivered first half performance ahead of our full year guidance,
slightly better than expected, informed by strong business delivery
and the dynamics of prior year comparators.
Predominantly reflecting a more challenging H2 2021 sales
comparator as well as the expected increase in R&D spend, we
expect lower reported growth in the second half. Key external
factors that will influence the second half of 2022 include the
continued risk from COVID-19 dynamics and possible developments in
the current uncertain global economic environment.
Notwithstanding
uncertain economic conditions across many markets in which we
operate, we observe evidence of healthcare systems recovering and
continue to expect full year sales of Specialty Medicines to grow
approximately 10% CER and sales of General Medicines to show a
slight decrease, primarily reflecting increased genericisation of
established Respiratory medicines. Vaccines sales are now expected
to grow at a low to mid-teens percentage at CER for the year.
Specifically for Shingrix,
we continue to expect strong double-digit growth and record annual
sales in 2022, based on strong demand in existing markets and
continued geographical expansion. However, we do expect sales in
the second half to be slightly lower than in the first half of 2022
due to some channel stocking in the first half in the
US.
These
planning assumptions as well as operating profit guidance and
dividend expectations assume no material interruptions to supply of
the Group’s products, no material mergers, acquisitions or
disposals, no material litigation or investigation costs for the
Company (save for those that are already recognised or for which
provisions have been made) and no change in the Group’s
shareholdings in ViiV Healthcare. The assumptions also assume no
material changes in the healthcare environment or unexpected
significant changes in pricing as a result of government or
competitor action. The 2022 guidance factors in all divestments and
product exits announced to date.
The
Group’s guidance assumes successful delivery of the
Group’s integration and restructuring plans. Material costs for investment in new product
launches and R&D have been factored into the expectations
given. Given the potential development options in the Group’s
pipeline, the outlook may be affected by additional data-driven
R&D investment decisions. The guidance is given on a constant
currency basis.
Assumptions and cautionary statement regarding forward-looking
statements
The
Group’s management believes that the assumptions outlined
above are reasonable, and that the guidance, outlooks, ambitions
and expectations described in this report are achievable based on
those assumptions. However, given the forward-looking nature of
these guidance, outlooks, ambitions and expectations, they are
subject to greater uncertainty, including potential material
impacts if the above assumptions are not realised, and other
material impacts related to foreign exchange fluctuations,
macro-economic activity, the impact of outbreaks, epidemics or
pandemics, such as the COVID-19 pandemic and ongoing challenges and
uncertainties posed by the COVID-19 pandemic for businesses and
governments around the world, changes in legislation, regulation,
government actions or intellectual property protection, product
development and approvals, actions by our competitors, and other
risks inherent to the industries in which we operate.
This
document contains statements that are, or may be deemed to be,
“forward-looking statements”. Forward-looking
statements give the Group’s current expectations or forecasts
of future events. An investor can identify these statements by the
fact that they do not relate strictly to historical or current
facts. They use words such as ‘anticipate’,
‘estimate’, ‘expect’, ‘intend’,
‘will’, ‘project’, ‘plan’,
‘believe’, ‘target’ and other words and
terms of similar meaning in connection with any discussion of
future operating or financial performance. In particular, these
include statements relating to future actions, prospective products
or product approvals, future performance or results of current and
anticipated products, sales efforts, expenses, the outcome of
contingencies such as legal proceedings, dividend payments and
financial results. Other than in accordance with its legal or
regulatory obligations (including under the Market Abuse
Regulation, the UK Listing Rules and the Disclosure and
Transparency Rules of the Financial Conduct Authority), the Group
undertakes no obligation to update any forward-looking statements,
whether as a result of new information, future events or otherwise.
The reader should, however, consult any additional disclosures that
the Group may make in any documents which it publishes and/or files
with the SEC. All readers, wherever located, should take note of
these disclosures. Accordingly, no assurance can be given that any
particular expectation will be met and investors are cautioned not
to place undue reliance on the forward-looking
statements.
All outlooks, ambitions and expectations should be read together
with pages 5-7 of the Stock Exchange announcement relating to an
update to investors dated 23 June 2021, paragraph 19 of Part 7 of
the Circular to shareholders relating to the demerger of Haleon
dated 1 June 2022 and the Guidance, assumptions and cautionary
statements in this Q2 2022 earnings release.
Forward-looking
statements are subject to assumptions, inherent risks and
uncertainties, many of which relate to factors that are beyond the
Group’s control or precise estimate. The Group cautions
investors that a number of important factors, including those in
this document, could cause actual results to differ materially from
those expressed or implied in any forward-looking statement. Such
factors include, but are not limited to, those discussed under Item
3.D ‘Risk Factors’ in the Group’s Annual Report
on Form 20-F for 2021 and any impacts of the COVID-19 pandemic. Any
forward looking statements made by or on behalf of the Group speak
only as of the date they are made and are based upon the knowledge
and information available to the Directors on the date of this
report.
|
|
Directors’
responsibility statement
The Board of Directors approved this Half-yearly Financial Report
on 27 July 2022.
The Directors confirm that to the best of their knowledge the
unaudited condensed financial information has been prepared in
accordance with IAS 34 as contained in UK-adopted International
Financial Reporting Standards (IFRS) and that the interim
management report includes a fair review of the information
required by DTR 4.2.7 and DTR 4.2.8.
After making enquiries, the Directors considered it appropriate to
adopt the going concern basis in preparing this Half-yearly
Financial Report.
The Directors of GSK plc are as follows:
|
|
|
|
|
|
Sir Jonathan Symonds
|
Non-Executive Chair, Nominations & Corporate Governance
Committee Chair
|
|
Dame Emma Walmsley
|
Chief Executive Officer (Executive Director)
|
|
Iain Mackay
|
Chief Financial Officer (Executive Director)
|
|
Dr Hal Barron
|
Chief Scientific Officer and President, R&D (Executive
Director)
|
|
Charles Bancroft
|
Senior Independent Non-Executive Director, Audit & Risk
Committee Chair
|
|
Dr Anne Beal
|
Independent Non-Executive Director, Corporate Responsibility
Committee Chair
|
|
Dr Harry (Hal) Dietz
|
Independent Non-Executive Director
|
|
Dr Laurie Glimcher
|
Independent Non-Executive Director
|
|
Dr Jesse Goodman
|
Independent Non-Executive Director, Science Committee
Chair
|
|
Urs Rohner
|
Independent Non-Executive Director, Remuneration Committee
Chair
|
|
Dr Vishal Sikha
|
Independent Non-Executive Director
|
|
|
|
|
|
|
|
By order of the Board
|
|
|
Emma Walmsley
Chief Executive Officer
27 July 2022
|
Iain Mackay
Chief Financial Officer
|
|
Independent review report
to GSK plc
|
|
We have
been engaged by GSK plc (“the Company”) to review the
condensed financial information in the Results Announcement of the
Company for the three and six months ended 30 June
2022.
|
|
What we have reviewed
|
|
|
The
condensed financial information comprises:
|
|
|
●
|
the
income statement and statement of comprehensive income for the
three month period ended 30 June 2022 on pages 39 to
40;
|
|
●
|
the
balance sheet as at 30 June 2022 on page 44;
|
|
●
|
the
statement of changes in equity for the six month period then ended
on page 45;
|
|
●
|
the
cash flow statement for the six month period then ended on page 46
and;
|
|
●
|
the
accounting policies and basis of preparation and the explanatory
notes to the condensed financial information on pages 41 to 43 and
47 to 58 that have been prepared applying consistent accounting
policies to those applied by the Group in the Annual Report 2021,
which was prepared in accordance with International Financial
Reporting Standards (“IFRS”) as adopted by the United
Kingdom.
|
|
|
|
|
We have
read the other information contained in the Results Announcement,
including the non-IFRS measures contained on pages 41 to 43 and 47
to 58, and considered whether it contains any apparent
misstatements or material inconsistencies with the information in
the condensed set of financial statements.
This
report is made solely to the Company in accordance with
International Standard on Review Engagements (UK and Ireland) 2410
“Review of Interim Financial Information Performed by the
Independent Auditor of the Entity” issued by the Financial
Reporting Council. Our work has been undertaken so that we might
state to the Company those matters we are required to state to it
in an independent review report and for no other purpose. To the
fullest extent permitted by law, we do not accept or assume
responsibility to anyone other than the Company, for our review
work, for this report, or for the conclusions we have
formed.
Directors’ responsibilities
The
Results Announcement of the Company, including the condensed
interim financial information, is the responsibility of, and has
been approved by, the directors. The directors are responsible for
preparing the Results Announcement of the Company in accordance
with the Disclosure Guidance and Transparency Rules of the United
Kingdom’s Financial Conduct Authority.
As
disclosed in Note 1, the annual financial statements of the Company
are prepared in accordance with United Kingdom adopted
International Financial Reporting Standards. The condensed
financial information included in this Results Announcement have
been prepared in accordance with United Kingdom adopted
International Accounting Standard 34, “Interim Financial
Reporting”.
Our responsibility
Our
responsibility is to express to the Company a conclusion on the
condensed financial information in the Results Announcement based
on our review. Our conclusion, including our Conclusions Relating
to Going Concern, are based on procedures that are less extensive
than audit procedures, as described in the Scope of Review
paragraph of this report.
Conclusion Relating to Going Concern
Based
on our review procedures, which are less extensive than those
performed in an audit as described in the Basis for Conclusion
section of this report, nothing has come to our attention to
suggest that the directors have inappropriately adopted the going
concern basis of accounting or that the directors have identified
material uncertainties relating to going concern that are not
appropriately disclosed.
This
conclusion is based on the review procedures performed in
accordance with this ISRE (UK), however future events or conditions
may cause the entity to cease to continue as a going
concern.
Scope of review
We
conducted our review in accordance with International Standard on
Review Engagements (UK and Ireland) 2410 “Review of Interim
Financial Information Performed by the Independent Auditor of the
Entity” issued by the Financial Reporting Council for use in
the United Kingdom. A review of interim financial information
consists of making inquiries, primarily of persons responsible for
financial and accounting matters, and applying analytical and other
review procedures. A review is substantially less in scope than an
audit conducted in accordance with International Standards on
Auditing (UK) and consequently does not enable us to obtain
assurance that we would become aware of all significant matters
that might be identified in an audit. Accordingly, we do not
express an audit opinion.
Conclusion
Based
on our review, nothing has come to our attention that causes us to
believe that the condensed financial information in the Results
Announcement for the three and six months ended 30 June 2022 are
not prepared, in all material respects, in accordance with United
Kingdom adopted International Accounting Standard 34 and the
Disclosure Guidance and Transparency Rules of the United
Kingdom’s Financial Conduct Authority.
Deloitte LLP
Statutory
Auditor
London,
United Kingdom
27 July
2022
|
|
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date:
July 27, 2022
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|